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Dietary Polyunsaturated Fatty Acids Regulate Mammary Tumor
Growth and Metastasis by Modulating Tissue
Microenvironments
Saraswoti Khadge, Ph.D.
University of Nebraska, 2018
Supervisor: James E. Talmadge, Ph.D. and Geoffrey M. Thiele Ph.D.

Omega (ω)-6 and ω-3 polyunsaturated fatty acids (PUFAs) are essential fatty acids (FAs)
and the precursors of pro- and anti-inflammatory mediators respectively. Epidemiological
studies have shown a lower incidence of breast cancer (BC) in the countries where longchain (LC)-ω-3FAs consumption is higher; however, the role of ω-3FAs in BC growth and
metastasis is poorly understood. We used isocaloric, isolipidic ω-6 and ω-3 (contains LCω-3FAs) diets and a pair-fed model to evaluate the effects of dietary PUFAs in mammary
tumor metastasis. Our studies have resulted in several novel observations including that
dietary LC-ω-3FAs modulate mammary gland (MG) microenvironments in non-tumor
bearing (NTB) mice by lowering MG ductal density, epithelial cell proliferation, adipocyte
hypertrophy and adipose tissue inflammation compared to the MGs in the ω-6 group.
Similarly, we reported that dietary LC-ω-3FAs modulate the hepatic microenvironment (a
common site of metastasis) by lowering hepatic steatosis, hepatocyte apoptosis,
extramedullary myelopoiesis and NFκB expression relative to the respective observations
in the ω-6 group. Finally, 4T1 mammary tumor studies in mice pre-exposed to these diets
showed that, dietary LC-ω-3FAs delays mammary tumor induction and growth, and
enhances survival of mice by lowering incidences/frequencies of spontaneous metastases
to multiple organs including, lungs, liver, bone, heart, kidneys, ovaries and contralateral
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mammary glands compared to the respective analyses in the mice fed a ω-6 diet. In tumor
microenvironments of mice fed a ω-3 diet, there were significantly lower numbers of
proliferating tumor cells, neo-vascularization and a higher incidence of apoptotic tumor
cells. Similarly, there was a significantly lower infiltration of myeloid cells including F-4/80+
macrophages and neutrophil elastase positive cell (granulocytes), and a higher infiltration
of CD3+ T-Cells in tumors from mice fed an ω-3 diet relative to the ω-6 diet-fed group.
There was a direct correlation between the neutrophil to T-cell ratio with tumor size and
macrophage infiltration with neovascularization.

There was also a direct correlation

between T-cell infiltration and frequency of apoptotic tumor cells, indicating their roles in
tumor growth. IL10 mRNA expression in tumors of mice fed an ω-3 diet was six fold higher,
relative to the expression in the tumors from the ω-6 group, indicating a potential role of
IL10 in the tumor growth suppression by dietary LC-ω-3FAs. In summary, our studies
using isocaloric/isolipidic diets and a pair-fed model showed for the first time that dietary
LC-ω-3FAs delay tumor growth and lower metastasis, and enhance survival by modulating
the tissue microenvironments including MGs and liver.
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Chapter 1:
Introduction1
1.1. Commentary: Background of the project design
A team of researchers, led by Dr. James E. Talmadge (expertise in cancer biology), Dr.
Geoffrey M. Thiele (expertise in immunological disorders and alcoholism-associated
pathologies) and Dr. John Graham Sharp (expertise in pathology and stem cell biology),
initially conceived of the project and the aims to analyze the effects of alcohol on
pathological alterations and mammary carcinoma development. Dr. Thiele’s lab has been
using Lieber-Decarli liquid diets and the pair-feeding model for alcohol-related studies. Dr.
Talmadge’s lab has been studying 4T1 mammary tumor for decades. Thus, the initial
project was designed to analyze the effects of chronic alcohol consumption on 4T1 tumor
cell growth and metastasis. To investigate this, preliminary studies using the LieberDeCarli diet with altered alcohol concentrations (5.5% to 16.6%) were administered for 48 weeks before an orthotopic inoculation of 50,000 4T1 cells. The results showed a
significant increase in tumor growth in mice fed the Lieber-Decarli alcohol diet relative to
the Lieber-Decarli control diet but no difference in survival days was observed between
the groups. In these experiments, we observed a few 4T1 tumor-bearing (TB) mice from
both of the dietary groups had posterior paralysis, which led us to analyze bone
morphology and metastasis by micro-CT and histology. As we expected, the mice with
posterior paralysis had tumor metastasis in their femurs/tibia. To our surprise, we also
observed mild osteopenia in non-tumor bearing (NTB) mice fed the Lieber-Decarli control

1

A part of this chapter is derived from previously published book chapter: Saraswoti Khadge, John Graham
Sharp, Timothy R. McGuire, Geoffrey M. Thiele, and James E. Talmadge. "Lipid Inflammatory Mediators
in Cancer Progression and Therapy." In Tumor Immune Microenvironment in Cancer Progression and
Cancer Therapy, pp. 145-156. Springer, Cham, 2017.
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diet compared to the mice on standard chow diet. Thus, we revisited the diets’ composition
and their roles in the outcomes we observed.
The Lieber-Decarli control diets contain 35.5% of calories from fat, which is a higher fat
level compared to the 16% calories from fat in standard chow diets. Based on this, we first
analyzed the effect of fat calories in altering the histopathology and immunological
markers in spleen, liver and bone marrow (BM) from NTB mice fed isocaloric diets
containing moderate fat (35.5%) versus low fat (12.5%) calories. However, there were no
significant differences in immunological phenotypes in liver, spleen and BM between the
various dietary groups. We did observe was hepatic macro-steatosis, and micro-steatosis
in moderate-fat versus low-fat pair-fed mice. Surprisingly, the fat droplets in hepatocytes
of low-fat diet-fed mice were more extensive than the droplets observed in the livers from
chow fed mice, which has higher calories from fat compared to the low-fat diet. These
results suggested a unique role of dietary fat composition in hepatic pathology and
metabolism. Thus, our results from these preliminary experiments suggested that the
observations in the original alcohol studies were confounded by many factors; including,
alcohol, calories from fat, and the composition of the fats. Clarification of relevant factors
was necessary to evaluate the effects of a single component without overlapping effects
from others. We noted that the Lieber-Decarli control diet incorporates insignificant levels
of long chain (LC) omega-3 (ω-3) polyunsaturated fatty acids (PUFAs), but contained
significant amounts of safflower oil, which is rich in omega-6 (ω-6) PUFA and olive oil
(mono unsaturated fatty acid; MUFA). Thus, the present study has the aim of analyzing
the effects of these PUFAs on the tissue microenvironments, which might play a role in
regulating in mammary tumor pathogenesis.
Therefore, the role of PUFAs, in regulating tissue microenvironments and tumor
progression, was the major aim of these studies. The first research section of the thesis
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is oriented toward the analysis of mammary gland macro and microenvironments by
dietary PUFA (Chapter 3). Since the liver is a frequent site of breast cancer metastasis;
although less frequent in mice, we also analyzed alterations in the hepatic
microenvironment by PUFA diets. In the second research section, we investigated PUFA
modulation of hepatic tissue in NTB mice (Chapter 4). After analyzing the changes in
tissue microenvironments by diets in NTB mice, we evaluated the effects of chronic
exposure to PUFA diets in mammary tumor progression and metastasis to multiple organs
(Chapter 5).
The introduction in this thesis is presented in the order the studies are discussed in the
subsequent sections. The introduction starts with breast cancer epidemiology and the
potential effects of diets; followed by a general background of PUFA, metabolism, and
their role in inflammation. I then discuss mammary gland biology, the hepatic
microenvironment and PUFA regulation of the metabolism and pathobiology of these
organs. Finally, the pathogenesis of breast BC and the role of microenvironments and
chronic inflammation in BC progression are discussed.

1.2. BC epidemiology
BBC is the most common cancer in women, regardless of race or ethnicity, and is the
second most common cause of death from cancer in American women [1]. According to
statistics from the National Cancer Institute, there were an estimated 3,418,124 women
living with female breast cancer in the United States in 2015. About 266,120 women are
expected to be diagnosed with invasive BC and 40,920 women are expected to die from
BC in 2018 in the United States [2] The global pattern of BC incidence reflects the
availability of BC screening as well as BC risk factors in the population. The highest BC
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incidence rates are in most of Western countries including North America, Australia/New
Zealand, and Europe, while the lowest rates are in Africa and Asia (Fig. 1 and Fig. 2) [3].
Besides the major risk factors relating to age, hormonal exposure, genetics and obesity
[4], there are modifiable lifestyle factors such as alcohol, smoking, sedentary life, obesity
and dietary factors that have been associated with an increased BC risk. The
epidemiological studies investigating possible effects of dietary behavior on BC incidence
are confounded by the close relationship among, dietary composition, caloric consumption
and body weight, making it difficult to define the effects of one variable, independent of
the others [5]. However, epidemiological and animal-based studies have shown a direct
association between BC and total fat intake [6, 7], high saturated fat intake [8, 9] and a
higher intake of omega (ω)-6 polyunsaturated fatty acid (PUFA), relative to the dietary
level of ω-3 PUFA [10-13]. In contrast, the consumption of marine-derived long-chain (LC)ω-3FAs have been associated with a lower risk of BC [14-17]. Despite extensive evidence
of an association of dietary PUFA composition with neoplasia, the regulatory mechanisms
driving such effects are little understood.

5

Figure 1. World BC map showing differences in incidence between countries.

The data are presented as cases per 100,000 population. Color code: the darker the color
the greater the incidence [3].

6

Figure 2. Breast cancer incidence between the years 1975 to 2010.
(A) Asian countries (B) and (C) many Western countries [3].

7

1.3. PUFAs
PUFAs are a class of lipids having two or more double bonds in their carbon chain. Among
the PUFAs, ω-3 and ω-6 PUFAs are essential FAs important for human health. The name
ω-3 and ω-6 are given based on the location of the last double bond relative to the terminal
methyl end of the molecule (Fig. 3) [18]. The biological reactivity of fatty acids is defined
by the length of the carbon chain and by both the number and position of any double bonds
present. Thus, differences in the position of the last double bond between ω-3 and ω-6
PUFAs result in various biological functions. Linoleic acid (LA) (C18:2; ω-6) and αlinolenic acid (ALA) (C18:3; ω-3) are the simplest members of the ω-6 and ω-3 PUFA
families, respectively, and are precursors to the long-chain (LC) series of the respective
series of PUFA families. Saturated FAs (SFAs) and most monounsaturated FAs (MUFAs)
can be synthesized in mammalian tissue from non-fat precursors such as glucose and
amino acids. However, mammals cannot convert oleic acid (MUFA, 18:1; n-9) to LA and
LA to ALA due to lack of 12-desaturase and 15-desaturase respectively [19], which are
enzymes found only in plants and lower animals like C. elegans. Thus, LA and ALA are
termed essential FAs as the human body must obtain these FAs from external sources
[20]. LA is plentiful in nature and found in the seeds of most plants, except for coconut,
cocoa, and palm. On the other hand, ALA is found in the chloroplasts of green leafy
vegetables, and in flax, rape, chia and perilla seeds, and in walnuts [20, 21]. In the human
body, most of the biological functions of PUFAs are mediated by the LC series of ω-6 and
ω-3 FAs. Arachidonic acid (AA) is a LC-ω-6FA and is obtained efficiently from eggs,
poultry and red meat, while LC-ω-3FAs such as eicosapentanoic acid (EPA) and
docosahexaenoic acid (DHA) are obtained from cold water fish such as salmon [22].
Besides external sources, LC-ω-6FAs and LC-ω-3FAs can be derived from LA and ALA
respectively in the human body by competitively using the same series of enzymes:
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desaturases and elongases (Fig. 4). In general, these enzymes have greater affinity for
ALA than LA, but due to increased availability of LA in diets and intake of at least 10 times
more LA than ALA, more AA is formed than EPA and DHA [22-24]. As noted above, LA
cannot be converted to ALA in mammals due to lack of converting enzyme ω-3 desaturase
[25]. Further, studies using increased dietary ALA have shown the conversion of LA to LCω-3FAs, specifically to DHA, is generally poor in humans [26, 27]. Thus, the consumption
levels of ω-6 and/or ω-3 FAs directly affect their bioavailability and their respective
downstream biological functions. Therefore, dietary consumption of LC-ω-3FAs (EPA and
DHA) might be more effective than ALA for ω-3FAs-related functions.

9

Figure 3. Molecular structure of different classes of fatty acids.
Red arrows indicating position of the first double bond in ω-3 and ω-6 PUFA. Figure
source [28]
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1.4. PUFAs metabolism
PUFA uptake to cells is a facilitated membrane translocation process that involves FA
translocases (i.e., CD36), FA transport proteins and membrane-bound FA binding proteins
[29-32]. The transported PUFAs are converted to FA acyl-CoA thioesters prior to entering
one of three major metabolic pathways. The first pathway is a beta-oxidization pathway to
generate energy (ATPs). The second pathway is one in which FA acyl-CoA thioesters of
PUFAs are metabolized for the synthesis of neutral lipids (triglycerides, cholesterol,
esters) or polar lipids such as phospholipids and sphingolipids. The third pathway occurs
if PUFAs are consumed in the form of LA or ALA, where they may undergo a series of
desaturation and elongation reactions and form LC-PUFAs such as AA, EPA and DHA
respectively [33-35]. LA and ALA are not efficiently synthesized nor incorporated into
phospholipid membranes. However, LC-ω-6FA (AA) and LCω-3FAs (EPA and DHA) can
be efficiently incorporated into phospholipid membranes [24, 36]. The incorporation of LCPUFAs affects the biological functions and/or signaling of immune cells in a variety of
ways, including the fluidity of cell membranes, alterations of lipid raft composition, acting
as ligands for G-receptors, or by being substrates for cyclooxygenase (COX) and
lipoxygenase (LOX) enzymes for the production of bioactive lipid mediators or eicosanoids
[19, 35, 37].

11

Figure 4. The metabolism of plant-derived essential ω-3 and ω-6 PUFAs.

Both ω-3 (n-3 in Fig) and ω-6 (n-6 in Fig) PUFA precursors competitively use the same
set
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1.5. PUFA and inflammation
Eicosanoids are a group of key, biologically active mediators that regulate inflammation
signaling [38, 39]. They are typically synthesized from 20-carbon PUFAs, such as AA,
dihomo-γ-linolenic acid (20:3; n=6) (DGLA) and EPA that are released from membranes
by the action of phospholipase A2, after activation of the membrane receptors by growth
factors or hormones [19]. These free AA, DGLA and EPA are metabolized to eicosanoids
such as prostaglandins (PGs), leukotrienes (LTs) and thromboxanes (TXs) depending on
the action of COX (COX-1, a constitutive enzyme, or COX-2, an inducible enzyme) and
LOX (5-, 12-, or 15-LOX) enzymes. The activity of COX on AA leads to the formation of 2series prostanoids such as PGE2 and TXA2; whereas the activity of LOX on AA generates
4-series LTs.

Similarly, the activity of COX and LOX on EPA produces 3-series

prostanoids (PGE3 and TXA3), and 5-series LTs and resolvins respectively. On the other
hand, DGLA is metabolized by COX resulting in 1-series PGs. Since AA is the most
abundant PUFA in most cells [18], relative to EPA and DGLA, eicosanoids that are
synthesized are mostly derived from AA. However, the concentrations of EPA and DGLA
modulate synthesis of AA derived eicosanoids as they are competitively used by the same
enzyme system to generate eicosanoids [19, 22, 24]. Further, eicosanoids derived from
EPA are less potent in inflammatory signaling. Thus, the competitive presence of EPA as
a substrate for COX and LOX enzymes reduces inflammation by either inhibiting the
production of inflammatory eicosanoids from AA or by producing fewer inflammatory
eicosanoids or anti-inflammatory resolvins [40].

1.6. ω-6 PUFA- and PGE2-mediated inflammation
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Among eicosanoids, PGE2 is the most abundant AA (ω-6) metabolite and has a crucial
role in inflammation. Depending on the duration and extent of PGE2 production, it has proinflammatory functions such as induction of fever and pain [41-43], vasodilation [42], and
local attraction and activation of neutrophils, macrophages, and mast cells at early stages
of inflammation [44-46]. Thus, the inhibition of PGE2 synthesis is an important antiinflammatory strategy that has been used for more than 100 years [47]. PGE2 can be
produced by any cell in the body, but the major source is immune cells. Although PGE2 is
unambiguously an inflammatory mediator, the finding of its role in the induction of
suppressive IL10, and suppression of lymphocyte proliferation, natural killer cells activity,
limitation of phagocytosis by alveolar macrophages and TNFα and IFNγ secretion,
emphasizes the importance of PGE2’s role as a mediator of immune suppression
associated with chronic inflammatory conditions including cancer [48-53]. Further, PGE2
can enhance Th2 responses, promote Th17 differentiation, and facilitate the development
of immunosuppressive macrophages and myeloid-derived suppressive cells (MDSC), all
of which emphasize the critical role of PGE2 signaling in tumor progression [54-57].
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1.7. Regulation of inflammation by ω-3FAs
Clinical and experimental studies have shown beneficial effects of ω-3FAs in controlling
chronic inflammatory diseases. Thus, increased consumption of ω-3FA-enriched diets or
endogenous synthesis of ω-3FAs are directly associated with increased incorporation of
EPA and DHA in cell membranes [58-60]. The presence of higher levels of EPA in
membranes competitively inhibits production of PGE2 and LTA4 from AA and elevates the
production of the non-inflammatory eicosanoids PGE3 and LTB5 (Fig. 5) [61]. These
effects have been shown in macrophages from fish oil-fed mice [62] and neutrophils from
humans consuming fish oil supplements [63]. Further, fish oil consumption is able to
decrease LTB4-mediated chemotaxis of neutrophils and monocytes [63, 64], reduce
expression of adhesion molecules in endothelial and immune cells [65-67], and decrease
production of inflammatory cytokines such as IL6, TNFα, MCP1, IL1B and the
inflammation pathway-associated gene NFkB [68-71].
Besides modulation of classical inflammatory pathways, EPA and DHA anti-inflammatory
activities can be developed by further metabolizing them to the pro-resolving/antiinflammatory lipid mediators, including resolvins (Rvs), protectins (PDs) and maresins [7277]. These novel, pro-resolution lipid mediators provide insight into the mechanisms of
actions by ω-3FAs and their beneficial actions in the moderation of the unresolved
inflammation, associated with chronic disorders. Resolvins (Rvs) are synthesized from
EPA (E-series) and DHA (D-series) via differential COX-2 pathways, in the presence or
absence of aspirin, while protectin D1 (PD1) is synthesized by the 15-LOX pathway using
DHA as a substrate [72, 78]. Rvs are found to inhibit TNFα-induced NFkB activation,
decrease polymorphonuclear leukocyte (PMN) activation by antagonistic effects of LTB4
mediated chemotaxis, and to decrease dendritic cell (DC) migration and cytokine
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production [79, 80]. Similarly, PDs have tissue specific bioactivities in the resolution of
inflammation. Pre-administration of PD1 dampens allergic airway inflammation and acute
kidney injury-associated inflammation [81, 82]. Both Rvs and PDs protect mice from colitis
[83], and improve insulin sensitivity by reducing the chronic inflammation associated with
obesity [84]. Further, a recent study demonstrated that Rvs inhibit cancer progression by
enhancing clearance of tumor cell debris by macrophage phagocytosis, [85] which
emphasizes ω-3FA associated lipid mediators as novel therapeutic targets, that may
complement

cytotoxic

cancer

therapies. Maresins

are

primarily produced

by

macrophages, shift macrophage phenotypes by inhibiting pro-inflammatory mediators [86,
87], and have been found to suppress breast tumor growth by stimulating phagocytosis of
apoptotic tumor cells and enhancing anti-inflammatory cytokines [88]. Despite recent
advances in identifying the role(s) of these novel ω-3FA-derived lipid mediators in multiple
inflammatory disorders and understanding their mechanisms of actions, their role(s) in the
modulation of tumorigenesis and associated mechanisms of action is not fully defined.
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Figure 5. PUFA and inflammation.
Arachidonic acid (active metabolite of ω-6FA) metabolizes into prostaglandins (PGs)
leukotrienes (LTs) with high pro-inflammatory potential. In contrast, LC-ω-3FAs such as
eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA) metabolize into low- proinflammatory PGs and LTs and anti-inflammatory resolvins and protectins respectively.
Figure source: [89]
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1.8. MG: Primary site of tumorigenesis
To understand the role of macro and microenvironment in mammary tumorigenesis, the
understanding of MG development and morphology is crucial. In the following section, the
normal development of MG and the various factors, including PUFA-modulated alteration
in morphology, that may impact mammary tumorigenesis will be discussed.
1.8.1. Breast/MG development and morphology
MG morphogenesis is similar between women (breasts) and rodents (multiple MGs). The
structural and functional parts of MG develop after birth and morphogenesis occurs in
different stages of life.

During fetal development, MGs develop from ectodermal

thickening called the milk line, that extends on each side of the body from the neck to the
inguinal region [90]. One MG on each side of the milk line develops into a breast in humans
while mice have 5 pairs of MGs. MG epithelium originates from the milk bud (which later
develops into a nipple) and extends into the mammary fat pad as a series of branching
ducts. In humans, the nipple contains outlets for 5-10 lactiferous ducts, which extend and
branch out in a radial pattern to form a triangular structural lobe supported by collagenous
stromal tissues [90]. In contrast, MGs in rodents contain a single lactiferous duct arising
from each nipple but the duct subsequently divides into 5-10 secondary ducts. In both
humans and mice, the end structures at the tip of the terminal ducts/ductules resembles
bud-like structures during early puberty and are called terminal end buds (TEBs) that in
humans are also known as lobular buds. These TEBs contain progenitor cells, which are
highly proliferative during puberty, in the process of ductal branching and formation of MG
functional units known as terminal duct lobular units (TDLU) in humans. In rodents, these
units are known as lobuloalveolar units (LAU) (also called as terminal buds, side buds,
alveolar buds or terminal ducts) [90, 91]. Besides cell proliferation, active cell death occurs
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in TEBs during puberty, which leads to lumen formation. Both TDLU and LAU contain
hormone-responsive cells and undergo continuous morphogenesis both per hormonal
cycle or based on functional needs. Since these units contain proliferative cells, there is a
higher chance of mutagenesis in the cells of these units and thus, they are tumor initiation
sites for most mammary carcinomas [90-92]. As shown in Fig. 6, TDLU (LOB in the figure)
of an adult nulliparous woman contains multiple alveolar buds of different sizes that can
exist in various stages of differentiation depending on the menstrual cycle. In contrast, the
LAU of an adult mouse resembles a single bud or blunt terminal duct without any subunits.
During pregnancy and in a lactating woman, both the number of TDLU and the number
and size of alveolar buds per TDLU will increase, forming a morphological unit (lobule or
LOB 3 in Fig. 6), which resembles a cluster of grapes. In pregnant and lactating mice,
LAUs undergo extensive morphogenesis, forming a lobule-like structure, but at the
completion of involution, murine mammary ducts and lobule-like structures return to
morphology similar to that of nulliparous mice, which contains only ductal ends but not
lobules [92, 93].
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Figure 6. Different developmental phases of the mammary gland.
Human (upper part) and mouse (lower part) mammary gland. LOB = Terminal ductal
lobular unit; LA = lobuloalveolar unit; TEB = terminal end bud; AB = alveolar bud [92]

20
1.8.2. MG morphology and BC risk
Besides the morphogenesis of MGs in response to hormonal effects in different stages of
life, other external factors, including nutrition, can influence the morphology of MGs. The
glandular mass of a breast/MG is represented by the total number and size of lobules and
ducts in a MG of an adult nulliparous human, and total number and or size of terminal
ducts and buds in a nulliparous mouse. Breast density is a measure of glandular mass,
along with associated stromal tissues relative to adipose mass in the breast, and can be
measured by mammographic analysis [94]. Epidemiological studies show that increased
mammographic density (MD) is directly associated with the risk of BC and appears to be
a major risk factor for interval BC (BC diagnosed within a year from the negative
mammographic result) [95, 96]. The risk of BC development was found to be 4-6 fold
higher in women with breasts that have 75% greater MD compared to the women with
breasts that have 10% or lower MD [97, 98]. In murine models, MG density can be
measured by the evaluation of total glandular area, ductal length, thickness and branching
complexity and total number of TEB (younger mouse) and/or terminal and side ducts
(older mouse) [99, 100]. Consistent with human epidemiological studies, murine studies
have shown that mice with more TEBs, epithelial proliferation, and MG density develop
spontaneous and carcinogen-induced mammary tumors more frequently [101-104].
Molecular mechanisms supporting an association of BC risk with dense breasts remain to
be defined. However, possibilities include an increased number of epithelial cells [105]
that may provide a greater chance for somatic mutations, increased epithelial cell
proliferation [106, 107], alteration in stromal tissues [98, 108] and increased local
inflammation in breast tissues [98, 109] of women having dense breasts. In experimental
studies, higher MG density in mice was associated with a thicker ductal stroma, a higher
number of proliferating ductal epithelial cells and increased infiltration of inflammatory cells
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[110], and the interaction of stroma epithelium and inflammatory microenvironments [111,
112]. Further mechanistic studies are needed to evaluate the role of the microenvironment
in the development of BC. The difference in MD has been found to be influenced by
multiple factors, including genetic components, race, parity status, hormonal therapy and
dietary factors [113].

1.8.3. Dietary PUFA composition and MG tumorigenesis
Experimental studies have shown that exposure to different levels and compositions of
dietary PUFAs modulate mammary tumor carcinogenesis. Since MG morphogenesis is
extensive before and during puberty, most murine studies are conducted at an early stage
of life. Pregnant mice fed diets high in ω-6 have high levels of serum estrogen, which is
associated with an increased incidence of mammary tumors in female offspring [114-116].
In contrast, the risk of mammary tumor development is reduced when fish oil is included
in a maternal ω-6-containing diet [117]. Similarly, a delayed appearance of tumors and
slower tumor growth is observed in offspring of mice fed a diet high in canola oil (ω-3FA)
compared to the mice fed a corn oil diet (ω-6FA) [116]. In murine experiments using prepubertal mice, the results are similar, with ω-3 diet-fed mice having a lower incidence of
carcinogen induced or transgenic mammary tumors [118-120] and delayed growth of
transplanted xenograft tumors [121] compared to mice fed diets high in ω-6FA. However,
when the results from mice fed a high-fat ω-3 diet were compared with mice fed a low fat
ω-6 diet, the mice fed the high-fat ω-3 diet had a greater incidence of mammary tumors
[118]. These results emphasize the importance of both dietary ω-6 and ω-3, as well as,
the total dietary lipid calories in the diet with respect to mammary tumorigenesis. Further,
these observations document the importance of using isocaloric diets for the analysis of
FA composition on tumorigenesis.
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The mechanism of action by ω-3FA in mammary tumorigenesis might be influenced by
the stage of MG development and morphogenesis during LC-ω3FA exposure. Exposure
to LC-ω-3FA, in-utero or early in life, modulates metabolic programming of PUFA
pathways in the offspring [122, 123]. Similarly, ω-3FA exposure early in life suppresses
tumorigenesis by regulating MG development as ω-3FAs enhance the differentiation of
TEBs, reducing the possibility of mutations in highly proliferative TEBs [124-126]. Besides
these age-dependent effects, other potential mechanisms for ω-3FA-mediated regulation
of tumorigenesis may be due to the modulation of the stromal and inflammatory
microenvironments.

Dietary incorporation or endogenously metabolized ω-3FA, in

rodents, significantly increases EPA and DHA levels, as well as decreases AA levels, and
mRNA expression of fatty acid synthase, COX-2, and 5-LOX in mammary tumor tissues
[125, 127]. Further, the incorporation of ω-3FA results in inhibition of NFkB activation,
decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-XL, increased caspase 3
activity, and reduced activation of EGFR in mammary tumor cells [128, 129].
Metabolites of ω-6 and ω-3FAs are pro- and anti-inflammatory respectively, and
differential PUFA composition regulates the activity of inflammatory cells. Therefore, the
regulation of the numbers and functions of inflammatory cells and their signaling pathways
might be one of the mechanisms by which ω-3FAs suppresses tumor growth and
metastasis as discussed in Section 1.4. Prior studies have shown that feeding LC-ω-3FA
can increase natural killer cell cytotoxicity, decrease expression of related transcripts to
macrophage proteins, inflammatory cytokines TNFα, IL6, CCL2, IL10, and NFkB pathwayrelated targets [130, 131]. However, few mechanistic studies have analyzed ω-3FA
regulation of inflammatory cells in the tumor microenvironment and no published reports,
to our knowledge, have used the essential controls of isocaloric, isolipidic diets in a pairfeeding model to evaluate these effects.
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1.9. Liver: One site of breast/mammary tumor metastasis
Since the aim of the study is to analyze the role of diet-modulated tissue microenvironment
in the regulation of metastasis to an organ, we analyzed PUFA-mediated modulation of
hepatic macro and microenvironments, which may regulate hepatic metastasis. In this
section, we will discuss normal histology and the metabolism by the hepatic tissue
microenvironments, in response to dietary PUFA regulation. We posit that the
modulated/altered microenvironments may have an impact on the arrest and survival of
metastatic tumor cells in the liver.
1.9.1. Overview of anatomy and histology of liver
The liver is the largest visceral organ in the body. It is structurally and functionally
heterogeneous and has been considered second only to the brain in complexity [132]. The
liver has a crucial role in the efficient uptake of amino acids, carbohydrates, bile acids,
cholesterol, proteins, vitamins and lipids for storage and metabolism, subsequently to
release into the bile and/or blood [132, 133]. The fundamental structure of livers from
humans and rodents are similar. A liver in a human has 4 lobes(right, left, quadrate and
caudate) [134]. Livers of rodents (mice and rats) also have 4 major lobes named as right,
left, median and caudate. The median and caudate lobes are further subdivided into 2 or
more parts. Mice and humans have a gallbladder, but not the rat [134-136]. The functional
unit of liver, i.e. a lobule, has the same histologic appearance, regardless of the angle a
liver is sectioned [137]. Histologically, a hepatic lobule is a hexagonal region of the liver
parenchyma (hepatocytes) around the central vein. At the vertices of the lobule, portal
triads can be observed, which include a bile duct and branches of the hepatic artery and
hepatic portal vein [138] (Fig. 7). Hepatocytes are arranged radially around the central
vein, and blood sinusoids form between them. The hepatic parenchyma is divided into
three zones. The hepatic parenchymal area near the portal triads is termed the peri-portal
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(or zone 1), the area near the central vein is centrilobular (or zone 3) and the area in
between the zone 1 and zone 3 is midzonal (or zone 2) [132, 138]. Hepatocytes (liver
parenchymal cells) are the most numerous cells in the liver and comprise 60% of total
cells. They perform the major functions of the liver and their cytoplasm contains varying
levels of glycogen and lipids, depending on the metabolic stage. Among the nonparenchymal cells in liver, sinusoidal epithelial cells (SECs) are the primary barrier
between the blood and hepatocytes and act to filter fluids and particles that are exchanged
between the sinusoidal lumen and the space of the Disse [139]. Kupffer cells are resident
hepatic macrophages and are derived from circulating monocytes. They represent 15% of
the liver cells (30% of sinusoidal cells) and are the major producers of cytokines providing
cross-talk with other cells [140]. Other resident cells in the liver include hepatic stellate
cells (HSCs), which comprise 5% of the liver cells and have a major role in the
regeneration and fibrogenesis of hepatic tissue [141, 142].
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Figure 7. Hepatic lobule from a section of pig liver
Hematoxylin and eosin-stained section of a liver from pig showing hepatic lobule distinctly lined
by sinusoids [143]
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1.9.2. Hepatic extra-medullary hematopoiesis
Beside, the resident cells of the liver, foci of immature-inflammatory cells or hematopoietic
progenitor cells are frequently observed in human fetal liver. The process of proliferation
by hematopoietic progenitor cells (erythroid and myeloid progenitors), outside of the
medullary space is called extra medullary hematopoiesis (EMH) [144]. Under normal
circumstances, after birth, there is little proliferation of hematopoietic elements outside of
the medullary space except in pathological conditions [144, 145]. In fetal life, the liver
provides a niche for colonization, proliferation and differentiation of circulating
hematopoietic progenitor cells, making the liver the primary site of EMH, which generally
ceases after birth when the bone marrow develops. However, EMH is observed normally
in neonatal life, especially following a premature birth or in pediatric patients with hepatic
disorders such as hepatitis [133, 145, 146]. In contrast, hepatic EMH in adult life is
associated with pathological conditions, including sepsis, solid organ and stem cell
transplantation and malignancy [147-149]. While myeloid precursors are the predominant
proliferating cells in EMH, the process is called extra medullary myelopoiesis (EMM) [150].
The occurrence of EMH or EMM in an adult might be the result of the arrest of immature
cells that become trapped in extra-medullary tissues. Such an increase in the number of
circulating hematopoietic stem cells might also be due to inadequate or inhospitable
marrow space for EMH or over production of marrow elements, as a consequence of
pathological conditions. Modulation of local tissue microenvironment, including an
increase in hypoxia and/or inflammatory cytokines and growth factors, stimulates the
proliferation of immature hematopoietic cells in extra-medullary tissue [144, 150, 151].
Hepatic EMH/EMM is mostly found in the vicinity of sinusoidal areas, which might be due
to the supporting role of sinusoidal endothelial cells in the proliferation of progenitor cells
[152]. Besides pathological conditions, changes of the hepatic micro-environment or
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inflammatory signaling, due to life style factors such as chronic inflammation or due to
alcohol consumption or diets, may influence hepatic EMH/EMM [153-155]. However,
further studies are needed to examine this since the role, or effects and consequences of
EMH or EMM foci and their signaling in hepatic microenvironments, is still not understood.

1.9.3. Lipid versus glycogen metabolism in liver
The liver is the primary metabolic organ for the storage or metabolism of both glucose and
lipids, depending on the host energy requirement. The liver synthesizes glycogen and
triglycerides as two major forms of energy storage, and metabolizes them to provide
energy during different phases of food deprivation. However, how the dietary composition
affects the liver’s metabolic preferences, for synthesis of glycogen versus triglycerides, is
not clearly understood.

1.9.3.1. Glycogen metabolism in liver
Glycogen is synthesized in the liver after consumption of food (energy sufficient or fedstate). Glucose enters hepatocytes via GLUT2 transporters and is phosphorylated by
glucokinase to synthesize glucose 6-phosphate (G6P) and glycogen synthase, which uses
G6P as a precursor to synthesize glycogen [156, 157]. In the fasted or energy deprivation
state, due to exercise, glycogen is hydrolyzed to generate glucose by glycogen
phosphorylase in the process called glycogenolysis [158]. The mechanism of glycogen
synthesis versus glycogenolysis is regulated directly by the availability of glucose in the
circulation and indirectly by insulin. In the fed-state, when the glucose levels are increased
in the circulation, more glucose is converted to G6P, which is an allosteric activator of
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glycogen synthase, whereas an inhibitor of glycogen phosphorylase thus increases G6P
and enhances glycogen synthesis. Similarly, insulin is secreted by pancreatic β cells in
response to an increase in blood glucose, amino acids, and fatty acids. Insulin stimulates
glycogen synthase by inactivating inhibitors of glycogen synthase (glycogen synthase
kinase 3) via activation of Akt (protein kinase B) [157, 158]. Insulin also stimulates
acetylation of glycogen phosphorylase, which promotes dephosphorylation and inhibition
of glycogen phosphorylase by protein phosphatase 1; thus, suppressing glycogenolysis
[159]. Under fasting conditions, insulin secretion is downregulated, which leads to
inhibition of glycogen synthase and activation of glycogen phosphorylase. Further,
counter-regulatory hormones (epinephrine and norepinephrine) secreted by pancreatic α
cells activate protein kinase A, which directly or indirectly activates glycogen
phosphorylase, resulting in increased glycogenolysis [157-159].

1.9.3.2. Fatty acid metabolism in the liver
Hepatocytes obtain FAs from the plasma or by de novo synthesis. After a meal, dietary fat
is digested, mainly in the small intestine and absorbed into enterocytes, where FAs are
esterified with glycerol 3-phosphate into triacetylglycerol (TAG) and incorporated into
chylomicrons before they are secreted into the gut lymphatic system [157, 160]. Those
triglyceride-rich chylomicrons enter into plasma, from which 70% of FAs are delivered into
adipose tissues. The remaining FAs circulate to the liver and are incorporated into
hepatocytes as non-esterified FAs (NEFAs) or free FAs formed by lipoprotein lipase
mediated lipolysis [160, 161]. If dietary carbohydrates are excessive to energy
requirements, de novo FAs synthesis occurs from glucose in the liver. FAs convert into
TAGs as described above or are esterified with cholesterol to produce cholesterol esters.
TAG and cholesterol esters are either packed into very low-density lipoprotein (VLDL)
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particles and delivered into adipose and extrahepatic tissues via the circulation, or stored
within hepatocytes as lipid droplets, depending on metabolic circumstances. In normal
metabolism, hepatic de novo lipogenesis can be driven by excess dietary carbohydrates,
by multiple transcription factors related to glycolysis and lipogenesis, insulin production or
the metabolic state (fed versus fasted) [157, 161, 162]. Besides the liver’s metabolic role
in synthesis and storage of FAs, hepatocytes also metabolize (oxidize) FAs to generate
energy by the process of β oxidation. In a fasted state or when energy requirements
cannot be fulfilled by the available glucose, β oxidation of FAs occurs in the mitochondria
of the liver and provides energy locally, or generates ketone bodies that are exported into
the circulation for delivery to energy deficient extrahepatic tissues [162]. Similarly, hepatic
β oxidation is regulated by the fasting state or multiple factors related to PPARα signaling
[157, 162, 163].
Although hepatic lipid metabolism is a tightly regulated process, different lifestyle
modifying factors can modulate metabolic parameters, resulting in benign to pathologic
hepatic conditions. The most notable factors are ethanol consumption and high calorie
and high fat diets resulting in accumulation of excess fats in the liver, a condition known
as fatty liver disease. Nonalcoholic fatty liver disease (NAFLD) is becoming the most
common cause of liver disease in Western countries and 30% of the people of the United
States have various levels of NAFLD [164, 165]. If uncontrolled, NAFLD can progress to
non-alcoholic steohepatitis (NASH) and cirrhosis, and is associated with hepatic
carcinoma [165]. NAFLD is directly associated with obesity, which is further associated
with consumption of a high fat, high calorie diet, although the liver is not a primary site of
lipid deposition. However, energy excess states, either diet or obesity can stimulate
hepatic TAG synthesis and/or free FA accumulation in hepatocytes [166, 167]. Besides
being hyper-caloric and high-fat, Western diets also have high amounts of ω-6 PUFA and
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mostly lack ω-3 PUFAs. However, little is known about the effects of dietary PUFA
composition, independent of calorie consumption and obesity, in hepatic lipid metabolism
and/or storage. Recent clinical studies have shown that obese patients with diabetes and
metabolic syndrome have low levels of LC-PUFAs in blood and tissue [168, 169].
Experimental studies, using obesity-resistant A/J mice and susceptible C57BL/6J, have
shown an inverse regulatory role of enzymes involved in LC-PUFA synthesis in obesity
associated fatty liver, so that elevated expression of these enzymes protects A/J mice
from obesity and fatty liver [170-172]. Among PUFAs, ω-3FAs have been associated with
decreased hepatic fat [173]. Additionally, dietary fat was found to modulate membrane
lipid composition of hepatocytes, which may alter their metabolic functions and associated
pathologies including NAFLD [174, 175].
Recent studies have demonstrated a correlation between lipid and glycogen metabolism
in high fat diet-feddiet-fed animals [176] and shown that liver glycogen levels reduce food
intake and prevent diet-induced obesity [177]. However, the mechanisms that switch lipid
to glycogen metabolism in non-obese conditions is not understood, nor is the role of PUFA
composition in the regulation of these metabolic processes. Altogether, an alteration in
hepatic lipid or glycogen metabolism results in the modulation of liver microenvironments
including steatosis, inflammation and fibrosis. The regulatory roles of diet-induced
alternation in the metabolism of the hepatic microenvironment, which can modulate
hepatic metastasis, are not known. Few epidemiological studies aimed to address a
correlation between fatty liver diseases including NAFLD with hepatic metastasis from BC
however the results from such studies are conflicting [178, 179]. Thus, further clinical,
experimental and mechanistic studies are warranted to address the role of PUFAs in
hepatic metastasis.
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1.10. Inflammation and cancer induction progression and metastasis
In 1863, Rudolf Virchow first proposed the hypothesis that cancer cells originate at the site
of chronic inflammation (irritation at that time) and that inflammation also enhances cell
proliferation [180]. It is now widely accepted that chronic inflammation is a risk factor for
cancer initiation and the type of inflammatory cells present in the tumor microenvironment,
and their cross talk with stromal cells and tumor cells has been shown to regulate tumor
progression and therapy resistance in multiple cancers, including BC. The role of
inflammation in BC development can be evaluated in two stages of cancer pathogenesis:
1) chronic local or systemic inflammation modulating BC development, and 2) double
edged roles of inflammatory cells in the tumor microenvironment
1.10.1. Chronic local or systemic inflammation modulating BC development
Clinical and epidemiological studies have shown an association between breast cancer
and obesity [181]. Adipose tissue is an endocrine organ and able to secrete bioactive
adipokines, cytokines, chemokines and hormone-like growth factors, depending on the
metabolic and/or inflammatory state [182]. Adipose tissue expansion, either due to
adipocyte hyperplasia (increase in cell number) or hypertrophy (increase in cell size),
induce local hypoxia, which is associated with dysregulated production of adipokines and
inflammatory cytokines [183, 184]. A chronic hypoxic condition results in apoptosis of
adipocytes, and the release of free fatty acids, which stimulate Toll-like receptors (TLRs)
on adipocytes and macrophages, and initiate the NFB pathway, activating the expression
of inflammatory cytokines including TNF‐α, IL1β, IL6, IL8 and CCL2 [182, 185]. Several
cytokines, specifically CCL2, attract circulating monocytes to the site of adipocyte death
where they differentiate to macrophages, resulting in the formation of crown-like structures
(CLS). The inflammatory signaling pathways needed to form CLS, or by the CLS, induce
chronic adipose tissue inflammation. Adipocyte death and/or CLS formation is mostly
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found in visceral/subcutaneous fat of humans and mice, and correlates with adipocyte size
[186, 187]. However, recent findings of CLS in adipose tissue from breast cancer patients
and normal weight women undergoing mastectomy for breast cancer risk reduction or
therapy not only emphasize the role of local adipose inflammation in tumor progression,
but also raise a potential new direction for the investigation of CLS pathways in BC
development, independent of obesity [188, 189].
Adipose tissue hypoxia also induces hypoxia-inducible factor-1 (HIF-1) that acts as a
molecular oxygen sensor and upregulates leptin and vascular endothelial growth factors
(VEGF) and downregulates adiponectin; thus, enhancing both systemic chronic
inflammation and angiogenesis [190]. Leptin levels in serum are directly correlated with
obesity, and higher leptin levels are associated with increased risk of BC [191]. Further,
leptin and leptin receptor expression are higher in breast adipose tissues of BC patients,
and in vitro studies have shown the efficiency of leptin in enhancing the proliferation of
normal mammary epithelial cells and mammary tumor cells, which further emphasizes a
potential role of leptin in mammary carcinogenesis [192-194].

1.11. Inflammatory cells in the tumor microenvironment
There are complex interactions between inflammatory microenvironments and tumor cells,
including the type of inflammatory cells that infiltrate tumors, and the activities regulating
hallmarks of cancer, such as cell proliferation, apoptosis, angiogenesis, invasion and
metastasis [195]. Immune cells can be of a cytotoxic (or tumor suppressing) phenotype,
and tumor-secreted growth factors and cytokines can modulate the immune cell
phenotype. Thus, tumor-infiltrating immune cells can have multiple roles in tumor
pathogenesis and control. Some of the important immune cell types in the mammary tumor
microenvironment are discussed below.

33

1.11.1. Tumor associate macrophages (TAMs)
Macrophages are one of the most abundant immune cells in the tumor microenvironment
of solid tumors, including BC. Intratumoral infiltration by TAMs has been associated with
a higher proliferation index and poorer disease-free survival in BC patients [196, 197].
TAMs are comprised of functionally heterogeneous populations of macrophages, and can
acquire different phenotypes, depending on activation signals. M1 and M2 macrophages
represent

two

functionally

microenvironments.

M1

distinct

phenotypes
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are

that

activated

are
by

identified
IFNγ

and

in

tumor

bacterial

lipopolysaccharides, and are associated with higher expression of proinflammatory
cytokines such as TNF-α, IL1, IL6, IL12 or IL23, antigen presentation and generation of
reactive oxygen species and are capable of killing pathogens and enhancing anti-tumor
immune responses. M2 macrophages (alternatively activated) are differentiated by IL4
and IL13 and are associated with the production of anti-inflammatory cytokines,
upregulation of scavenging receptors and participate in tissue remodeling, angiogenesis,
immunoregulation, and tumor promotion [198-200].

1.11.2. Tumor-associated neutrophils
High neutrophil numbers in the circulation (neutrophilia), or increased neutrophil to
lymphocyte ratios (NLR) have been associated with a poor prognosis of BC patients [201]
However, there is limited information on the regulatory role of neutrophils in tumor
microenvironments in BC patients. Neutrophils recruited to the tumor microenvironments
are known as tumor associated neutrophils (TANs) and chemokines skewed by tumor
cells recruit TANs into tumors [202, 203]. Thus, as with macrophages, tumor
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microenvironments can modulate TAN frequency and phenotypes [204]. A recent study
showed that TGFβ, within the tumor microenvironment, induce a pro-tumor TAN
phenotype N2, and the blockade of TGFβ increased the anti-tumor cytotoxic (N1)
phenotype of TANs [204]. The N2 TANs promote tumor growth by expressing matrix
degrading enzymes such as metalloproteases (MMP)-9, oncostatin M and chemokines
enhancing invasiveness of tumor cells and angiogenesis [202, 205]. However, additional
studies are needed to improve the understanding of TAN cross talk in tumor
microenvironments.

1.11.3. Myeloid derived suppressor cells (MDSCs)

MDSCs are heterogeneous population of myeloid precursor cells that were initially
identified as myeloid hyperplasia associated with tumor progression [206], but later were
found to be associated with other pathological conditions including bacterial infections,
autoimmune diseases and obesity [207-209]. As there is cellular heterogeneity in MDSCs,
the phenotypic characterization was initially contentious [206] and the markers to define
MDSCs have been evolving [210]. Classically, MDSC subsets were categorized as
granulocytic (G)-MDSCs versus monocytic (M)-MDSCs but G-MDSCs have also been
known as polymorphonuclear (PMN)-MDSCs based on their morphological and
phenotypical characteristics [210]. PMN-MDSCs are morphologically and phenotypically
similar to TANs and a recent study has shown a subgroup of tumor promoting TANs (N2).
Thus, it is likely that N2 TANs identified in tumor microenvironment are PMN-MDSCs [204,
211]. Tumors secrete growth factors including G-CSF, GM-CSF and M-CSF that induce
myelopoiesis [144, 145], and have been correlated with MDSC numbers. Similarly, tumorsecreted chemokines, and inflammatory mediators including TNFα, IL6, IL1β and PGE2
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have roles not only in mobilization but also may limit the maturation and differentiation of
MDSCs, resulting in accumulation [206, 211, 212] [127, 136-138]. Further, the
accumulation of their MDSCs in tumor microenvironments promote tumor growth by
regulating tumor invasion, angiogenesis [212, 213], reducing T-cell frequency and/or
suppressing T-cell function [206, 214]. MDSCs mediate T-cell suppression, support tumor
growth and can impede tumor therapies. Thus, recent studies have been focusing on the
mechanisms involved, including mechanisms of MDSC mediated suppression of T-cells:
1) down-regulation of T-cell receptor-zeta, which is required to transmit signal for
activation; 2) down-regulation of L-selectin, a plasma membrane molecule necessary for
homing of naïve T-cell to lymph nodes; and, 3) depletion of cysteine (an amino acid that
is essential for T-cell activation) from the microenvironment [215-217].

1.11.4. T-cells (Tumor infiltrating lymphocytes)
The impact of T-cells or tumor infiltrating lymphocytes (TIL) in tumor microenvironments
in the tumor progression has been studied for decades. Based on IHC evaluation of solid
tumors including BC, an increase in the frequency of TILs has been positively correlated
with a good prognosis and a response to cancer therapy [218, 219]. Among the subsets
of T-cells, the number of CD8+ cells has the greatest correlation and is most promising in
predicting responses. However, Th1 CD4+ infiltration has also been found to be a positive
prognostic marker [220, 221]. It is unclear if the presence of CD8+ in tumor
microenvironments has a strong effect on the killing of tumor cells or if having CD4+ in the
periphery will have additional effects.
Among T-cells, regulatory T-cells (T-regs) or Foxp3+CD25+CD4+ T-regs, play an important
role during immunological self-tolerance in healthy individuals. In BC patients, increased
tumor infiltration by T-regs has been correlated with poor prognosis; however, there is

36
limited information on the immunosuppressive mechanism and cross talk of T-regs in the
tumor microenvironment [222, 223]. Tumor-derived chemokines recruit T-regs into tumor
microenvironment and induce them to express high levels of CD25+ by tumor-derived
TGFβ and drive them to a suppressive phenotype [224]. One, well-studied T-reg-mediated
immune suppression mechanism, includes the activation of immune checkpoint
molecules, including T-lymphocyte associated protein 4 (CTLA-4) and program death 1
(PD1). CTLA-4 is a highly potent, co-inhibitory molecule expressed constitutively by Tregs and by conventional T-cells after activation. Since CTLA-4 has much higher affinity
than CD28 for their common ligands CD80 and CD86, constitutive CTLA-4 expressed by
T-regs may outcompete CD28 on conventional T-cells for binding to CD80/CD86 on
antigen-presenting cells resulting in inhibition of co-stimulation of conventional T-cells
[225]. The success of anti-tumor immunotherapy, using anti-CTLA-4 antibody, has been
previously attributed to augment the activity of tumor infiltrating CD8+ cells; however,
recent studies have suggested the possibility of the role of anti-CTLA-4 antibody in
depletion of T-regs, resulting in enhancing of anti-tumor immune response [226].

1.12. Breast cancer metastasis: Role of the tissue microenvironment
The metastasis of tumor cells from primary sites to distant organs is a non-random
process, and the successful development of metastasis in specific organs is a result of
tumor cell properties (seed) and the supportive environment of the host organ (soil).
Stephen Paget first proposed the seed and soil hypothesis in 1889 [227]. Fidler and
coworkers verified different aspects of the seed and soil hypothesis repeatedly in their
seminal findings; including the clonal origin of metastasis [228], organ selectivity [229]
and the role of cross talk between the tumor cells and the host microenvironment in the
formation of the metastases [227, 229-234]. By now the hypothesis has been widely
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accepted, although the definitions of seed and soil have been updated with the new
insights in the molecular properties of both seed and soil [230]. However, most efforts to
define therapeutic targets to control metastases have focused on the properties of the
tumor cells, while modifiable properties of the host organs have been less emphasized.
Studies have shown that the tumor supportive microenvironments, known as premetastatic niches, occur prior to colonization by the seed (metastatic tumor cell). Tumorderived factors or tumor-induced bone marrow-derived factors, and immune cells, have
been shown to have a role in the formation of pre-metastatic niches. Additionally,
modulation of the host organ microenvironments by chronic inflammation, immune
suppressive cell infiltration or local PGE2 production (influenced by the tumor or other
mechanisms) have a role in the preferential homing by tumor cells [235, 236]. The
emerging concepts of infiltration by myeloid cells, including MDSCs in pre-metastatic sites
prior to arrival of tumor cells, further indicate the role of inflammatory microenvironments
in tumor metastasis [237]. However, the mechanism of dietary factor mediated regulation
of the pre-metastatic niche remains to be understood. BC preferentially metastasizes to
bone, liver, brain, lungs and distant lymph nodes [235], while BC metastasis to heart,
kidney and ovaries are rarely reported.

1.13. Bone metastasis in BC
Around 70% of metastatic BC patients develop bone metastasis, indicating bone as one
preferable metastatic site for BC cells [238]. Therapeutic targeting of bone metastasis is
difficult, and the consequences of bone metastasis, including pathological bone fractures,
pain, hypercalcemia, and spinal cord and nerve-compression syndromes, significantly
reduce the quality of life amongst BC patients [239]. Although of great clinical importance,
molecular mechanism(s) underlying bone metastasis have not been elucidated, and more
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research is needed to understand the role of pre-metastatic bone microenvironments that
attract tumor cells. Based on the type of bone lesions, bone metastases are classified into:
osteoblastic, or osteoclastic. The major differences are that the osteoblastic lesions are
the consequence of tumor growth and tumor-derived factors. In contrast, osteoclastic
lesions are due to osteoclasts under the influence of tumor cells. Bone metastases in
prostate cancer are predominantly osteoblastic, while BC metastases are predominantly
osteoclastic [240]. In osteoblastic metastases, C-X-C chemokine receptor type 4 (CXCR4) is a major mediator that induces migration of tumor cells towards bone
microenvironments by interacting with C-X-C motif ligand 12 (CXCL12) on osteoblasts.
The invaded tumor cells produce multiple growth factors that alter the remodeling process
in the affected bone. Since osteoclastic metastases are important in BC, they are
discussed in more detail below.

1.13.1. Mechanisms of osteoclastic or osteolytic bone metastases
As described above, osteolytic lesions are due to the activities of osteoclasts under the
influence of tumor cells. BC cells produce factors such as parathyroid hormone related
peptide 1 (PHRP1) that binds to parathyroid hormone receptor 1 (PHR1) on marrow
stromal cells and induces the expression of receptor activator of nuclear factor-κB (RANK)
ligand (RANKL). The newly formed RANKL binds the RANK receptor on osteoclast
precursors and induces them to differentiate into mature osteoclasts, which resorb bone
by secreting proteases and acid to dissolve the matrix and release bone mineral into the
extracellular space [240, 241]. The bone resorption enhances TGFβ expression, which
induces PHRP1 production by BC cells [242]. Further, bone resorption enhances local
calcium levels, which promote tumor growth in bone, resulting in more PHRP1 production
[243]. Thus, this reciprocal cross talk between BC cells and bone microenvironments via
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PHRP1 and PHR1 results in a vicious cycle, increasing both bone destruction and
promoting tumor growth in the bone. Besides PHRP1, other factors such as TNFα, IL6,
macrophage colony-stimulating factor and IL1 produced by BC cells or microenvironments
may play a role in osteoclast formation. PGE2 can enhance osteoclast formation by
increasing expression of RANKL [244]. However, it is unclear if these factors/mediators,
in pre-metastatic bone microenvironments, modulate bone metastatic BC cells to produce
PHRP1 for colonization in bone, or if preselected bonetropic BC cells produce those
factors/mediators to initiate the vicious cycle of the osteolytic bone metastases in BC
patients. Osteopenia is also observed in post-menopausal women secondary to hormonal
factors [245]. Other life style factors such as alcohol consumption can enhance
osteopenia, and high fat diets lead to marrow adiposity modulating the marrow
microenvironments [246, 247]. However, how such pre-existing BM microenvironments
regulate BC bone metastasis is not clear and needs further evaluation.
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Chapter 2:
Materials and Methods
2.1. Animals and housing:
Female BALB/c mice (6 weeks old) purchased from Charles River Laboratories were
housed in micro-isolators in groups of five mice per cage, under standard conditions of
temperature and humidity, with a 12 h light-dark cycle. The micro-isolators were attached
to high efficiency particulate air (HEPA)-filtered ventilation blowers to provide sterile air.
The animal housing facility was maintained as a specific pathogen free (SPF) area. The
Institutional Animal Care and Use Committee at the University of Nebraska Medical Center
approved the animal protocol for the study. After two to three weeks of acclimation to the
laboratory conditions, mice were divided at random into two dietary groups based on the
experimental liquid diets (ω-6 or ω-3 diet). At least n=20 mice per group were used for
each pair-feeding dietary experiment. All the animal experiments were repeated at least 3
times for analysis of the outcomes. At least n=5 mice/group were used for each histological
experiment in non-tumor bearing mice and at least n=10 mice/group used for histological
and metastasis analysis of tumor-bearing experiments. The exact number mice/ group for
each experiment is mentioned in the respective result section of each chapter (chapters
3-5).

2.2. Diets and pair-feeding:
The diets were isocaloric and isolipidic and had identical protein, fiber, and micronutrient
contents. The ω-6 diet was the Lieber-DeCarli control diet (Dyets # 710027) containing
28.4 gm/L olive oil, while the ω-3 diet was customized by using the base diet (Dyets #
710166) and adding 8.4 gm/L olive oil and 20 gm/L of fish oil (NutriGold Triglyceride
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Omega-3 Gold capsules; Lot # 0081-3180-2) (Table 1). Both liquid diets provided 1.0 Kcal
energy per ml of diet and equal calories from macronutrients (35% derived from fat, 47%
from carbohydrate, and 18% derived from protein). The ω-6 and ω-3 diets differed
primarily by the absence or presence of LC-ω-3FAs from fish oil and ω-6 PUFA from olive
oil respectively. Omega-3 capsules and Lieber-DeCarli powder diets were stored at 4oC.
Diets were prepared and delivered daily (within 24-26 hours) and daily intake was
monitored. Ad libitum access to the liquid diets was provided for the first 5 days to
acclimatize the mice to the liquid diets. From day 6, the ω-6 diet group mice were pair-fed
based on mean consumption of the ω-3 diet group from the previous day, and this was
continued throughout the study for 10 or 20 weeks. Body weights were recorded twice a
week. In addition, a limited number of control studies were undertaken with age matched,
chow fed (#7912, Teklad) mice, as a baseline control.
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Table 1. Composition of the diets used in the study

Ingredient in Diet
Casein
L-Cystine
DL-Methionine
Corn Oil
Olive Oil
Safflower Oil
Maltose Dextrin
Cellulose
Mineral Mix
Vitamin Mix
Choline Bitartrate
Xanthum gum
Fishoil
Total

ω-6 Diet ω-3-Diet
Grams/L
Grams/L
41.4
41.4
0.5
0.5
0.3
0.3
8.5
8.5
28.4
8.4
2.7
2.7
115.2
115.2
10
10
8.75
8.75
2.5
2.5
0.53
0.53
3
3
0
20
221.8
221.8
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2.3. Blood Collection:
At the end of each experiment, blood was collected, without fasting, prior to the mice being
euthanized and hematological parameters, such as total white blood cell count (WBC)
count, red blood cell (RBC) count, hemoglobin level, hematocrit and mean corpuscular
volume (MCV) were determined using a vet ABC animal blood counter (Scil animal care
company, Grayslake, IL).

2.4. Fatty acid analysis:
Portions of liver, MG tissues and plasma samples were collected after 10 weeks of diet,
snap frozen and stored at -80oC for FA analysis. Portions of ready-to-use ω-3 and ω-6
diets were also frozen until needed for lipid extraction. Omega-3 capsules were stored at
4oC and used directly for FA analysis. Total lipid extraction from tissues and diets were
undertaken using antioxidant β-hydroxy-toluene (0.05%, wt/vol) as previously described
[248, 249]. Heptadecanoic and nonadecanoic acid (100 μg each) were added to all
samples to estimate the recovery of FA. Complex lipids were hydrolyzed by adding 0.5
ml of methanol containing 1% (wt/vol) sulfuric acid and 0.25 ml of toluene, and then were
incubated at 60°C overnight. Following incubation, 1.25 ml of water containing sodium
chloride (5%, wt/vol) was added, and esters were extracted using hexane (2 X 1.25 ml per
sample). The hexane layer was washed using 1 ml of water containing potassium
bicarbonate (2%, wt/vol), and dried over anhydrous sodium sulfate. The solvent was
removed under a stream of nitrogen and the FA methyl esters were analyzed by gas
chromatography-mass spectrometry (GC-MS) using an Agilent 6890 series gas
chromatograph, equipped with a 5873 mass-selective detector. For assessment of sterols,
100 μg of 5α-cholestane was added to samples as an internal standard. Sterols were
separated and detected by GC-MS using a DB-17ms column. FA concentration was
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analyzed as µg/µl or µg/mg of the samples, analyzed, and compared between the diets
and tissues from ω-3 and ω-6 diet-fed mice

2.5. Histological analysis of mammary ducts and adipocytes:
The MFP and abdominal fat tissues from non-tumor-bearing mice (Chapter 3) were fixed
in zinc fixative for 24-48 hours, and transferred to 70% ethanol, prior to paraffin
embedding, and sectioned at 4 μm. Sections were stained with hematoxylin and eosin (H
& E) or trichrome stain for histological analysis. The sections were analyzed under light
microscopy using a Zeiss Axioplan-2 microscope, and images were obtained using a HRc
camera using Zeiss AxioVision Rel 4.8 software from 10 randomly selected fields at 100x
or 200x magnifcation. The size of mammary ducts and stromal and epithelial layers in the
ducts were analyzed in trichrome stained MFP sections using Image-J software. The
average number and size of adipocytes per high power image was evaluated in H & E
stained sections of MFP and abdominal fat using MRI_Adipocyte_Tools, a plug-in tool
from Image-J as per the software protocol. The mean adipocyte size/number from the 10
high power field/sample were evaluated for the quantitative data. Two persons examined
the sections as “blinded” group assignments and an experienced pathologist validated the
results.

2.6. Hepatic steatosis analysis:
Steatosis was initially examined in H & E stained sections, then further confirmed and
quantified by counting Oil Red O (ORO) stained lipid droplets in hepatocytes. For ORO
staining, fresh liver tissues were embedded in optimal cutting temperature (O.C.T)
compound medium (Tissue-Tek #4583, Sakura Finetek, CA U.S.A) and stored at -80oC
until sectioned and stained. Lipid droplets, the size of a hepatic nucleus or larger, were
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enumerated to analyze macro-vesicular steatosis, whereas smaller lipid droplets were
enumerated for micro-vesicular steatosis analysis. To quantify hepatic steatosis, the
number of lipid droplets per 1000x magnification field were counted for 10 random fields
per liver sample.

2.7. Hepatic EMM analysis:
EMM was assessed based on foci of immature myeloid inflammatory cells and their
nuclear morphology in H & E stained sections. The number of foci per field and the
number of inflammatory cells per focus were counted in 10 fields at 200x magnification.
Biliary duct size and the area of biliary epithelium were measured in the biliary ducts
present in 10 random fields at 200x magnification using Image-J software.

2.8. Hepatic glycogen storage analysis
Hepatic glycogen deposition was measured using Periodic Acid-Schiff (PAS) staining on
paraffin embedded liver tissue sections. Magenta color PAS positive hepatocytes were
confirmed as glycogen-deposited hepatocytes by comparing glycogen degradation in a
serial section treated with PAS-diastase (PAS-digest). The average number of PASpositive hepatocytes were counted in 10 fields of hepatic lobular regions (200x).

2.9. Immunohistochemistry (IHC) analysis:
For IHC staining, slides of paraffin-embedded tissue sections were warmed on a slide
warmer for 30 minutes to 1 hour. The slides were deparaffinized and rehydrated by serial
incubations in xylene (3x), 100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, and
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water. For IHC analysis of liver tissue (data presented in Chapter 4), rehydrated sections
were steamed in preheated sodium citrate antigen retrieval buffer (pH 6.0) for 20 minutes
using a steamer (HS1000, Black and Decker, Miramar, Florida). Slides were cooled,
washed 3 times in TRIS-buffered saline, pH 7.6 (TBS) containing Tween-20 (TBST).
Endogenous peroxidase was blocked by hydrogen peroxide, slides were washed in TBST
and blocked with 5% goat serum in TBST (ab7481; Abcam Inc.) for 1 hour at room
temperature (RT). Primary antibodies were diluted in antibody diluent (BD559148; BD),
and incubated at 4oC overnight. For negative controls, serial sections were incubated in
the diluent without the primary antibody and all other staining procedures were
undertaken. Sections were washed 3 times with TBST and incubated in Signal Stain Boost
IHC detection reagent (HRP, Rabbit 8114S Cell Signaling Technology; Danvers, MA.) for
30 minutes at RT in a humid chamber. The washed sections were incubated with DAB
chromogen (BD550880; Becton Dickinson, New Jersey) until a mild brown color was
detected. Sections were briefly dipped in a hematoxylin solution (MHS32; Sigma-Aldrich,
St. Louis, MO) followed by 0.1% sodium bicarbonate for counter staining. Images were
captured on a Zeiss Axioplan-2 microscope as described above. The number of CD45+
cells in each cluster, and the number of clusters of CD45+ cells per 100x field were counted
in 10 random fields per sample.
For IHC analysis of mammary fat pads and tumor tissues, the same procedures and
incubation times were used as discussed above, however, different reagents were used
for some steps as mentioned below. For antigen retrieval, EDTA-based retrieval buffer,
pH 8.0 (ab93680, Abcam) was used instead of citrate buffer. Endogenous
peroxidase/phosphatase was blocked with BLOXALL (SP6000, Vector labs, Burlingame,
CA). Non-specific antibodies were blocked using 2.5% normal horse serum (S-2012,
Vector labs). For detection, ImmPRESS-AP, anti-rabbit Ig (MP-5401, Vector labs) was
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used for 30 minutes at RT in a humid chamber and staining was detected using ImmPACT
Vector Red alkaline phosphatase reagent (SK-5105). Counter staining was performed as
described above. The stained sections were dehydrated with serial incubations in water,
increasing concentrations of ethanol and then xylene and mounted with Permount, before
evaluation of the stain-positive cells by microscopy. (Fisher, SP15-100). For analysis of
staining, 10 random high power fields (HPF) were evaluated for the number of positive
cells or clusters of cells (for CD45+ cell clusters in liver) or CD31+ vessels per HPF. All the
IHC analyses of tumor tissues were performed by evaluating positive cells in sub-capsular
oxic areas of the tumors.
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Table 2. List of antibodies used in IHC experiments

Antibody

Reactivity

Anti-F4/80

Mouse
Mouse,Rat,
Human

Anti-Ki67
AntiNeutrophil
elastase
Anti-CD3
Anti-CD31
Anti-CD45

Mouse,
Human
Mouse,
Human
Mouse,Rat,
Human
Mouse,Rat,
Human

Host
species

Supplier

Rabbit

Cambridge, MA

ab111101

1:100'

Rabbit

Cambridge, MA

ab16667

1:100'

Rabbit

Cambridge, MA

ab68672

1:2000'

Rabbit

Cambridge, MA

ab16669

1:100'

Rabbit

Cambridge, MA

ab182981

1:2000'

Rabbit

Cambridge, MA

ab10558

1:2000'

Catalogue Dilution
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2.10. TUNEL labeling of liver tissues (Fluorescent based)
The terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate nick
end labeling (TUNEL) assay was performed on deparaffinized liver sections according to
the manufacturer's instructions (Roche, Indianapolis, IN). The label solution without TdT
was used as a negative control and liver sections with known tumor metastases were used
as positive controls. Slides were cured overnight, in the dark, with ProLong® Diamond
Antifade Mountant with DAPI (P36971; Thermo-Fisher, Grand Island, NY). Fluorescent
images were captured on a Zeiss LSM-710 confocal microscope at 630x magnification,
and the images were processed using the Zeiss Zen 2012 stitching software and merged
into a single image. The number of TUNEL positive nuclei and DAPI positive hepatic nuclei
per field at 630x magnification were counted in 10 random fields to calculate the number
of apoptotic nuclei and relative percentages of apoptotic hepatocytes.

2.11. Protein extraction of hepatic lysates and western blotting:
Freshly isolated liver sections were collected in ice-cold Tissue Protein Extraction Reagent
(T-PER™; #77510; Thermo-Scientific, Grand Island, NY) containing complete™ ULTRA
Tablets, EDTA-free, Protease Inhibitor Cocktail (#5892953001, Roche, Indianapolis, IN)
and PhosSTOP™ phosphatase inhibitor cocktail (#04906837001, Roche, Indianapolis,
IN), and then homogenized using a tissue homogenizer with disposable tips (Omni TH;
Omni International, Kennesaw, GA). The homogenized tissues were centrifuged at
10,000g for 10 minutes at 4oC. Protein concentrations of the whole tissue extracts were
determined according to the manufactur’s protocol (Pierce™ BCA Protein Assay Kit;
#23227, Thermo-Fisher, Grand Island, NY). For Western blotting, whole cell protein
samples were separated by SDS PAGE using a 4-15% Mini-PROTEAN TGX Precast Gel
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(456-1084, Bio-Rad), and blotted using Trans-Blot® Turbo™ Mini PVDF Transfer Packs
(1704156, Bio-Rad) Trans-Blot® Turbo™ Transfer System (Bio-Rad, Hercules,
California). The blotted membranes were blocked using 5% BSA in TBST for 1 hour at
RT, followed by incubation in diluted primary antibodies anti-NF-kB p65 [E379] (ab32536),
anti-beta Actin (ab8227) overnight at 4oC. After washing 3 times, blots were incubated with
the secondary antibody [goat anti-rabbit IgG H&L chain, HRP] (ab6721, Abcam Inc.) for 1
hr at RT. All the antibodies were purchased from Abcam Inc. The protein bands were
examined by using SuperSignal™ West Pico Chemiluminescent Substrate (34078,
Thermo-Fisher, Grand Island, NY). Blots were exposed and digital images were acquired
using a myECL™ Imager, and relative protein quantities were determined by using
myImageAnalysis™ Software (62237, Thermo-Fisher, Grand Island, NY).
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Table 3. List of antibodies used in Western blot analyses

Antibody

Reactivity

Host species

Supplier

Catalogue

Dilution

Anti-NF-kB p65
[E379]

Mouse,
Human

Rabbit

Cambridge,
MA

ab32536

1:50,000'

Anti-Beta Actin

Mouse, Rat,
Human

Rabbit

Cambridge,
MA

ab8227

1:25,000'

Goat Anti-Rabbit
IgG H&L (HRP)

Rabbit

Goat

Cambridge,
MA

ab6721

1:10,000'
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2.12. Flow cytometry and colony forming units-granulocyte/macrophage
(CFU-GM)
Freshly isolated livers were minced into small pieces, treated with collagenase-IV (17104019, Gibco) and DNAse I (D5025, Sigma), and filtered through cell dissociation sieves to
prepare single cell suspensions. Hepatic leukocytes (WBCs) were isolated using mouse
cell separation media, Lympholyte M (CL5035, Cedarlane). Then the total hepatic WBC
count was analyzed using a vet ABC animal blood counter and data assessed as WBC
count/gram of liver. For flow cytometry, isolated leukocytes were stained with the indicated
antibodies for 30 minutes at 4oC. The antibodies used were anti-CD45-V450 (clone 30F11, BD Pharmingen) anti-CD201-APC (clone ebio1560, ebioscience) and anti-CD27BV650 (clone LG3A10, BD Pharmingen). Flow cytometry was performed using a BD
LSRFortessa X50 platform, and results were analyzed using FlowJo software version
9.9.5 (TreeStar). For CFU-GM assays, 105 hepatic leukocytes were cultured in 1.1 ml of
methylcellulose-based medium for myeloid progenitor cells (MethoCult™ GF M3534,
STEMCELL technologies) as per company protocol. Colonies of at least 50 cells were
scored for analysis of CFU-GM.

2.13. RNA extraction / quantitative real time PCR
Tissues were collected in RNA stabilizing solution, RNAlater (#76106, Qiagen) and stored
at -20oC until used. RNA was extracted by using TRIzol reagent (15596026, Invitrogen).
RNA concentrations were measured using NanoDrop (ND1000, Thermofisher). In order
to confirm the integrity of the RNA, the RNA (2 µg) was separated in a denaturing agarose
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gel (1%) in formaldehyde, and samples with two distinct bands of RNA (16S and 23S) in
the gel were used for further analyses. Complimentary DNA (cDNA) was prepared from 2
µg of RNA using a high-capacity cDNA synthesis kit (4374966, Applied Biosystems; AB)
as per the kit protocol.
The qRT-PCR master mix was prepared using TaqMan gene expression master mix
(4370074, AB), anti-mouse probes and 10 ng of cDNA in Micro Amp fast optical 96 well
plates (4346906, AB). Pre-synthesized mouse probes from Applied Biosystems were used
for the study as listed in Table 4. Negative controls were run for every probe in the plate.
The samples were run using a StepOnePlus qPCR machine (Applied Biosystems) with
the program: pre-heating at 95oC for 10 minutes, 40 cycles of 15 seconds at 95oC and 60
seconds at 60oC. Each qRT-PCR experiment was carried out in triplicate (technical
replicates) so that the average cycle thresholds (Cts) from technical replicates was used
as a Ct value of the sample. Then the average Ct values (for each target or reference)
from all samples (each tissue) in the dietary group, from the same experiment (biological
replicates) were obtained for each dietary group. The relative quantities of target mRNAs
was determined using the Levak method [250]. Briefly, the Ct of GAPDH was subtracted
from the Ct value of the target to obtain a delta (d) Ct. Then the dCt of each of samples
from the ω-6 group was compared with the average dCt from the ω-3 group to obtain ddCt
values. The fold changes between the samples was calculated as 2-ddCt as described
previously [250].
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Table 4. List of probes used in qRT PCR analyses

Gene
symbol

Taqman gene
expression assay ID

Target
species

GAPDH

Mm99999915_g1

IGF1

Supplier

Translated protein

Mouse

Applied
Biosystem,
Foster city, CA

glyceraldehyde-3phosphate
dehydrogenase

Mm00439560_m1

Mouse

Applied
Biosystem

Insulin like growth
factor 1

IGF1R

Mm00802831_m1

Mouse

Applied
Biosystem

Insulin like growth
factor 1

ESR1

Mm00433149_m1

Mouse

Lep

Mm00434759_m1

Mouse

Adipoq

Mm00456425_m1

Mouse

IL6

Mm00446190_m1

Mouse

PTGS2

Mm00478374_m1

Mouse

IFNγ

Mm01168134_m1

Mouse

PGR

Mm00435628_m1

Mouse

AREG

Mm01354339_m1

Mouse

TNFα

Mm00443258_m1

Mouse

CCL2

Mm00441242_m1

Mouse

Applied
Biosystem

chemokine (C-C
motif) ligand 2

NFκB

Mm00476361_m1

Mouse

Applied
Biosystem

nuclear factor NFkappa-B

IL10

Mm01288386_m1

Mouse

Applied
Biosystem

Interleukin 10

CSF3

Mm00438334_m1

Mouse

Applied
Biosystem

Granulocyte colonystimulating factor

CSF2

Mm01290062_m1

Mouse

Applied
Biosystem

granulocytemacrophage colonystimulating factor

Applied
Biosystem
Applied
Biosystem
Applied
Biosystem
Applied
Biosystem
Applied
Biosystem
Applied
Biosystem
Applied
Biosystem
Applied
Biosystem
Applied
Biosystem

Estrogen receptor 1
Leptin
Adiponectin
Interleukin 6
prostaglandinendoperoxide
synthase 2 (COX-2)
Interferon gamma
Progesterone
receptor
Amphiregulin
Tumor necrosis
factor
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2.14. MG morphological analyses: Whole mount assays
The intact inguinal MGs (#4) were excised from the mice at necropsy. The MGs were
spread onto a glass slide immediately after collection and fixed in Carnoy’s solution (100%
EtOH, chloroform, glacial acetic acid; 6:3:1) for 4 hours in a fume hood at room
temperature (RT). The fixed MGs were then gradually rehydrated in graded ethanols
(70%, 35%, 15%) ending in water. The MGs were stained using carmine alum staining
solution [0.2% Carmine (C6152, Sigma, MO) and 0.5% aluminum potassium sulfate
dodecahydrate (#237086, Sigma, MO) with a few flakes of thymol (#16254, Sigma, MO)
overnight. The stained MGs were washed in water and dehydrated in ascending graded
ethanol solutions (50%, 70%, 95%, 100%), cleared by incubating in xylene overnight and
mounted with Permount (SP 15-100, Fisher scientific). Whole slide images were acquired
using the Invitrogen™ EVOS™ FL Auto Imaging System. For quantitative analysis, higher
magnification images were acquired using the Zeiss Discovery V8 Stereo Microscope with
a Axiocam 105 color camera. We used the term “ductal terminus/termini” for all the end
structures of ducts and ductules present in the high power field (HPF). The number of
ductal termini were counted in 10 images (40x magnification) per sample and used to
calculate the average value for each sample. The extent of ductal branching was analyzed
by counting the total number of lateral branches in 3-4 primary ducts and five secondary
ducts (between lymph node and distal ends of ducts) at 12.5x magnification. The results
were expressed as a number of lateral branches per mm of a duct (primary/secondary).
The quantitative results of ductal termini and lateral branching were discussed as ductal
end-point densities and branching densities respectively, as described previously [100].
The total area of the MG ductal tree, the length of the primary duct (from nipple to end of
the duct) and lymph node area, were quantified using Image-J software.
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2.15. Culture of 4T1 cells and orthotopic inoculation:
Mammary adenocarcinoma 4T1 cells derived from BALB/c mice [228] were used in an
orthotopic mammary tumor model. These tumor cells were a generous gift from Dr. Fred
R. Miller [228]. The cells were grown in 4T1 culture media at 37oC with 5% CO2. The
composition of the media is shown in Table 5.
Cells growing in log phase (40-60% confluent) were treated briefly with 0.05% trypsinEDTA (Gibco# 25300-054), washed twice at 4oC and re-suspended in Ca++-Mg++ free
(CMF) Hank’s balanced salt solution (HBSS) (Gibco# 14170-112). Live cells were counted
using trypan blue (Corning, 25-900CI) and re-suspended in concentrations of 5000
cells/100ul CMF-HBSS [ ]. For tumor inoculation, 100ul of 4T1 cells were injected in the
left inguinal (fifth) mammary fat pad (MFP).

2.16. Tumor growth and survival analyses
The MFPs were palpated daily, from day 3 of injection until all animals had palpable
tumors. Body weights and tumor volumes were measured every 3 days. Tumor volume
was calculated using the formula (0.5 (short diameter) 2 x long diameter). For survival
analysis, mice were monitored for the signs of morbidity and autopsied at morbidity or
necropsied at death. The days between tumor injection and autopsy or death was
recorded as survival days.
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Table 5. Composition of 4T1 culture media
Reagent name
Dulbecco’s modified eagle medium
(DMEM)
Fetal bovine serum

Supplier

Catalogue

Volume (ml)

Gibco, Grand Island NY

11995-065

500

Atlanta biologics

S11150

50

100 X MEM Vitamins

Gibco, Grand Island NY

11120-052

10

200 mM L-Glutamate

Gibco, Grand Island NY

25030-081

5

100 mM Sodium pyruvate

Gibco, Grand Island NY

11360-070

5

50 X MEM Amino acids

Gibco, Grand Island NY

11130-051

5

100 X Non essential amino acids

GE Healthcare

SH30238.01

5

50 mg/ml Gentamycine

Gibco, Grand Island NY

15750-060

2.5
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2.17. Metastases analyses:
Groups of mice were autopsied on day 35 post tumor injection for single time point
metastases analyses in two independent experiments. For overt metastases (overt-met)
analyses, whole organs (lungs, livers, hearts and kidneys) were fixed in Bouin’s fixative
for 24 hours prior to counting of the total number of nodules of overt-mets per organ
(n=10/group/experiment, two independent experiments) using a Stereoscope (Zeiss #
Stemi DV4). After overt-met analysis, heart and kidneys were sectioned longitudinally
(including cephalo-caudal regions of each organ). One-half of the organ was embedded,
and cross-sectioned from the deeper tissue side. A piece of liver and spleen were also
embedded and sectioned. Both ovaries and a half of the CMGs were collected and fixed
in 10% normal buffered formalin (NBF) (Fisher # SF100) for 24 hours at RT prior to
embedding and cross-sectioning. Histological analyses for the presence of metastatic foci
in cross/longitudinal sections of organs was performed in all animals from a single
experiment (n=10/group). The histologically analyzed metastatic foci were abbreviated as
histologically-observed metastases (HO-met). All the tissues were sectioned at 4 µm
thickness and stained with H & E for HO-met analyses. The number and size of HO-met
foci per cross-section of heart, kidney and ovaries were evaluated quantitatively using
Image-J software. The presence of metastases in liver and spleen was confirmed by
scanning sections of the tissue at 200x and 400x. Individual tumor cells (ITC) were
identified based on 4T1 tumor cell morphology.

2.18. Bone metastasis analyses:
For bone metastasis analyses, both hind limbs were collected and fixed in 10% NBF for
24 hours, washed in 1x PBS, and muscles removed to isolate the femurs and tibias. The
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bones were decalcified by immersing them in decalcification solution (15% EDTA in 1X
PBS, pH 7.6) at 4oC until the bones became soft enough to section (10-15 days). Laterallongitudinally sectioned femurs-tibias (4 µm) were stained with H & E. Bone metastases
were analyzed in medullary spaces of epiphysis/metaphysis and diaphysis of the femurs
and the epiphysis/metaphysis areas of the tibia and presented as the number and size of
HO-met present per longitudinal section of femurs-tibias.

2.19. Apoptotic nuclei detection in tumor tissue (Colorimetric method)
Apoptotic nuclei were detected using “In situ Apoptosis Detection Kit” (ab206386, Abcam)
as per the kit’s protocol. Briefly, deparafinized and rehydrated tumor sections were
permeabilized with Proteinase K for 20 minutes followed by washing in 1X TBS.
Endogenous peroxidases were inactivated by treating the sections with 3% H2O2. Then
the sections were treated with Terminal deoxynucleotidyl Transferase (TdT) and detected
with a conjugate and DAB chromogen based method, and counter-stained with methyl
green. Apoptotic nuclei were analyzed in the subcapsular areas (oxic) of the tumors and
evaluated in 10 HPF per each tumor sample.

2.20. Statistical Analyses:
Results are expressed as a mean ± standard error of the mean (SEM) for animal weights,
liver/MG/abdominal fat weights of NTB studies and IHC quantification data, and were
compared between the dietary groups by Student’s t-test for independent samples. The
differences in the incidences of metastases was analyzed by Fisher’s exact test for the
differences in the proportions between the experimental groups. Metastases analyses
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data including organ, weights, metastases number, and HO-met area were presented as
median values and compared by Mann Whitney’s test. Longitudinal plots for change in
body weights and tumor growth and dietary consumption were based on the mean ± SEM
value for each time point, and the curves between the dietary groups were compared by
repeated measures analysis (two-way). Graphs were plotted using Sigma Plot or Graphpad Prism. Survival analysis was presented as Kaplan-Meier plots and statistical
significance was analyzed using the log-rank test. All data were analyzed using SPSS for
statistical significance. For qRT-PCR data, dCt values were compared by independent
sample t-test. In all instances, differences where p<0.05 were considered to be statistically
significant.
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Chapter 3:
Long-Chain Omega-3 Polyunsaturated Fatty Acids Modulate
Mammary Gland Composition and Inflammation2

3.1. Abstract
Studies in rodents have shown that dietary modifications as MGs develop, regulates
susceptibility to mammary tumor initiation. However, the effects of dietary PUFA
composition on MGs in adult life, remains poorly understood. This study investigated
morphological alterations and inflammatory microenvironments in the MGs of adult mice
fed isocaloric and isolipidic liquid diets with varying compositions of ω-6 and LC-ω-3FA
that were pair-fed. Despite similar consumption levels of the diets, mice fed the ω-3 diet
had significantly lower body-weight gains, and abdominal-fat and mammary fat pad (MFP)
weights. Fatty acid analysis showed significantly higher levels of LC-ω-3FAs in the MFPs
of mice on the ω-3 diet, while in the MFPs from the ω-6 group, LC-ω-3FAs were
undetectable. Our study revealed that MGs from ω-3 group had a significantly lower ductal
end-point density, branching density, an absence of ductal sprouts, a thinner ductal
stroma, fewer proliferating epithelial cells and lower transcription levels of estrogen
receptor 1 and amphiregulin. An analysis of the MFP and abdominal-fat showed
significantly smaller adipocytes in the ω-3 group, which was accompanied by lower
transcription levels of leptin, IGF1, and IGF1R. Further, MFPs from the ω-3 group had
significantly decreased numbers and sizes of crown-like-structures (CLS), F4/80+

2

A part of this chapter is derived from previously published original article: Saraswoti Khadge,
Geoffrey M. Thiele, John Graham Sharp, Timothy R. McGuire, Lynell W. Klassen, Paul N. Black,
Concetta C. DiRusso, and James E. Talmadge, “Long-Chain Omega-3 Polyunsaturated Fatty
Acids Modulate Mammary Gland Composition and Inflammation,” Journal of Mammary Gland
Biology and Neoplasia, Volume 23, Issue 1-2, pp 43-58, June 2018.
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macrophages and decreased expression of proinflammatory mediators including Ptgs2,
IL6, CCL2, TNFα, NFκB, and IFNγ. Together, these results support dietary LC-ω-3FA
regulation of MG structure and density and adipose tissue inflammation with the potential
for dietary LC-ω-3FA to decrease the risk of MG tumor formation.
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3.2. Introduction

A growing body of evidence suggests a linkage between MG development and diet [251]
that can also modify breast cancer risk [252]. The majority of studies into dietary PUFA
regulation of MG development have been undertaken with in utero, fetal, post-natal and
prepubertal manipulated rodents but are rarely undertaken in adult mice. These studies
have shown that feeding a LC-ω-3FA (fish oil)-containing diet reduces the number of
terminal end buds (TEB), which are a marker of MG development [114, 253, 254]. Indeed,
rodent studies have suggested that ω-6 and ω-3 PUFA have opposing effects on TEB
formation, with ω-3 PUFA reducing the number of TEBs [124, 251, 254] and MG-density
[255], while high ω-6 PUFA diets reduce the differentiation of TEBs to alveolar buds [256].
During puberty, the majority of TEBs differentiate into terminal ducts or alveolar buds,
while lateral branching of MG ducts occurs post-pubertal. As tumor initiation typically
occurs post pubertal, it is critical to study the effect of PUFA on MG differentiation in adult
mice.

Further, it is critical that studies into dietary regulation of MG development be

undertaken using isolipidic diets differing only in PUFA composition [254]; specifically, the
presence or absence of LC-ω-3FA. It is clear that dietary PUFA composition can regulate
carcinogenesis and tumor progression [257]; however, the potential for dietary epigenetic
modification of molecular targets, in early life, requires additional investigation [258] as do
the effects on post-pubertal MG structure and composition
MFPs in rodents are comprised of epithelial cells in the MG (or ductal tree), and adipose
tissue, stroma and extracellular matrix which provides physical support for the MG ductal
network [259]. Recently, mammary adipocytes have also been shown to have an active
role in the chronic inflammation [260] that is associated with adipocyte IL6 secretion, and
likely plays a regulatory role in mammary cancer induction and progression [189, 261].
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Adipocytes within the MFP contribute to the regulation of MG development. For example,
in the absence of mammary fat in A-ZIP/F-1 transgenic mice, abnormal MG development
occurs [262]. MG adipocytes also regulate changes in mammary tissue during pregnancy,
lactation, and involution, via local signals between mammary epithelium and adipocytes
[261].
Emerging research suggests that the timing of PUFA exposure is critical to the increased
risk of mammary cancer [263]. As MG development is age-dependent, specifically during
puberty, most studies to date have used pre-pubertal exposure [264, 265]. These studies
have demonstrated that pre-pubertal ω-3 PUFA incorporation into the MG regulates the
morphological development of the MG during puberty [265], and reduces mammary
tumorigenesis [118]. However, the role of dietary LC-ω-3FA exposure in post-pubertal life,
and its regulation of the MG stromal microenvironments and morphogenesis is little
studied.
Based on these observations, we examined the hypothesis that dietary LC-ω-3FA
regulates mammary gland morphology. We report that in the absence of dietary LC-ω3FA the FA composition within the adipose tissue of MG varies, resulting in local-regional
inflammation and increased ductal branching density and mammary epithelial cell
proliferation, all of which may potentially contribute to MG carcinogenesis.
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3.3. Results
3.3.1. Food consumption, body weight, and MG and abdominal fat weights:
Pair-feeding was undertaken, as described previously [266], to assure isocaloric and
isolipidic consumption. To acclimate the mice to a liquid diet, the first five days of feeding
was ad libitum. During this time, average liquid diet intake was assessed daily, with the
observation of increased diet consumption of the ω-6 diet. Based on this observation, the
ω-3 diet consumption was used as the baseline for pair feeding. During this five-day
period of ad libitum feeding the ω-6 group of mice gained more weight than the ω-3 group
in association with increased liquid diet consumption. Following the initiation of pair
feeding, on day 6, no significant differences in food intake occurred between the dietary
groups. (Fig. 8A). The initial body weights were comparable between the dietary groups.
However, mice (n=20) on the ω-3 diets had a significantly lower body weight gain
throughout the study (Fig. 8B), despite the use of isocaloric diets. The weights of the
abdominal fat in the mice on the ω-3 diet were 45% lower (Fig. 8C) and 42% lower as
abdominal fat weight relative to the body weight (Fig. 8D) compared to the ω-6 group (n=8)
(both p<0.05). Similarly, the weight of the fourth (left inguinal) MGs were assessed after
the mice were fed the diets for 20 weeks (n=10). Significant decreases in the MG weights
(-43%) (Fig. 8E) and MG weight relative to the body weight (-41%) (Fig. 8F) were observed
in the mice on the ω-3 diets compared to the MGs from the mice receiving the ω-6 diets
(p<0.05) (n=10).
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Figure 8. Effects of LC-ω-3FAs on body weight, MG weight, and abdominal fat
deposits

Mice were pair-fed omega-6 (ω-6) and omega-3 (ω-3) PUFA diets for 10 - 20 weeks
[n=20/group]. The average amount of diet consumed/day (A). Differences in percent
changes in body weights between the pair-fed groups compared by a repeated measure
test (B). Differences in abdominal adipose tissues deposits (C) [n=10/group], and
abdominal fat weight relative to the body weight (D). Weights of the fourth rear MG at the
age of 30 weeks (E). MG weight relative to body weight (F) [n=10/group].
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3.3.2. Modulation of MG, FA profile by the ω-3 versus ω-6 isolipidic PUFA diets:
The FA composition of the diets and MFPs are shown in Table 6. There was a significant
effect of the dietary FA composition on the lipid profile of the MFPs from mice fed the diets
for 10 weeks. The ratio of ω-6:ω-3 FA of the ω-6 and ω-3 diet were 21:1 and 0.7:1
respectively. The ω-6 diet did not have detectable levels of LC-ω-3FA such as EPA and
DHA, which were major sources of ω-3FA in the ω-3 diet. Consistent with the dietary FA
composition, significantly higher levels of ω-3FAs such as LNA (0.7 ± 0.2), EPA (11.1 ±
1.2) and DHA (7.5 ± 0.6) µg/mg were observed in the MFPs of mice fed the ω-3 diet. In
contrast, all ω-3FAs were below the detection levels in the MFPs of the ω-6 diet-feddietfed mice. The levels of ω-6FAs were not significantly different between mice fed ω-6 and
ω-3 diets, nor in the MFPs from mice fed the respective diets. However, a lack of Lc-ω3FAs in the ω-6 diet significantly increased the ratio of ω-6:ω-3 FA in MFPs from the mice
fed the ω-6 diet. Besides PUFA, the levels of total saturated fatty acid (SFA) were
increased (1.5 fold), and oleic acid (a major monounsaturated fatty acid from olive oil) was
decreased (1.5 fold) in MFPs from mice fed a ω-3 diet compared to the levels in MFP from
the ω-6 diet group. The total levels of FAs were similar between the ω-6 and ω-3 diets
and not significantly different between the MFPs from the mice fed the diets.
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Diet
(FA µg/ml of
diet)
ω-3
ω-6

Fatty Acid (FA) Name
Carbon
chain
Saturated fatty acid (SFA)
Tetradecanoate
Hexadecenoic
Octadecenoic
Monounsaturated fatty acid (MUFA)
9-Hexadecenoic

Mammary fat pad
(FA µg/mg of MFP ±
SEM)
ω-3
ω-6

C14:0
C16:0
C18:0

0
1.53
0.28

0.2
3.02
0.76

6.3 ± 0.7
105.3 ± 8.8 *
19.8 ± 2.5

2.8 ± 0.6
68.5 ± 8.3
13.9 ± 2.0

C16:1

0

0.2

18.2 ± 1.4

9-Octadecenoic

C18:1

3.77

15.62

166.1 ± 7.0 *

cis-13-Eicosenoic

C20:1

0.7

0

9.2 ± 0.5 *

12.3 ± 2.4
252.2 ±
31.4
3.0 ± 0.5

13-Docosenoic acid
Polyunsaturated fatty acid (ω-6 FA)
cis-8,11-Octadecadienoic (Linoleic)
cis-5,8,11,14-Eicosatetraenoic (Arachedonic
acid; AA)
Polyunsaturated fatty acid (ω-3 FA)
cis-9,12,15-Octadecatrienoic acid (Linolenic)

C22:1

0.25

0

1.3 ± 0.1 *

0.0 ± 0.0

C18:2

6.67

5.03

71.3 ± 3.3

55.2 ± 7.4

C20:4

0.51

0

0.7 ± 0.2

0.2 ± 0.2

C18:3

0.14

0.24

0.7 ± 0.2 *

0.0 ± 0.0

7,10,13-Eicosatrienoic

C20:3

0

0

0.7 ± 0.2 *

0.0 ± 0.0

cis-5,8,11,14,17-Eicosapentaenoic (EPA)

C20:5

7.52

0

11.1 ± 1.2 *

0.0 ± 0.0

cis-4,7,10,13,16,19-Docosahexaenoic (DHA)

C22:6

2.64

0

7.5 ± 0.6 *

0.0 ± 0.0

cis-4,7,10,13,16-Docosapentaenoic acid
Total omega 6 FA level
Total omega 3 FA level

C22:5

0.26
7.18
10.56

0
5.03
0.24

1.7 ± 0.1 *
72 ± 3.5
21 ± 2.0 *

Total MUFA level

4.72

15.82

193.5 ± 8.7

Total SFA level

1.81

3.98

131.4 ± 11.9*

Total FA mass per mg/ml of MFP/diet

24.27

25.07

420.3 ± 20.1

Ratio of total ω-6 FA to ω-3 FA (ω-6:ω-3)

0.7:1

21:1

3.4:1

0.0 ± 0.0
55.5 ± 7.3
0.0 ± 0.0
267.5 ±
32.6
85.3 ±10.0
442.2 ±
47.0
55.5:0
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Table 6. Fatty acid profiles of the diets and mammary fat pads
MFPs were collected from the mice fed respective diets for 10 weeks. (n=5/group). The
ready to use diets were used for fatty acid (FA) analysis. FA profile was measured by gas
chromatographic mass spectrophotometry (GC-MS) analysis. The results were expressed
as microgram of fatty acid per milligram of MFP tissue.
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3.3.3. Dietary PUFA regulation of mammary ductal branching
A histopathologic analysis of the inguinal MFPs of mice fed the diets for 20 weeks, was
performed to evaluate structural/morphological alterations in MGs. (n=10). A significant
morphological difference was observed in the ductal tree network and the total glandular
area between the two dietary groups (Fig. 9A and 9B). The total area of the MG tree of
MFPs from ω-3 fed mice was 20% smaller (143.3 ± 10.4 mm2) relative to the area of the
MFPs from ω-6 fed mice (177.6 ± 11.8 mm2) (p<0.05) (Fig. 9C). A comparison of the
quantitative differences in the ductal tree compared the number of ductal termini (endpoint density) and the extent of lateral branching (branching density). Since the mice used
in the study were post-pubertal adults, TEBs had differentiated into terminal ducts, alveolar
buds or end buds and we use the term ductal termini for these end structures. MFPs from
mice fed the ω-3 diet had 63% fewer ductal termini/HPF (25.9 ± 1.9) compared to the
numbers in the MFPs from ω-6 diet-fed mice (70.9 ± 5; p<0.05) (Fig. 9D). Similarly, there
were significantly fewer lateral branches per mm of primary ducts (0.7 ± 0.1) (a 60%
decrease) and secondary ducts (1.3 ± 0.1) (a 65% decrease) compared to the numbers
in each mm of primary duct (1.7 ± 0.1) and secondary ducts (3.8 ± 0.2) of MFPs from the
ω-6

diet-fed group (Fig. 9E).

In the microscopic analysis, there was a significant

difference in the ductal morphology, including the presence of ductal sprouts, along the
ductal wall in MFPs from ω-6 diet-fed mice, which were absent in the ducts of the MFPs
from ω-3 diet-fed mice (Fig. 9F-9G). Despite the differences in lateral branching, there
was no significant differences in the length of the primary ducts in mice fed the ω-3 diet
(25.9 ± 1.2 mm) compared to the primary ductal length (28.1 ± 1.6 mm) in MFPs from ω6 diet-fed mice. Similarly, the average lymph node (LN) area (2.7 ± 0.1 mm 2) of the ω-3
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diet-fed mice were not significantly different from the LN area (2.7 ± 0.3 mm2) of ω-6 dietfed mice.
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Figure 9. Effects of LC-ω-3FAs on MG ductal branching and morphology
MGs were analyzed for ductal termini (end-point density), lateral branching (branching
density) and sprouts in mice fed the diets for 20 weeks [n=10/group]. Whole mounts of
carmine-alum stained fourth rear, MGs from 30-week old ω-3 diet-fed mouse (A) and ω-6
diet-fed mouse diets (A) [n=10]. MGs were analyzed for the number (B). The total ductal
tree area (C), number of ductal terminus (D) and number of lateral branches/mm of primary
or secondary ducts (E). High power analysis of ductal branches showing absence of
sprouts in MFP of ω-3 diet-fed mouse (F) and presence of sprouts (shown by arrows) in
MFP of ω-6 diet-fed mouse (G). Images of (A and B) are 12.5x and (F and G) are 40x
magnification. [*=p<0.05]
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3.3.4. Dietary PUFA regulation of ductal epithelial cell proliferation
The ductal histology of the MFPs from mice, fed each of the diets for 20 weeks, were
analyzed using Mason’s trichrome stain and proliferating epithelial cells assessed by Ki67
staining. As shown in a representative Mason’s trichrome stained MG duct (Fig. 10A), we
analyzed ductal lumen (DL) area, ductal epithelium (DE) area and ductal connective tissue
(blue stained) or ductal stroma (DS) area. The ω-3 diet feeding for 20 weeks (Fig. 10B –
10E) resulted in a 34% decrease in the DE area (1883.3 ± 145.0 µm2) and a 54% decrease
in the DS area (3034.5 ± 377.9 µm2), compared to the DE area (2863 ± 189.6 µm2) and
the DS area (6,593.1 ± 493.9 µm2) respectively from mice fed the ω-6 diets for the same
duration (p<0.05). Further, the effects on ductal size, based on a comparison of the ductal
lumen (DL) area between the dietary groups, documented that mice fed a ω-3 diet had
42% smaller ducts with an average DL area of 1,497.1 ± 243.6 µm 2, compared to the
MFPs from ω-6 fed mice, (2,568.7 ± 380.9 µm2) (p<0.05). As there were significant
differences in ductal size, we further evaluated the area of DE and DS relative to the DL.
The results showed that the DS relative to DL were 33% smaller in the MFPs of ω-3 dietfed mice (3.6 ± 0.3) compared to the same in MFPs of the ω-6 group (5.3 ± 0.5) (Fig. 10F)
(p<0.05). However, there was no significant difference in the DE relative to DL area
between the dietary groups (Fig. 10G). These results suggest that the differences in ductal
connective tissue were independent of ductal size; however, the size of ducts between the
dietary groups might affect the DE area. Thus, proliferating epithelial cells were evaluated
to confirm the effect of dietary PUFA on DE, which showed there were 88% fewer
proliferating cells in the DE of ω-3 diet-fed mice (1 ± 0.5) compared to ω-6 diet-fed mice
(8.3 ± 3.1) (Fig. 10H – 10J) (p<0.05). The regulation of estrogen signaling is one
mechanism of epithelial proliferation in MG ducts. To address this, we assessed the
relative mRNA expression of amphiregulin (AREG) and estrogen receptor-1 (ESR1) as a
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potential mechanism for the dietary PUFA regulation of DE cell proliferation. These studies
revealed that the MFPs from mice fed the ω-6 diet had 3.1-fold and 1.4-fold higher
transcription levels of AREG and ESR1, respectively, compared to MFPs from agematched, isocaloric ω-3 diet-fed mice (Fig. 10K). However, there were no differences in
the levels of progesterone receptor and prolactin mRNA levels were below the level of
detection (data not shown).
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Figure 10. Effects of LC-ω-3FAs on MG ductal histology
Mammary ductal histology analyzed in trichrome stained MFP sections, using 200x
images (n=10fields/mouse from five mice/group). In each duct, the area of lumen marked
as (DL), epithelium (DE) and stroma or connective tissue (DS) were analyzed as illustrated
(A). Masson’s trichrome stained MFP from ω-3 diet-fed mice (B) and ω-6 diet-fed mice
(C). The difference in the area of ductal stroma (D), ductal epithelium (E), stroma relative
to luminal area (F) and epithelial area relative to luminal area (G) were analyzed. MFP
sections stained with the anti-Ki67 antibody were analyzed for Ki67+ proliferating ductal
epithelial cells (H). Images showing Ki67+ cells in ducts of MFP from ω-3 diet-fed mouse
(I) and ω-6 mouse (J). Relative mRNA expression (fold change compared to the ω-3
group) of ESR1 and AREG in MFP of mice fed the ω-6 diet for 20 weeks (n=15/group) [#
=p<0.05 compared to the ω-3 group]. Images were taken at a magnification of 200x (A
and F) [*=p<0.05]
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3.3.5. Dietary PUFA regulation of MFP and abdominal fat adipocytes

A comparison of adipocyte histology in the MFPs and abdominal fat deposits of mice, fed
the two diets for 20 weeks, revealed (Fig. 11) that adipocytes in the MFPs of mice fed the
ω-3 diet, were approximately 45% smaller compared to MFP adipocytes from ω-6 diet-fed
mice (p<0.05) (Fig. 11A and 11B). The increase in MFP adipocyte size was validated by
an analysis of the adipocyte number/100x image, which documented that the adipocyte
number/field was increased 67% in the MFPs of the ω-3 diet-fed group, compared to the
ω-6 diet-fed mice (Fig. 11A and 11B) (p<0.05). Consistent with variations in MFP
adipocyte sizes, an analysis of adipocytes size and the number of adipocytes/100x field
in abdominal fat showed that mice fed the ω-3 diet had 53% smaller adipocytes and 113%
more adipocytes per 100X field compared to isocaloric ω-6 diet-fed mice (Fig. 11C and
11D) (p<0.05). We also assessed potential mechanisms for the differences in adipocyte
size. This focused on alterations in fat storage/metabolism in the MFP and abdominal fat
between the dietary groups by analyzing the relative mRNA expression of genes
associated with fat metabolism. The results revealed that mice on the ω-6 diet had
significantly increased mRNA expression for leptin (LEP) levels (3.1-fold), insulin-like
growth factor-1 (IGF1) (1.8-fold) and IGF1 receptor (IGF1R) (1.7-fold) compared to the
MFPs from mice fed the ω-3 diet (Fig. 11E) (p<0.05). Similarly, mRNA analysis of the
abdominal fat showed that mice fed an ω-6 diet had significantly increased mRNA levels
of Lep (5.1-fold) and IGF1 (1.9-fold) but did not differ in the expression of IGF1 (0.6-fold)
compared to the mice fed diets high in ω-3 FA. (Fig. 11F).
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Figure 11. Effects of LC-ω-3FAs on adipocytes histology and metabolic gene
expression
Analysis of adipocytes in H & E stained mammary fat pad (MFP) (A) by measuring an
average adipocyte size (area) and the number of adipocytes per 100x field (B) [10
fields/mouse in five mice]. H and E stained sections of abdominal fat (C), adipocyte size
and the number of adipocytes per 200x field (D) [n=10 fields/mouse in five mice]. Relative
mRNA expression (fold change compared to ω-3) of leptin, IGF1, and IGF1R in MFP (E)
[n=15/group] and an abdominal fat of mice fed an ω-6 diet for 20 weeks (F) [n=8/group] [#
=p<0.05 compared to ω-3 group]. Images were taken at a magnification of 100x (A and
C) [*=p<0.05].
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3.3.6. Dietary PUFA regulation of adipose tissue inflammation
The MFPs from groups of mice on the two FA diets for 10 and 20 weeks were assessed
for CLS, macrophage infiltration and expression of inflammatory cytokines (Fig.12). The
number of CLS per 100 adipocytes and infiltrating immune cells/CLS were analyzed in H
& E stained MFP sections (Fig. 12A). Mice on the ω-3 diet had 64% fewer MFP-CLS (11.0
± 0.8) compared to MFP-CLS (30.7 ± 3.2) in the ω-6 diet-fed mice (Fig. 12A and 12B)
(p<0.05). Similarly, there was a 31% decrease in the number of infiltrating macrophages
per CLS i.e. (2.8 ± 0.4) compared to the number of infiltrating macrophages (4.0 ± 0.6)
cells/CLS in the MFPs from the ω-6 diet-fed mice (Fig. 12A and 12C). Macrophage
infiltration of MFPs was confirmed by F4/80+ staining (Fig. 12D). This analysis revealed
that mice on the ω-3 diet had 60% fewer adipocytes with at least one adjacent F4/80+
cell/s (1.5 ± 0.1) compared to adipocytes (5.2 ± 0.2) in the MFPs from ω-6 diet-fed mice
(Fig. 12D and 12E) (p<0.05). As high levels of inflammatory mediators have been
associated with the increased numbers of CLS in adipose tissue [260], we analyzed the
mRNA levels of inflammatory cytokines by qRT-PCR. These studies revealed that the
MFPs of mice fed an ω-6 diet, had higher levels of mRNA for Prostaglandin- Endoperoxide
Synthase 2 (Ptgs2) (2.3-fold), interleukin-6 (IL6) (2.0-fold), C-C motif chemokine ligand 2
chemokine (CCL2) (2.3-fold), interferon gamma (IFNg) (2.8-fold), NFkB (1.5-fold) and
TNFα (1.7-fold) in the MFPs from ω-6 diet-fed mice compared to ω-3 diet-fed mice (Fig.
12F).
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Figure 12. Effects of LC-ω-3FAs on adipose tissue inflammation
Analysis of crown-like-structures (CLS) in H & E stained mammary fat pad (MFP) (A) [n=10
fields/mouse from five mice/group]. Number of CLS per 100 adipocytes (B) and the
number of inflammatory cells per CLS (C) were compared. Macrophages infiltration
analyzed in F4/80-stained MFP sections (D) [n=10 fields/mouse in five mice]. The number
of adipocytes surrounded by at least one F4/80+ cell/s were counted in 200x field (E)
Relative mRNA expression (fold change compared to ω-3) of inflammatory mediators,
such as ptgs2, IL6, CCL2, IFNγ NFκB and TNFα in MFP of mice fed the ω-6 diet for 20
weeks (F) (n=15/group) [# =p<0.05 compared to ω-3 group). Images were taken at a
magnification of 400x (A) and 200x (D) respectively. [*=p<0.05]
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3.4. Discussion
In this study, we provided moderate fat, isocaloric diets to pair-fed groups of mice for 10
or 20 weeks of adult life. Our goal was to assess the effects of dietary LC-ω-3FAs on the
structural, inflammation and morphological alterations and differentiation of post-pubertal
murine MGs. These studies demonstrated that a post-pubertal exposure to LC-ω-3FAs
modulates MG FA composition, lateral branching, ductal epithelial proliferation and
adipose tissue inflammation relative to the mice fed ω-6 diet, which contained high levels
of ω-6FA and oleic acid but lacked LC-ω-3FAs.
A difference in dietary consumption (likely due to palatability) may be a factor when
analyzing effects specific to the dietary composition, independent of total caloric intake or
obesity [266]. We report that mice fed an ω-6 diet consumed significantly more liquid diet
compared to the ω-3 diet during a 5-day initial ad libitum feeding period. This difference
was subsequently controlled by pair feeding based on consumption of the ω-3 diet.
Despite pair feeding and isocaloric and isolipidic diet consumption, the inclusion of LC-ω3FA in the diet significantly decreased body weight gains and abdominal fat deposits (45%) in mice. These results are consistent with prior studies comparing diets high in ω-3
or ω-6FA [265, 266]. In addition, studies have reported a 50% reduction in retroperitoneal
fat mass [267], and a 25% reduction in epididymal fat deposits in mice fed a high ω-3FA
diet [268]. This suggests that dietary LC-ω-3FA are associated with the regulation of fat
mass via stimulatory or inhibitory roles of ω-6FA and ω-3FA metabolites respectively in
the differentiation of adipocytes [269, 270]. Further, increasing β-oxidation and
suppression of lipogenic enzymes, such as leptin in adipose tissue, may provide potential
mechanisms for reducing body fat by ω-3FA exposures [271, 272].
To analyze the effects of dietary PUFA in MGs, we compared MFP weights of the fourth
MG, after feeding the diets for 20 weeks, and observed 43% lighter MFPs in mice on a ω-
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3 diet as compared to the ω-6 diet group. This was associated with the novel observation
of a significant higher incorporation of LC-ω-3FAs in the MFPs from ω-3 diet-fed mice as
compared to the MFPs from ω-6 mice. The ω-6 and ω-3 diets used in the present study
contained a ω-6:ω-3 ratio of 21:1 and 0.7:1 respectively. The only ω-3FA in the ω-6 diet
was ALA, whereas LC-ω-3FAs such as EPA and DHA were prominent ω-3FAs in the MGs
of the ω-3 diet-fed mice (Table 2). Thus, our results document that the incorporation of
LC-ω-3FAs in MFP depends directly on the dietary intake rather than in vivo conversion
to ω-3FAs from dietary ALA. We note that dietary ALA can be endogenously converted to
LC-ω-3FAs in mammals; however, the process is not efficient and <5% of ALA consumed
is converted to LC-ω-3FAs in humans [273]. The observation might explain the lack of
LC-ω-3FAs in the MFPs of mice fed the ω-6 diet. The LC-ω-3FA levels of mammary
adipose tissue might be of clinical relevance as the breast adipose tissue from breast
cancer patients has significantly higher and lower levels of ω-6FA and LC-ω-3FA
respectively [274, 275]. Besides the differences in ω-3 and ω-6FA composition between
the diets, the level of oleic acid was significantly higher in ω-6 diet and in MFPs of mice
fed ω-6 diet compared to the levels in the ω-3 group. However, there is no significant data
on oleic acid regulation of inflammation and mammary gland density published rather;
oleic acid is known to prevent inflammation in adipose tissue [276]. Thus, we believe the
alterations in outcomes between the dietary groups potentially be due to the differences
in LC-ω-3FA levels between the diets.
Although MFP weights may be a gross indicator of MG density in animal models,
significant differences in MG adiposity might influence the MG weights. Pubertal exposure
to HF diets has been shown to result in heavier MGs and stunted development in C57BL/6
mice due to higher adiposity [264], while in-utero exposure to an HF-ω-6 diet increased
the TEB number and enhanced susceptibility to carcinogenesis in BALB/c mice [277]. Our
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data suggest that the observed difference in MFP weight might be the result of combined
effects by the difference in MFP adipocyte size and alterations in MG glandular structure
and composition including ductal epithelial cells proliferation and leucocytes infiltration
between the dietary groups. MG development is age-dependent such that MGs undergo
extensive modeling and remodeling during fetal development, puberty and pregnancy.
The majority of dietary intervention studies use pre-pubertal mice that have a correlation
between a higher number of TEBs and an increased risk of cancer [118, 264, 277].
However, in this study we used post-pubertal mice whose TEBs had differentiated into
terminal ducts. Despite the post pubertal status, we observed that feeding an ω-3 diet in
early adulthood (10-30 weeks of age) was associated with a decreased number of ductal
termini, lateral branching of primary and secondary ducts, and a different total ductal area
compared to isocaloric, isolipidic ω-6 diet-fed mice. Previous studies, based on ω-3 diets
using a LF-ω-3 (16% energy) diet in pre-pubertal mice [118] and offspring of HF-ω-3 (39%
energy) diet-fed mice, had a reduced number of TEB associating with the lower risk of
tumorigenesis compared to same fat level ω-6 dietary group [278]. However, when HF-ω3 (39% energy) were compared to LF-ω-6 (16% energy), the former developed more TEB
and an increase in tumorigenesis compared to the latter, emphasizing the differential
effects of fat-calories versus fat composition of the diets in MG differentiation and
tumorigenesis [118]. Since we used an isocaloric diet and pair-feeding, our observation of
differences are indicative of the regulation of MG structure and morphology by dietary LCω-3FA, independent of caloric intake and obesity. Total ductal tree area and ductal endpoint and branching density represents epithelial and stromal mass of MG in animals,
which can be considered equivalent to breast density as shown by mammographic scans
in humans [100, 279]. Animal and clinical studies showed MG or breast density as a
predictor of carcinogenic response or breast cancer risk [280, 281], while an increase in
plasma DHA was associated with a decreased breast density in obese, postmenopausal
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women [282]. We did not observe a significant difference in ductal lengths between the
dietary groups, which might be due to the age of the mice (post-pubertal) at the start of
the diet, since mice at this age have already gained full primary duct length, as a result of
the extension which occurs mostly during pubertal age [265]. Rather, the effects of the
diets alter the frequency of lateral branches, ductal terminus and formation of ducts
(shown by a presence of sprouts in ducts in ω-6 diet-fed mice) and likely the total epithelial
mass of MG. Further, future studies will need to evaluate the effects of dietary PUFA
composition in mammary tumor growth and metastasis.
The observation of structural and morphological alterations in MG ductal trees was
confirmed by immune-histological analysis of MG ducts. Mice fed the ω-3 diet had
significantly smaller ducts, and a thinner layer of epithelium and connective tissue (stroma)
in the ductal wall, as compared to the ducts from the ω-6 group. Since there was a
difference in ductal size, we further evaluated those parameters relative to the ductal
luminal area and found that the difference in the stroma was independent of ductal size,
but the differences in epithelium thickness might be secondary to the ductal size. However,
a significant decrease in proliferating ductal epithelial cells in the ω-3 group suggests a
regulatory role of LC-ω-3FAs in mammary epithelial cells proliferation. Our observations
of an increased ductal stroma and proliferating ductal epithelial cells in MFPs from mice
receiving the ω-6 diet were in agreement with previous reports that showed higher stromal
density [283] and proliferating epithelial cells [284] in mammary ducts of mice fed a high
fat-diet. However, effects of isocaloric PUFA diets and/or dietary LC-ω-3FAs in ductal
stromal tissue have not been reported before.
Evidence from clinical studies showed that women with cytological atypia had a higher
ratio of ω-6:ω-3FA in breast tissue [285], which was associated with a reduced number of
Ki-67+ cells with increased levels of LC-ω-3FAs in erythrocyte phospholipids [286].
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Further, animal studies have shown that pre-pubertal exposure to low-fat (LF)-ω-3 was
able to reduce chemical induced tumorigenesis [118] and inhibit atypical ductal
hyperplasia at early stages of mammary carcinogenesis [287]. In addition, a recent finding
of the regression of established pre-neoplastic lesions, by combined treatment of fish oil
and tamoxifen and its correlation with tissue levels of LC-ω-3FA, demonstrated preventive
and therapeutic roles of dietary LC-ω-3FAs in MG malignancies [288].
In our studies, we detected estrogen receptors in the MFPs, consistent with prior reports
of their presence on adipocytes and fibroblasts, within MFPs. This supports the critical
role of estrogen receptors in epithelial proliferation, mediated by both endocrine-derived
and locally produced estrogen [261, 289, 290]. We also studied message levels of AREG,
a ligand for epidermal growth factor receptor (EFGR), which is induced by estrogen
binding to ESR1 stimulating the proliferation of mammary epithelium. Further, the
overexpression of AREG has been associated with mammary tumorigenesis [291, 292].
Recent studies have shown estrogen stimulated ductal side branching by enhancing IGFI action, while an overexpression of IGF-I was associated with ductal hyperplasia [293,
294] as observed in our studies. Further, both estrogen and IGF-I are required for
progesterone-mediated formation of mature mammary gland alveoli. Thus our observation
of increased lateral branching, stromal thickness and epithelial proliferation in mice fed the
ω-6 diet might be due to additive effects of IGF-I to estrogen signaling, as shown by
significant higher expression of AREG and ESR1 respectively in MFPs of ω-6 diet-fed
mice. However, as there were no differences in progesterone receptor mRNA expression
in the MFPs. These observations indicate progesterone message levels might have little
effect on lateral branching of the ducts in virgin, nulliparous adult mice.
We also assessed the effects of PUFA on adipocytes, which may regulate MG ductal
morphogenesis. Adipocyte hypertrophy is one mechanism for storing excess energy, and
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has been observed in both omental and subcutaneous fat of obese humans [295], and in
HF, high calorie-fed animals, [296] and genetically susceptible animals [297]. In our
studies, we used moderate fat (MF), isocaloric diets and a pair-fed model in BALB/c mice,
which are known to be less susceptible to obesity [298]. Thus, our observation of
significantly smaller adipocytes in abdominal and mammary adipose tissue from ω-3 mice
suggests differential regulation of lipid metabolism, storage and/or beta-oxidation in
adipose tissue by dietary ω-3 and ω-6FAs [299-301]. Studies showed that ω-6FAs
consumption triggered adiposity in human [302] and rodents [303]

potentially by

promoting pre-adipocyte differentiation or adipogenesis [304] while, DHA was able to
inhibit differentiation to adipocytes and promote lipolysis [305]. In this study, the ω-3 dietfed group had significantly higher number of adipocyte per microscopic field, which further
validates our observation of smaller adipocytes in the ω-3 group. However, since we did
not analyze a total adipocytes number per MFP or abdominal fat, further studies are
required to analyze PUFA regulation of adipogenesis in this pair-fed model. Further, prior
reports have shown that EPA can reduce hypertrophy of abdominal adipocytes [296, 306].
However, the role of LC-ω-3FAs in decreasing MFP adipocyte hypertrophy, have not been
done previously, even though adipocytes have been actively researched for their crucial
role in MG growth, development and carcinogenesis [261].
Adipocyte’ size and fat mass are important determinants in adipokine regulation of energy
homeostasis. Leptin expression increases with adipocyte size [307] and fat mass [308],
while adiponectin (Adipoq) expression is inversely correlated with obesity [309]. However,
the fat deposit distribution depends on the levels of leptin expression [310]. Leptin is a
hormone of satiety; however, elevated plasma leptin levels do not induce a reduction of
food intake nor increased energy expenditure in obese people, due to development of
leptin resistance [311]. Although the mouse strain we used is less sensitive to obesity
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[312], the absence of LC-ω-3FAs in the ω-6 diet led mice to gain adipose tissue resulting
in a significant increase in Lep and no effects on Adipoq expression in abdominal fat tissue
and MFP. Our results in Lep expression are in agreement with prior studies using HF diets
with and without EPA [308, 313], while no effect in Adipoq might be due to dietary FA
levels, mouse strain, or type of adipose tissue analyzed. Fish oil was able to induce
epididymal adipose tissue but not subcutaneous adipose tissue [314]. Besides their role
in lipid homeostasis, leptin levels have been associated with the induction of proinflammatory cytokines [315], and enhanced proliferation of normal and malignant breast
epithelial cells [316].
In addition, we observed that a lack of dietary LC-ω-3FAs significantly enhanced
expression of IGF1 and IGF1R in MFPs and abdominal fat. IGF1 was originally believed
to be exclusively produced by the liver [317], but a recent study [318] showed IGF1
secretion by adipocytes and M2-macrophages. Further, ablation of IGF1R from myeloid
cells results in elevated adiposity, lowered energy expenditure and increased macrophage
infiltration into adipose tissue, and reduced phagocytosis [318, 319]. While IGF1 is
synthesized by MG adipocytes and promotes the growth of ductal epithelium [320],
overexpression of IGF1R can induce mammary epithelial hyperplasia in transgenic mice
(containing human IGF-IR under a doxycycline-inducible MMTV promoter) [321] and is
associated with increased risk of mammary cancer [322]. Our results are consistent with
a prior study, which showed a negative correlation of dietary ω-3FA with plasma IGF1
expression and ductal density [280]. However, the effects of ω-3 in local IGF1 expression
in MG and other adipose tissue have not been previously reported; thus, our results
indicate a need for additional investigation. Further, the similarities in IGF1 expression, in
both MFP and abdominal fat, but differential expression pattern of IGF1R, indicates
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morphological similarities between adipocytes, but potentially different mechanisms of
signaling.
Recent studies suggest that white blood cells, notably macrophages and eosinophils, are
attracted to the end bud [323] and are essential for their development [323]. This finding
raises a question regarding the regulatory role of chronic local/adipose tissue inflammation
in MG pathology. Further, macrophages may also have a role in other attributes of MG
morphogenesis such as lateral branching, terminal ducts, and ductal sprout formation,
potential mechanisms requiring additional study. In the studies reported herein, we
observed that the number/size of CLS and the number of macrophages infiltrating MGs
were significantly lower in MFPs of ω-3 diet-fed mice. CLS is a hallmark of chronic adipose
tissue inflammation, and increased numbers of CLS in the breast (CLS-B) have been
associated with increased risk and poor prognosis of breast cancer patients in both obese
individuals and those with normal BMI [324, 325]. CLS formation has been shown to
enhance the expression of inflammatory cytokines/chemokines potentially further
activating macrophages for clearing of apoptotic adipocytes. We observed significantly
increased expression of Ptgs2, NFkB, IL6, IFNγ, and the macrophage chemoattractant
CCL2 in the MFP of ω-6 diet-fed mice. These findings support an increase in proinflammatory signaling by ω-6 FAs and its metabolite, AA in the MFP microenvironment.
In these studies, the AA levels in the MGs did not differ between the ω-6 and ω-3 diet
groups; however, the MFP from ω-6 diet mice did not have detectable levels of LC-ω-3FA.
Thus, our results suggested that the lack of detectable LC-ω-3FA crucial relative to the
levels of AA for chronic inflammation. Local LC-ω-3FA has been shown to exert antiinflammatory and anti-chemotactic activity regulating adipose tissue inflammation [326].
Further, constitutive expression of CCL2 by mouse mammary epithelium has been
reported to increase stromal density and increase mammary tumor susceptibility [327],
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emphasizing a potential role of chronic inflammation in ductal epithelial proliferation and
carcinogenesis that could be modified by dietary ω-3FAs.
Findings from epidemiological, and animal studies using HF-fed or genetically obese
models have provided contradictory results regarding the role of dietary LC-ω-3FA in the
MG microenvironment and morphogenesis, depending on the age of mice and mixed
effects of dietary calories versus composition. In summary, this research show that dietary
LC-ω-3FA reduces MG density by decreasing ductal end-point density, branching density,
ductal stroma and epithelial proliferation in adult mice. This occurred in an amphiregulinestrogen and IGF-I-dependent manner, potentially by modulating adipocyte metabolism
and adipose tissue inflammation. Further, an absence of detectable levels of LC-ω-3FA,
such as EPA and DHA in MG might be an indicator of inflammation-associated
pathologies. Future, mechanistic studies using tumor models are justified to assess a role
for dietary LC-ω-3FA inhibition of mammary tumor development in adults.

After evaluation of PUFA modulations of MG microenvironments (as the primary site of
mammary tumor), we extended our studies to analyze alterations in hepatic
microenvironments (one of the major metastasis sites by mammary tumor) by dietary
PUFA composition that are discussed in the next chapter (chapter 4).
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Chapter 4:
Dietary Omega-3 and Omega-6 Polyunsaturated Fatty Acids
Modulate Hepatic Pathology3
4.1. Abstract

Recent evidence has suggested that dietary PUFAs modulate inflammation; however, few
studies have focused on the pathobiology of PUFA using isocaloric and isolipidic diets and
it is unclear if the associated pathologies are due to dietary PUFA composition, lipid
metabolism or obesity, as most studies compare diets fed ad libitum. Our studies used
isocaloric and isolipidic liquid diets (35% of calories from fat), with differing compositions
of ω-6 or LC-ω-3FAs that were pair-fed and assessed hepatic pathology, inflammation
and lipid metabolism. Consistent with an isocaloric, pair-fed model we observed no
significant difference in diet consumption between the groups. In contrast, the body and
liver weight, total lipid level and abdominal fat deposits were significantly higher in mice
fed an ω-6 diet. An analysis of the fatty acid profile in plasma and liver showed that mice
on the ω-6 diet had significantly more AA in the plasma and liver, whereas, in these mice
ω-3 fatty acids such as EPA were not detected and DHA was significantly lower.
Histopathologic analyses documented that mice on the ω-6 diet had a significant increase
in macrovesicular steatosis, extramedullary myelopoiesis (EMM), apoptotic hepatocytes
and decreased glycogen storage in lobular hepatocytes, and hepatocyte proliferation
relative to mice fed the diet containing LC-ω-3FAs. Together, these results support PUFA

3
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James E. Talmadge, "Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate
hepatic pathology." The Journal of Nutritional Biochemistry, Volume 52, pp 92-102, Feb. 2018.
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dietary regulation of hepatic pathology and inflammation with implications for enteral
feeding regulation of steatosis and other hepatic lesions.
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4.2. Introduction
Omega (ω)-6 and ω-3 PUFA are essential FAs, which cannot be interconverted in humans
due to a lack of ω-3 desaturase [328]. Besides their role in energy storage and production,
PUFA are important constituents of biological membranes and are precursors to
prostaglandin and pro-resolving lipid mediator pathways [329, 330]. Many lipid mediators
derived from ω-6FA have pro-inflammatory functions [331], whereas; those synthesized
from ω-3FAs have anti-inflammatory properties [332, 333]. Both ω-3 and ω-6FAs are
metabolized by the same enzymes, resulting in signaling molecules with opposing
bioactivities. Studies have suggested that humans evolved on a diet containing
approximately a 1:1 ratio of ω-6:ω-3 PUFA [25]; however, current western diets have a
high ω-6:ω-3 ratio [334]. A diet high in ω-6 PUFAs, such as LA, results in decreased
tissue levels of LC-ω-3FAs, including EPA, DHA [335], and a heightened risk of chronic
inflammatory disease processes [336]. In contrast, a diet containing a low ω-6:ω-3 PUFA
ratio, or one that is supplemented with LC-ω-3FAs, reduces risk factors for chronic
inflammatory diseases, including cardiovascular disease [337, 338], cancer [339, 340],
and obesity [341, 342]. Dietary LC-ω-3FAs can also reduce hepatic inflammation, fibrosis,
and steatosis in non-alcoholic fatty liver diseases (NAFLD), and non-alcoholic
steatohepatitis (NASH) [343, 344].
Although hepatic lipid storage is normal, excessive intrahepatic lipid accumulation (>5.6%
of liver weight) [345] is associated with steatosis, inflammation and cardiometabolic
syndromes. Several mechanisms are involved in the accumulation of intrahepatic lipids,
including increased accumulation of triglycerides in the liver, increased de novo
lipogenesis, and/or reduced clearance and obesity [167]. Approximately 30% of
Americans have a fatty liver [345], and this is increased up to 75% amongst obese
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individuals [346]. Further, hepatic steatosis occurs rapidly with excess calorie
consumption, independent of dietary composition [347]. In contrast, in humans a
hypocaloric diet reduces steatosis [348, 349], suggesting that it is crucial to differentiate
between the effects mediated by total caloric intake versus obesity to understand the role
of dietary composition in the modulation of the hepatic microenvironment. The majority of
studies on hepatic steatosis have used high-fat diets (60% of calories from saturated fatty
acids (SFAs)) and overfeeding to provide an animal model of NAFLD [350, 351]. To date,
little is known about the effects of ω-6 and ω-3FAs dietary composition, independent of
caloric intake on the hepatic microenvironment.
Mature myeloid cells are terminally differentiated and continuously renewed by the
proliferation of committed hematopoietic precursors, such that myelopoiesis is critical to
expand and replenish the myeloid cell pool. Numerous pathologic conditions stimulate
myelopoiesis, including infections, autoimmune and inflammatory conditions, neoplasia
and obesity in association with neutrophilia, splenomegaly and multifocal, hepatic EMM,
i.e. the formation of myeloid tissue outside of the bone marrow [352]. Hepatic EMM is
normal during fetal and early development [144, 150]; however, EMM in adult tissues is
associated with pathological conditions. Hepatocyte apoptosis indicates liver injury and
found significantly increased in patients with NASH [353]. High fat diets have also been
reported to increase the osmotic fragility of red blood cell (RBC) membranes resulting in
decreased RBC counts and hemoglobin concentration [354].
In the present study, we used an isocaloric, isolipidic liquid diet combined with pair feeding
that allows for controlled dietary caloric intake and limited weight changes between
groups. Using this model, we examined the effects of dietary ω-6 and ω-3FAs composition
on hepatic pathobiology and report that dietary PUFA composition regulates hepatic
steatosis, proliferation, apoptosis and EMM using a dietary model containing
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comparatively lower fat calories as a percent of total relative to previously reported studies
[350, 351].
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4.3. Results
4.3.1. Pair-feeding, food consumption and body weight
During the initial 5-day ad libitum diet acclimation period (Fig. 13A), mice on the ω-6 diet
consumed more feed than those in the ω-3-diet group (p<0.05). Therefore, when pairfeeding was initiated on day 6, the average amount of ω-3 diet consumed was used as
the baseline for the ω-6 diet (Fig. 13B). Studies of changes in body weight over time with
the isocaloric and isolipidic diets using a repeated measures test revealed significant
increases in weight in the mice (n=20/group) given the ω-6 diets (Fig. 13C). In part due
to the increased consumption of the ω-6 diet during a brief acclimation period a significant
difference in body weight was observed between the groups on day 5 (Fig. 13D). Similarly,
at the pair-feeding mid points (day 20, and day 40) and at autopsy on day 69 (Fig. 13D)
significant differences in body weights were also observed. Consistent with the higher
body weights at autopsy (20 weeks), mice fed the ω-6 diet had significantly more
abdominal fat (Fig. 13E) and abdominal fat weight relative to the body weight (Fig. 13F),
as compared to ω-3 diet-fed mice. On gross examination of the livers from the ω-3 (Fig.
13G) and ω-6 diet-fed mice (Fig. 13H), livers from ω-6 diet-fed mice were lighter in color
(pink) and significantly smaller than those from the ω-3 diet-fed mice, which were redbrown in color (Fig. 13H). In both groups, liver weights (Fig. 13I) and liver body weight
ratios (Fig. 13J) were significantly lower in mice fed the ω-6 diet.
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Figure 13. Isocaloric and isolipidic diets, pair-fed model and their impact on body
weight
Mice were pair-fed omega- (ω-6) and omega-3 (ω-3) PUFA diets for 10 or 20 weeks.
Experimental design for a pair-fed model (A). Mice were acclimatized to liquid diets by
feeding ad libitum amounts for the first five days. Thereafter, the ω-6 diet group mice were
pair-fed based on the diet consumed by the ω-3 mice on a cage basis on the preceding
day. The average amount of diet consumed/day (B). Differences in percent changes in
body weights between the pair-fed groups [n= 20] compared by a repeated measure test
(C). Body weights before the start of the liquid diet [day 0], at the start of pair-feeding [day
5], on day 20, and day 40, of pair feeding and before autopsy on [day 69] (n=20) (D).
Comparison of abdominal adipose tissues between the groups (E and F) (n=3), based on
abdominal fat weight (E), as well as, fat weight relative to body weight (%) at autopsy (F).
Photographs of representative livers document differences in color and size from mice fed
ω-3 (G) or ω-6 (H) diets. Comparison of liver weight (I) and liver weight relative to body
weight (J) (n=3). * = p < 0.05
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4.3.2. Effect of PUFA diet composition on the lipid profile of plasma and liver
The lipid composition of the plasma and livers were analyzed following autopsy at 10
weeks post dietary initiation (Table-7). These studies revealed an 8-fold higher level of AA
(0.64 µg/µl) in the plasma of ω-6 fed mice. However, as the ω-6 diet contained no AA
(C20:4); the AA is of a metabolic origin from the ω-6FA precursor, linoleic acid (C18:2),
which is contained in both diets. Both of the diets and the plasma of mice on these diets
had a comparable level of C18:2, but AA product:precursor ratio (C20:4/C18:2) was 5.8
fold higher in the plasma of ω-6 diet-fed mice. Further, there was a 2.8-fold higher level of
total ω-6 FAs in the plasma of ω-6 diet-fed mice compared to ω-3 diet-fed mice (p<0.05);
even though both of the diets had comparable amounts of total ω-6 PUFAs. In contrast to
ω-6 FA levels, the ω-3 PUFA, EPA was not detected in the plasma or livers of mice
consuming the ω-6-diet. Similarly, levels of the ω-3FAs, DHA were 2.8-fold lower (0.05
vs. 0.14 µg/µl) in the plasma of mice fed the ω-6 diet (p<0.05). There were also 1.9-fold
and 2.4-fold increases in the level of linoleic acid and AA respectively in the liver, resulting
in a significantly higher level of total ω-6 PUFA in livers of ω-6 diet-fed mice as compared
to ω-3 diet-fed mice (p<0.05). However, the C20:4:C18:2 FA ratio was not significantly
different between the livers of ω-6 versus ω-3 diet-fed mice. Consistent with the plasma
EPA levels, EPA was not detected in the livers of mice fed the ω-6 diet and the DHA
content was significantly (11-fold) lower (1.5 vs. 16.5 µg/mg), compared to mice fed the
ω-3 diet (p<0.05). We note that the mono unsaturated fatty acid (MUFA) content was
significantly higher in the liver, but not in plasma of mice fed the ω-6 diet. Table 2 also has
an analysis of the FA composition of the fish oil used in the diet, which contained 83.2%
of total FAs in the form of ω-3FA (from C20:5 and C22:6) resulting in a ω-6:ω-3FA ratio of
0.7:1 in the ω-3 diet compared to 21:1 in the ω-6 diet. The ω-6: ω-3FA ratios of the plasma
was similar to the dietary ratio.

103

Concentration

Carbon
chain
length
and
double
bonds

Fatty Acid (FA) Name

14:0

Diet (µg/µl)

Plasma (µg/µl ± SEM)

Liver (µg/mg ± SEM)

ω-3

ω-6

ω-3

ω-6

ω-3

ω-6

Fish
Oil
(µg/µl)

Tetradecanoate

0.00

0.20

0.01 ± 0.01

0.00 ± 0.00

0.00 ± 0.00

0.00 ± 0.00

0.00

16:0

Hexadecanoic

1.53

3.02

0.79 ± 0.08

0.79 ± 0.10

12.32 ± 4.12

15.83 ± 1.30

9.65

16:1

9-Hexadecenoic

0.00

0.20

0.00 ± 0.00

0.01 ± 0.01

1.01 ± 0.29

1.42 ± 0.18

0.00

18:0

Octadecanoic

0.28

0.76

0.57 ± 0.14

0.38 ± 0.01

5.18 ± 1.42

5.19 ± 0.21

0.00

18:1

9-Octadecenoic

3.77

15.62

0.20 ± 0.01

0.35 ± 0.02 *

8.35 ± 0.85

42.87 ± 3.11 *

27.44

18:2

6.67

5.03

0.31 ± 0.01

0.44 ± 0.03

5.78 ± 0.62

11.22 ± 0.83 *

4.73

0.14

0.24

0.00 ± 0.00

0.00 ± 0.00

0.00 ± 0.00

0.00 ± 0.00

0.00

20:1

cis-8,11-Octadecadienoic (Linoleic) (ω-6)
cis-9,12,15-Octadecatrienoic acid
(Linolenic) (ω-3)
cis-13-Eicosenoic

0.70

0.00

0.01 ± 0.01

0.00 ± 0.00

0.10 ± 0.10

0.86 ± 0.05 *

26.99

20:3

cis-7,10,13-Eicosatrienoic

0.00

0.00

0.00 ± 0.00

0.00 ± 0.00

0.69 ± 0.21

0.49 ± 0.04

0.00

20:4

cis-5,8,11,14-Eicosatetraenoic (AA) (ω-6)

0.51

0.00

0.08 ± 0.01

0.64 ± 0.03 *

2.13 ± 0.38

5.14 ± 0.20 *

7.52

0.00

0.25

0.00

0.19 ± 0.01
0.02 ± 0.02

0.00 ± 0.00 *
0.00 ± 0.00

5.58 ± 1.07
0.09 ± 0.09

0.00 ± 0.00 *
0.00 ± 0.00 *

0.26

0.00

0.00 ± 0.00

0.00 ± 0.00

2.22 ± 0.33

0.68 ± 0.08 *

2.64

0.00

0.14 ± 0.01

0.05 ± 0.01 *

16.55 ± 2.92

1.50 ± 0.06 *

Total omega 6 FA level
Total omega 3 FA level

7.18
10.56

5.03
0.24

0.39 ± 0.01
0.33 ± 0.01

1.08 ± 0.04 *
0.05 ± 0.01 *

7.91 ± 0.73
24.35 ± 3.13

16.36 ± 0.85 *
2.18 ± 0.10 *

42.33
587.45

Total MUFA level

4.72

15.82

0.23 ± 0.02

0.36 ± 0.02 *

9.55 ± 0.91

45.15 ± 3.12 *

66.97

Total SA level

1.81

3.98

1.37 ± 0.16

1.17 ± 0.10

17.50 ± 4.35

21.02 ± 1.32

9.65

Total Fatty Acid Concentration (µg/mg or µg/uL)

24.27

25.07

2.32 ± 0.16

2.66 ± 0.11

60.00 ± 5.49

85.20 ± 3.49

706.40

Ratio of total ω-6 FA to ω-3 FA (ω-6:ω-3)

0.7:1

21:01

1.2:1

21.6:1 *

0.32:1

7.5:1 *

18:3

20:5
22:1
22:5
22:6

cis-5,8,11,14,17-Eicosapentaenoic (EPA)
(ω-3)
13-Docosenoic acid
cis-4,7,10,13,16-Docosapentaenoic acid (ω3)
cis-4,7,10,13,16,19-Docosahexaenoic
(DHA) (ω-3)

37.60
409.70
12.54
17.97
159.78
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Table 7. Fatty acid profiles of diets, liver, and plasma
Sections of livers and plasma were collected from the mice fed respective diets for 10
weeks. (n=5/group). The ready to use diets and fish oil were used for fatty acid (FA)
analysis. FA profile was measured by gas chromatographic mass spectrophotometry (GCMS) analysis. The results were expressed as microgram of fatty acid per mg or ml of the
sample.
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4.3.3. Effect of dietary ω-3:ω-6 PUFA hepatic histopathology and steatosis
Histopathologic analysis of H & E stained liver sections from mice fed the different diets
for 10 weeks (Fig. 14A) revealed significant effects on hepatocyte steatosis. The livers
from mice fed the ω-3 diet had occasional hepatocyte lipid microvacuoles; whereas mice
on the ω-6 diet had an increase in macro- and micro-vesicular steatosis in their
hepatocytes (Fig. 14A).

Steatosis was quantified by counting the ORO positive fat

droplets that were about the size of a hepatic nucleus. There was a 7-fold increase in
macrovesicular steatosis in mice fed the ω-6 diet, compared to the ω-3 diet-fed mice
(p<0.05) (Fig. 14B and 14C). Moreover, an increase in microvesicular steatosis was
observed in the livers of ω-6 diet-fed mice (Fig. 14C). This suggested that the increase in
the dietary hepatic ω-6:ω-3 ratio in mice receiving the ω-6 diet (Table 6) enhanced hepatic
macro-steatosis, independent of total caloric consumption.
Hepatic glycogen storage was assessed by the histological analysis of PAS (+/- diastase
digestion) stained liver sections of mice fed the diets for 20 weeks (Fig. 15). The result
showed that livers from mice fed the ω-3 diet had significant glycogen storage in
hepatocytes around portal triads and central veins of hepatic lobules, which was absent
in mice fed the ω-6 diet (Fig. 15A- 15C). The presence of glycogen deposits in PAS
positive cells was confirmed by a comparison to a serial section that underwent glycogen
digestion (Fig. 15C). Thus, the results indicate that the dietary ω-6:ω-3FA ratio might
modulate energy storage and metabolism pathways, such that increasing consumption of
a diet with a high ω-6:ω-3FA ratio enhances hepatic fat storage whereas consumption of
LC-ω-3FA reduces fat storage but enhances energy storage in the form of glycogen.
Collectively, the increase in the dietary ω-6:ω-3FA ratio results in macrosteatosis, and
decreased glycogen deposition in lobular hepatocytes. We also undertook a histological
analysis of liver tissues from mice fed a chow control diet using H & E and ORO stained

106
sections (Fig. 17A-17C). The histological features of livers from chow controls were
distinct from the mice receiving liquid diets and had intermediate levels of steatosis (more
than the ω-3 group but less than the ω-6 group. Also, there were a few microgranulomas
in the liver from chow fed mice, but the size, number and features of those immune cells
were more distinct than what we reported as EMM in this study (Fig. 17B). Thus, mice in
a chow control group were not used in further analysis as their dietary composition had
multiple differences from our experimental liquid diets including lipid types, percentages,
protein and carbohydrate levels and calorie consumption.
The total WBC count of blood and liver was determined. There was no significant
difference in the peripheral blood WBC count between the dietary groups, i.e.; 11.3 x 106
+/- 1.1 x 106 and 9.3 x 106 +/- 1.0 x106 WBC cells per ml of blood in mice from ω-3 and ω6 diet groups respectively (n=20). In contrast, mice fed an ω-6 diet had a significant (10fold) increase in the number of WBC cells per gram of liver (7.9 x 106 +/- 1.3 x 106)
compared to ω-3 diet-fed mice (0.8 x 106 +/- 0.5 x 106). We also evaluated hepatic
inflammatory cell infiltration by H & E and anti-CD45 staining from mice receiving the diets
for 10 and 20 weeks (Fig 16A-16G). The differentiated inflammatory cells were observed
in cellular clusters composed of immature myeloid cells with variable size and nuclear
morphology (Fig. 16A), supporting hepatic EMM. Mice given the ω-6 diet for 10 weeks
had a significant (9-fold) increase in EMM foci (0.9+/-0.2 per 100x magnified field),
compared to ω-3 diet-fed mice (Fig. 16A and 16B). Similarly, mice given the ω-6 diet for
20 weeks had an inflammatory appearance, with a significantly higher number of EMM
foci (2-fold) compared to ω-3 diet-fed mice (0.2+/-0.06 per 100x magnified field) (Fig. 16B).
However, there was no significant difference in the number of EMM foci between the 10or 20-week diet-fed groups (Fig. 16B). Further, the EMM foci in ω-6 fed mice were larger
and located adjacent to the central veins, whereas the EMM foci in ω-3 diet-fed animals
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were smaller and located randomly in the hepatic sinusoids (Fig. 16A). The presence of
inflammatory cells (individually distributed or in clusters) was confirmed by staining the
liver sections with the anti-CD45 antibody (Fig. 16C-16G). The ω-6 diet-fed mice had
significantly higher numbers of individual CD45+ cells compared to the ω-3 diet-fed
groups, in both the 10 and 20 weeks’ diet-fed studies (Fig. 16C & 16D). Morphologically,
these CD45+ cells included both myeloid and lymphoid cells. In addition, ω-6 diet-fed mice
had a significantly higher number of CD45+ inflammatory cell foci (6.8+/0.4) compared to
ω-3 diet-fed mice (0.4+/-0.3 per 100x magnified field). The foci were approximately 3 times
larger (23.2+/-2.4 cells/cluster) in the livers of ω-6 diet-fed mice compared to the ω-3 dietfed mice (8+/-5.3 cells/cluster) (Fig. 16E-16G). Similar results were observed in the livers
of mice maintained on the diets for 20 weeks. Additionally, the number of inflammatory
cells per EMM foci were significantly increased in the 20-week diet-fed mice compared to
the 10-week mice, when studied using mice from both dietary groups. (Fig. 16F and 16G).
Confirmation of the increase in hepatic hematopoietic progenitor (CD201+CD27+) cells
[355] was obtained by flow analysis of isolated hepatic non-parenchymal cells and found
as a 24.4+/-4.9% of CD45+ cells in ω-6 diet-fed mice versus 3.7+/-1 % of CD45+ cells in
ω-3 diet-fed mice were of progenitor phenotype respectively. The myeloid phenotypes of
progenitor cells were further confirmed by CFU-GM analysis, which showed that ω-6 and
ω-3 dietary groups had 14.9+/-1.1 and 9.4+/-2.1 CFU-GM colonies/100,000 cells plated
respectively.
Since NF expression is associated with myelopoiesis, we examined the expression of
NF protein in the livers of mice fed the diets for 10 weeks and found that livers from ω6 diet-fed mice had a significantly higher level of NF expression (Fig. 16H and Fig. 16I)
(p<0.05, n=5), indicating inflammatory cell activation. Collectively, the higher ω-6:ω-3FA
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ratio in the diets appeared to be associated with inflammation and EMM in the hepatic
microenvironment.
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Figure 14. Differential effects of dietary PUFA on hepatic steatosis
Hepatic steatosis analysis of livers by hematoxylin and eosin (H & E) staining (A). Oil Red
O-stained liver sections analyzed for hepatic steatosis (B and C). Images were taken with
magnification of 400x (A) and 1000x (B) (n=5) [*=p<0.05].
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Figure 15. Differential regulation of hepatic glycogen storage by dietary PUFA
Liver sections stained with Periodic Acid-Schiff (PAS) showed glycogen-containing
hepatocytes around the regions of central vein and portal area of hepatic lobules in mice
fed ω-3 diet but absent in ω-6 diet group (A and B). The hepatic glycogen was digested
using PAS-diastase staining (PAS-Digest) (C). Images were taken with magnification of
200x (A and C) and (n=5) [*=p<0.05].
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Figure 16. Differential regulation of hepatic EMM by PUFA
Livers of mice were compared for hepatic EMM by counting the number and size of EMM
foci in 10 microscopic fields/sample by H & E staining (A) (n= 3 to10). Arrows indicate a
focus of EMM. Comparison of EMM foci between 10 weeks and 20-week diet-fed mice of
the dietary groups (B). Analysis of 100x magnified fields of CD45 stained liver sections for
CD45+ single cells (C and D). Analysis of number and size of CD45+ cell clusters in dietary
groups (E, F, and G). Images were taken at a magnification of 400x (A) and 100x (C and
E). Hepatic NFB protein expression was significantly higher in the ω-6 as assessed
based on Western blots (H and I) [*=p<0.05].
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Figure 17. Hepatic histology and fat accumulation in chow fed mice liver
Sections of liver from control mice fed chow diet. (A-B) Hematoxylin & eosin stained liver
sections at the magnification of (A) 200x and (B) 400x. (B) Cluster of immune cells in
hepatic tissue. (C) Oil red O stained hepatic section showing fat droplets in hepatocytes
at 1000x magnification.
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4.3.4. Dietary ω-3:ω-6 PUFA regulation of hepatocyte proliferation, degeneration,
and apoptosis
We examined hepatocyte proliferation (Ki67) and apoptosis (TUNEL) by IHC using mice
fed the experimental diets for 10 or 20 weeks. Mice fed the diet for ten weeks did not have
a difference in hepatocyte proliferation (data not shown). However, mice fed the ω-6 diet
for 20-weeks had a significantly lower number of proliferating hepatic nuclei (1.5-fold) as
compared to ω-3 diet-fed animals (Fig. 18A and 18B). In contrast to hepatocyte
proliferation, a 4-fold increase in the number of TUNEL positive hepatocyte nuclei was
observed in the livers of mice fed the ω-6 diet for 20 weeks (Fig. 18C and 18D). When the
number of TUNEL positive nuclei relative to total hepatocyte nuclei were compared, a
significantly higher frequency of hepatocytes in the livers of ω-6 diet-fed mice were TUNEL
positive (41%) as compared to 15% of the hepatocytes in the livers of ω-3 diet-fed mice
(Fig. 18E). Collectively, these results suggest a potential mechanism for the decrease in
liver weight in the ω-6 diet-fed animals.
Additionally, morphological differences were observed in the bile ducts of ω-3 versus ω-6
diet-fed mice although no differences were observed in RBC count and properties
between the dietary groups (Fig. 19).
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Figure 18. Dietary PUFA regulation of hepatocyte proliferation, and apoptosis
The livers of mice fed ω-3 and ω-6 diets for 20 weeks were compared based on
proliferation (Ki67) and apoptosis (TUNEL) by counting the number of positive cells per
10 microscopic fields per sample (n=3). The number of proliferating hepatocytes observed
are shown in A and B. The number of TUNEL+ (apoptotic) nuclei (C and D) and apoptotic
nuclei relative to total nuclei (C and E) observed in are shown. Images were taken at a
magnification of 100x (A) and 630x (C) respectively [*=p<0.05].
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Figure 19. Biliary histology and blood parameters
(A) H & E stained sections of liver (400x) showing bile duct histology, comparative analysis
of bile duct (B) diameter, (C) thickness of epithelial cell layer in bile duct and (D) bile duct
diameter relative to are of the adjacent artery. Blood samples were collected from
heparinized mice at autopsy from the mice fed the diets for 10 weeks and analyzed for (E)
RBC count (F) hemoglobin level, (G) hematocrit % and (H) blood mean corpuscular
volume (MCV) [*=p<0.05].
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4.4. Discussion
In the present study, we compared the biological effects of feeding ω-3 versus ω-6 PUFA
using Lieber-DeCarli, isocaloric liquid diets and a pair-fed model. During acclimatization,
the dietary preference was for the ω-6 diet, which was consistent with our earlier
observations. Thus, the ω-3 diet consumption was used as the base-line for pair feeding.
In contrast to prior reports of pair-fed mice given isocaloric diets [356, 357], in our studies
significant differences in body weight were observed between mice fed an isolipidic ω-3
versus ω-6 diet. It is noted that in the referenced prior studies, diets differed in components
other than PUFA and so are not directly comparable. This is relevant as in the one
published study, in which mice were pair fed, isocaloric and isolipidic diets differing in
PUFA composition (safflower oil (ω-6) versus fish oil (ω-3)) mice on the safflower oil diet
for nine months had a 31% increase in weight versus mice on the fish oil diet.[358] These
observations support a need for pair-feeding to achieve an isocaloric diet due to dietary
preferences by laboratory rodents, and a need for isolipidic diets to study PUFA regulation
of body weight. Further, despite providing isocaloric and isolipidic diets, we observed a
significant difference in fat mass measured as abdominal fat in ω-6 diet-fed mice,
suggesting differential metabolism between the two groups. This is consistent with prior
reports of PUFA regulation of dietary fat content and body fat deposition and distribution
[359, 360]. In one clinical study, consumption of PUFA diets was reported to decrease
visceral fat and increase lean muscle mass as compared to individuals receiving high
saturated fat diets [359]. Among the subtypes of PUFA, ω-3 can limit hypertrophy of
abdominal fat deposits [267] and reduce weight gain in pre-obese animals and humans
by a reduction in visceral fat [361-364]. Potential mechanisms for the divergent effects of
ω-3 and ω-6 FAs in adipose tissue biology include the regulation of adipogenesis [365],
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lipid

homeostasis

[366],

brain-gut-adipose

tissue

axis

[367],

and

systemic

inflammation,[368] suggesting that lowering the dietary ω-6:ω-3 ratio might help control
obesity [20]. The levels of LC-ω-3FAs used in this study was higher than the dose used in
clinical study [369], because the current study was primarily designed to analyze the
effects of a ω-6:ω-3 ratio of 1:1, which has been reviewed in literatures as the ω-6:ω-3
ratio upon which humans evolved [25].
The FA composition of diets can modulate the composition of stored and structural lipids
[370], including the FA profile of plasma and tissues [371, 372] In the present study, we
observed a significant increase in total ω-6FA, AA, and a decrease in DHA, and an
absence of EPA in the plasma of mice fed a ω-6-diet. These observations are in
agreement with a previous report, in which rats were fed a diet with a 1:1 ratio of ω-6:ω-3
FA resulting in a significantly higher levels of plasma EPA, DHA, and a lower level of AA,
compared to the rats fed a diet with a 30:1 ratio of ω-6:ω-3 PUFA [371]. The results are
also consistent with a clinical study in which the plasma FAs in humans were associated
with their dietary FA composition [373].
Our results suggest that the plasma level of LC-ω-3FAs, such as EPA and DHA, reflect
dietary intake. In contrast, plasma AA (C20:4) levels could only be explained by the
elongation and desaturation of the ω-6 linoleic acid (C18:2) in mice given the ω-6 diet.
Further, the ω-6 and ω-3FAs compete for incorporation into phospholipids and as
substrates contributing to these differences [374]. In this study, the concentration of total
ω-6 PUFAs and linoleic acid (precursor to AA) did not differ between the experimental
diets, although the AA: precursor linoleic acid was 5.8-fold higher in the plasma of mice
fed ω-6 diets. Thus, the decreased level of plasma AA in the ω-3 diet-fed mice is
apparently regulated by dietary LC-ω-3FAs, as a modulator of AA biosynthesis. This
observation is supported by reports that both EPA and DHA can reduce pro-inflammatory
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cytokines [375] and hepatic steatosis [376]. The observation of significantly higher MUFA
level in mice fed ω-6 reflected the dietary composition of the ω-6 diet. Previous studies
into the bioactivity of olive oil showed that an iso-energetic MUFA diet can reduce liver fat
in diabetic patients [377], higher oxidation of MUFA in the liver of rats [378] and protects
against experimental inflammation [379]. Thus, we posit that our observations of
inflammatory signals in ω-6 diet-fed mice is primarily due to changes in dietary ω-6:ω-3
or the absence of LC-ω-3FAs, rather than an increase in MUFA with the ω-6 diet. In our
studies, we evaluated DHA and EPA in the livers of mice fed ω-3 and ω-6 diets. In a
previous report, a decrease in total hepatic ω-6FA and AA levels were observed in a
mouse model of NAFLD, which was associated with the metabolic utilization of AA during
chronic inflammation [380]. A Majority of NAFLD studies were based on diet induced
obesity models including; over-consumption/hypercaloric diet compared to a control diet
[381], ad-libitum feeding of a high saturated fat diet (>60% calories from fat) [351, 382] or
a high fat Lieber-DeCarli diet (71% of energy from fat) compared to the Lieber-DeCarli
control diet (35% fat, that we used herein) [383]. Thus, the role of PUFA composition, as
opposed to obesity in the pathogenesis of “fatty liver” has been poorly evaluated. In these
studies, we report an increase in macro-vesicular steatosis in ω-6 diet-fed mice, an
observation consistent with previous clinical and animal model studies, which emphasized
that a western diet-induced hepatic steatosis [382, 384]. However, unlike previous animal
studies, we observed lower relative liver weights and higher steatosis in the ω-6 diet-fed
mice [382], supporting a role for dietary PUFA composition on the hepatic
microenvironment, independent of total caloric intake [385]. Most studies used high
fat/high caloric /high saturated fat diets to induce hepatic steatosis and compared the
results with liver from control mice fed a standard laboratory chow diet, which has ω-6:ω3 ratio of around 10:1 with variable dietary composition [386, 387]. The present study
compared the results between two liquid diets differed in FA composition only. Further, an

125
increase in liver weights in diet induced NAFLD/NASH studies might be a consequences
of severe steatosis along with induction of fibrosis in liver. Thus, it is possible that feeding
the moderately fat ω-6 diet for 20 weeks may be insufficient for the development of other
NASH symptoms such as fibrosis, which might be responsible for increasing liver weight
in steatosis studies using NAFLD/NASH model. In this study, the lobular hepatocytes from
ω-6 diet mice lacked glycogen storage (Fig.15) which is supported by the significant
increase in macrosteatosis in lobular and portal regions of the ω-6 mice (Fig. 14I). Hepatic
steatosis and glycogen storage levels vary depending on the strain of mice and the
percent of glycogen positive cells decrease with an increase in steatosis in high fat dietfed BALB/c mice [388]. Similarly, increased macrosteatosis in the livers of mice fed a high
carbohydrate diet was associated with a decrease in glycogen storage, which recoverd by
inclusion of ω-3FA in the diet [389]. The difference in hepatic glycogen storage might be
due to specific regulatory roles of ω-6 and ω-3FA in metabolic pathways. [390] However,
a comparison of hepatic glycogen content between moderately fat, isocaloric, isolipidic
and pair-fed model has not been reported previously, suggesting a need for further studies
to understand the metabolic regulation of the diets which might have modulated
mechanisms of energy storage in the form of fat or glycogen. In summary, the decreased
glycogen content (Fig. 15), together with increased steatosis (Fig. 14), decreased
hepatocyte proliferation and increased hepatocyte apoptosis (Fig. 18) might contribute to
the lower hepatic weight of the ω-6 diet-fed mice observed in the current study.
In these studies, we observed a significant increase in hepatic inflammatory cells in an
absence of leukophilia in the ω-6 diet group suggesting that the outcome of higher number
of inflammatory cells in the liver was independent of a systemic inflammatory response.
Further, histological analysis documented a significant increase in the number and size of
inflammatory cell foci, containing immature myeloid cells in the livers of mice fed a high
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ω-6:ω-3 diet. The foci closely resembles hepatic EMH as defined by National Toxicological
program [72] however, as majority of cells in the foci were early myeloid cells, likely
myeloid progenitor cells with a lack of erythroid progenitor cells [as defined in EMH], we
addressed the foci as EMM. We further confirmed the increase in hematopoietic
progenitors in livers of the ω-6 diet-fed mice by flow analysis and CFU-GM counts. Unlike
humans, mice have a smaller medullary space resulting in EMH during early development;
however, our observation of a significant increase in number and size foci of EMM in 30
weeks old mice fed an ω-6 diet compared to age matched ω-3 diet-fed mice cannot be
considered as a normal developmental phenomenon and needs further evaluation. An
increase in EMM foci in association with hepatic steatosis has not been reported
previously; however, prior hepatic steatosis studies were based on a NASH model, which
might have an infiltration of mature inflammatory cells, such that enhanced EMM was
obscured by regional inflammation. Modulation of the hepatic microenvironment and the
production of growth factors such as granulocyte-monocyte colony stimulating factor (GMCSF) by inflammatory cells may result in EMM [145]. Further, our observation of
degenerating hepatocyte morphology with large lipid inclusions, higher numbers of
apoptotic hepatocytes, and an increase in NF levels support an inflammatory cell role
in the modulation of the hepatic microenvironment resulting in the mobilization of
hematopoietic precursors leading to hepatic EMM in mice fed a high ω-6:ω-3 PUFA diet.
Hepatocyte proliferation [391] maintains hepatic mass and in our studies we observed
decreased hepatocyte proliferation in the ω-6 diet-fed mice. However, this differs from a
previous report of an increased hepatocyte proliferation in NAFLD hepatic steatosis [392].
The basis of this difference needs further evaluation, but likely contributes to the
decreased liver size in the ω-6 diet-consuming mice. Further, hepatocyte apoptosis is a
prominent clinical feature of NASH and positively correlates with hepatic inflammation
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[353]. Thus, the observation of increased apoptotic hepatocytes in livers of mice fed ω-6
diet, steatosis and EMM supports a role of for dietary PUFA in the initiation of liver
inflammation.
The significant increase in bile duct diameters at comparable levels of the biliary tree and
morphological alterations on the biliary epithelium in mice fed ω-3 versus ω-6 diet may be
secondary to the changes in liver mass between the dietary groups (Fig. 19). However,
additional mechanistic studies are needed to analyze a potential role for dietary PUFA on
the biliary system.
In summary, employing a pair fed, liquid diet with a lipid composition of 35% of dietary
calories, the present study demonstrates that consuming a high ω-6:ω-3 PUFA diet
regulates hepatic steatosis, EMM, glycogen deposition, and hepatocyte apoptosis. These
results indicate that dietary LC-ω-3FAs suppresses steatosis and prevents the “first hit”
mechanism of fatty liver development, and potentially lowers the risk of NAFLD and liver
injury associated hepatic disorders. This may support a role for a ω-6:ω-3FA ratio, but not
the average calories consumed from fat, (~35%) in the initiation of the formation of a “fatty
liver”. However, other attributes of metabolic changes due to hypercaloric consumption
and obesity might promote progression to NAFLD and NASH.

After evaluating the modulation of tissue microenvironments (MG and liver) by dietary
PUFA composition, we extended our studies to understand how pre-modulated modulated
tissue microenvironments by dietary PUFA regulate mammary tumor growth and
metastasis. The finding from our studies on 4T1 mammary tumor bearing mice are
discussed in the next chapter (Chapter 5).
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Chapter 5:
Long-chain Omega-3 Polyunsaturated Fatty Acids decrease
Mammary Tumor Growth, Multiorgan Metastasis and Enhance
Mouse Survival4

5.1. Abstract
Epidemiological studies show a reduced risk of B) in women consuming high levels of LCω-3 FAs compared with women who consumed low levels. However, the regulatory and
mechanistic roles of dietary ω-6 and LC-ω-3FAs on tumor progression, metastasis and
survival are poorly understood. Female BALB/c mice (10-week old) were pair-fed with a
diet containing ω-3 or an isocaloric, isolipidic ω-6 diet for 16 weeks prior to the orthotopic
implantation of 4T1 mammary tumor cells. Major outcomes studied included: mammary
tumor growth, survival analysis, and metastases analyses in multiple organs including
pulmonary, hepatic, bone, cardiac, renal, ovarian, and contralateral MG (CMG). The
dietary regulation of the tumor microenvironment was evaluated in mice autopsied on day35 post tumor injection. In mice fed the ω-3 containing diet, there was a significant delay
in tumor induction and prolonged survival relative to the ω-6 diet-fed group. The tumor
size on day 35 post tumor injection in the ω-3 group was 50% smaller and the frequencies
of pulmonary and bone metastases were significantly lower relative to the ω-6 group.
Similarly, the incidence/frequencies and or size of cardiac, renal, ovarian metastases were
significantly lower in mice fed the ω-3 diet. The analyses of the tumor microenvironment

4

This chapter is derived from previously submitted original article: Saraswoti Khadge, Geoffrey
M. Thiele, John Graham Sharp, Timothy R. McGuire, Lynell W. Klassen, and James E. Talmadge,
"Long Chain Omega-3 Polyunsaturated Fatty Acids decrease Mammary Tumor Growth,
Multiorgan Metastasis and Enhance Mouse Survival." Clinical and Experimental Metastasis,
July 2018.
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showed that tumors in the ω-3 group had significantly lower numbers of proliferating tumor
cells (Ki67+)/high power field (HPF),

and higher numbers of apoptotic tumor cells

(TUNEL+)/HPF, lower neo-vascularization (CD31+ vessels/HPF), infiltration by neutrophil
elastase+ cells, and macrophages (F4/80+) relative to the tumors from the ω-6 group.
Further, in tumors from the ω-3 diet-fed mice, T-cell infiltration was 102% higher resulting
in a neutrophil to T-lymphocyte ratio (NLR) that was 76% lower (p<0.05).

Direct

correlations were observed between NLR with tumor size and T-cell infiltration with the
number of apoptotic tumor cells. qRT-PCR analysis revealed that tumor IL10 mRNA
levels were significantly higher (six-fold) in the tumors from mice fed the ω-3 diet and
inversely correlated with the tumor size. Our data suggest that dietary LC-ω-3FAs
modulates the mammary tumor microenvironment slowing tumor growth, and reducing
metastases to both common and less preferential organs resulting in prolonged survival.
The surrogate analyses undertaken support a mechanism of action by dietary LC-ω-3FAs
that includes, but is not limited to decreased infiltration by myeloid cells (neutrophils and
macrophages), an increase in CD3+ lymphocyte infiltration and IL10 associated antiinflammatory activity.
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5.2. Introduction
Breast cancer (BC) is one of the leading causes of cancer deaths of women in the United
States [393]. However, there is a significant difference in BC incidence between
populations consuming Western diets, with those, who consume an Asian diet, typically
due to a higher intake of fish, supporting dietary PUFA composition as a risk factor for BC
[394-397]. A typical Western diet contains higher levels of ω-6FAs relative to ω-3FAs,
mainly LC-ω-3FAs [25]. The LC-ω-3FAs such as EPA and DHA are metabolized to
bioactive lipid mediators important in inflammation resolution [398]. In contrast, ω-6FA
metabolites such as AA are pro-inflammatory mediators and chronic production of AA has
been associated with inflammation-associated morbidity including BC patients [329].
Thus, the ratio of dietary ω-3 and ω-6 FA has a critical role in determining the inflammatory
status of tissue microenvironments, which can modulate tumor growth, metastasis and the
efficacy of therapeutic treatments [399, 400].
In murine studies, dietary LC-ω-3FAs early in life results in reduced incidences and growth
of mammary tumors compared to the mice fed diets high in ω-6FA [118, 401]. Further,
feeding LC-ω-3FA enriched diets in adult life results in significantly lower MG ductal
density, proliferation of epithelial cells in the MG, and adipose tissue inflammation, all of
which are associated with reduced risks of BC [110, 402, 403]. However, dietary LC-ω3FAs regulation of mammary tumor microenvironments, tumor progression, metastasis
and survival, has been little studied.
Despite recent advances in the development of molecularly targeted therapies, most
deaths due to cancer result from the progressive growth of therapy-resistant metastases
[234]. Metastasis is regarded as a highly inefficient process so that less than 0.01% of
circulating tumor cells eventually succeed in forming secondary tumor growths [404]. The
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growth of a metastatic lesion in a specific organ is determined by the intrinsic properties
of the tumor cells (seed) and the supportive role of the microenvironment of the target
organ (soil) so that some cancer cells grow preferentially in one organ while not in other
organs [227, 230]. Most invasive BC cells preferentially metastasize to bone, lungs, liver
and brain [230] while ovarian [405], cardiac [406] and renal [407] metastases have been
less frequently observed. Similarly, 4T1 mammary tumor cells predominantly metastasize
to lungs in the spontaneous metastasis model whereas metastases to liver, heart, kidneys
and bone have been less frequently reported, and there are no published data on ovarian
metastases by 4T1 cells [408-411]. In animal models and in-vitro studies, ω-3 and ω-6FA
have been shown to modulate tissue microenvironments of MG, liver, bone, ovaries, heart
and kidneys [110, 266, 412-416]. However, the role of the modulated microenvironments
by pre-exposure to PUFA in the regulation of metastasis to those organs has not been
studied. Further, the role of dietary PUFA composition in mammary tumor
microenvironments such as inflammation, neo-vascularization and apoptosis have been
little studied.
In this study, we hypothesize, that LC-ω-3FA diets can suppress mammary tumor cell
proliferation and metastasis by modulating tumor and metastatic microenvironments. By
pair-feeding isocaloric and isolipidic diets in an orthotopic model of mammary tumor, we
uniquely analyzed the effects of dietary LC-ω-3FA on tumor microenvironments,
measured as tumor cell proliferation and apoptosis, neo-vascularization and infiltrating
leukocytes with pro-and anti-tumor inflammatory activities. Further, with the injection of
low numbers of 4T1 cells, we established a tumor model capable of assessing the
differential regulation of dietary PUFA on spontaneous metastases to different organs
including bone, heart, kidneys, ovaries and CMG, which have not previously been
reported.
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5.3. Results
5.3.1. Dietary LC-ω-3FA regulate mammary tumor induction, growth and mouse
survival
Mice (n=20/group) were fed the experimental diets for 10-16 weeks before use in two
independent tumor experiments. The Fig. 20 shows the data from pair-fed groups of mice
in a single experiment (n=20/group). There was no difference in the average dietary
consumption between the groups during the non-tumor bearing (NTB) period; (Fig. 20A)
but the dietary consumption levels significantly decreased in the ω-6 group during the
tumor bearing (TB) phase of the experiments (Fig.20B).

The effects of dietary LC-ω-3FAs on the regulation of mammary tumor induction, growth
and survival from pooled data of two independent studies are shown in (Fig. 21). Out of n
= 40 mice/group used in the study, 100% (40/40) of the mice from the ω-6 group and 95%
(38/40) of mice from the ω-3 group developed palpable tumors within the experimental
period (89 days). Among the mice which developed tumors, the median time to a palpable
tumor were significantly delayed for the ω-3 group (10 days, range: 6 - 32 days) compared
to a median of 7 days, range: 5 - 22 days for the ω-6 diet group (Fig. 21A). Similarly, mice
fed the ω-3 diet had a significantly slower mammary tumor growth compared to the ω-6
diet-fed mice (Fig. 21B). These data are supported by a 50.2% smaller tumor volume
(446.3 ± 52.3 mm3), and 48.8% lower tumor weight (0.6 ± 0.1 g) in mice fed the ω-3 diet
compared to the tumor volume (888.5 ± 115.2 mm3), and weight (1.2 ± 0.2 g) in the mice
fed the ω-6 diet on the day-35 post 4T1-tumor injection autopsy (n=20/group, p<0.05) (Fig.
21C-21D). The body weights of the mice were evaluated at different times during the
experiment to analyze the effects of dietary PUFA composition on body mass, before and
during tumor growth (Fig. 21E). There was no difference in body weights when the
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experimental diets were started at the age of 10 weeks. However, after feeding the diets
for 16 weeks, mice given the ω-3 diet had significantly lower body weights compared to
the mice on ω-6 diet, resulting in a significant difference in the body weights on the day of
tumor injection. When the tumors are palpable, changes in body weights are influenced
by multiple factors in addition to diet, including tumor growth and weight, and tumorassociated metabolic changes (cachexia). Thus, we analyzed the body weights at autopsy
(day 35 post tumor injection Fig. 21E(c)) and after subtracting the weight of the tumor on
that day (fig. 21E (d)). Both dietary groups of mice lost significant body weight by the day
of autopsy compared to their weights at tumor injection. The ω-3 diet mice had significantly
lower body weights (with or without tumor) on day 35 post tumor injection; although, the
% change in body weights (-tumor weights) relative to their weights on tumor injection day
were not different between the groups (Fig. 21E(e)).
Among the mice used in the study, 20/group that were pooled from two studies were
autopsied on day 35 post injection and the extent and sites of metastases assessed and
the survival of the remaining 20 mice/group was monitored. During the study period of 89
days, two mice from the ω-3 group did not develop tumors, and one mouse had a palpable
tumor, which did not grow to a measurable size by 89 days post tumor injection, when the
study terminated. The survival analysis showed that a mice fed the LC-ω-3FA diet for 16
weeks of adult life, prior to tumor challenge, significantly prolonged overall survival (a
median survival time (MST) of 46.5 days) compared to the MST of 35.5 days for the ω-6
diet-fed mouse group (p<0.05) (Fig. 21F).
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Figure 20. Dietary consumption in pair-fed model
Dietary consumption levels in a single study were presented. Experimental diets were
started in mice (n=20/group) at the age of 10 weeks. Ad libitum amounts of diets were
provided for first 5 days of the experiment. Thereafter, mice on an ω-6 diet were pair-fed
depending on the average amount consumed by the mice on an ω-3 diet. (A) Diet
consumption levels during non-tumor-bearing (NTB) phase. (B) Diet consumption levels
after injection of 4T1 tumor.
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Figure 21. Dietary PUFA regulation of 4T1 tumor induction, growth and survival.
Mice were fed an isocaloric, isolipidic pair fed ω-3 (W3 in figure) or ω-6 (W6 in figure) diet
for 10 weeks prior to orthotopic injection of 4T1 cells in left rear mammary gland (MG).
Pooled data from two experiments is shown and analyzed. (A) Graph is a Kaplan-Meier
plot of the time to development of a palpable tumor (log-rank test). (B) Longitudinal
changes in tumor volume (repeated measures test). (C) Tumor volume and (D) tumor
weights were compared from mice autopsied on day 35 post-tumor injection. Horizontal
line represents median values and Mann-Whitney test was used to analyze the difference
between the dietary groups. (E) Body weights of the mice were compared at key study
landmarks: body weights at the start of the experimental diets, at the time of tumor
injection, at autopsy on day-35 post tumor injection, host weight at autopsy (body weight
minus tumor weight) and percent body weight loss at autopsy relative to the day of tumor
injection. $ and # indicate p<0.05 for the change in host body weight at autopsy in ω-3
and ω-6 group respectively compared to the respective weights on tumor injection day (ttest). (F) Kaplan-Meier survival plot of mice on ω-3 and ω-6 diets (n=20/group) (log-rank
test). *p<0.05 compared to mice fed the ω-6 diet.
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5.3.2. Effect of dietary PUFA in 4T1 tumor MET to lung, liver and bone
Metastasis analysis was performed on day 35 on autopsied mice from two independent
experiments (n=10/group/experiment). The extent of metastasis was determined by
counting overt metastases on the organ surfaces [417] and by evaluating the weights of
organs autopsied on the same day. Further, smaller and deep tissue metastases were
evaluated by analyzing histologically-observed metastases (HO-met in figures) in H & E
stained tissue sections. Among the organs investigated, the lungs had the highest number
of metastases in both dietary groups and metastases were detected in all animals (Table
7). However, the ω-3 diet group mice had a 64% lower number of pulmonary overtmetastases (median=28; range: 2 - 187) compared to the ω-6 group (Median = 78; range:
8 - 312) (p<0.05) (Fig. 22B). This observation was supported by the lower lung weights in
mice fed the ω-3 diet that were 36% lighter (median = 0.27g; range: 0.16 – 0.74g) relative
to the lungs of the ω-6 fed group (median = 0.47g; range: 0.16 – 0.96g) (p<0.05) (Fig.
22C). Histopathological analysis of lung metastases showed that the majority of metastatic
pulmonary foci were localized superficially on the lungs while metastatic foci in the lungs
from mice given the ω-6 diet were localized throughout the pulmonary parenchyma (Fig.
22A). An analysis of hepatic metastases (Table 8) (Fig. 22D-22F) showed that there was
a 47% lower incidence of mice with hepatic overt-metastases in the mice that received the
ω-3 diet (8/20 mice) compared to the incidence in the ω-6 group (15/20 mice) (p=0.05).
However, there were no significant differences in the median number of hepatic overtmetastases nor the weights of livers between the dietary groups (Fig. 22E-22F).
Histopathological analysis showed that the livers from ω-3 diet-fed mice had fewer and
smaller metastatic foci deeper in the hepatic parenchymal tissue compared to mice in the
ω-6 fed group (Fig. 22D). There were individual tumor cells and clusters of few tumor cells
in the livers from the ω-3 fed group, while the histologically observed metastases in the
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livers from the ω-6 group were macrometastases (≥2mm in size). Quantitative analysis of
the hepatic metastases size was challenging due to extensive extramedullary
myelopoiesis (EMM) within the metastatic foci, preventing reliable analyses of the
metastasis area. The tumor weights were directly correlated with the weights of lungs, the
number of overt metastases in lungs and the weights of and liver were directly correlated
with the tumor weights suggesting a direct relationship to tumor growth with
metastasesMETs to these organs (Fig. 23A -23C).

The effects of dietary PUFA on the spleen was evaluated based on weights and
histological analyses. There were significantly lower spleen weights in the ω-3 dietary
groups compared to the ω-6 group (Fig. 22H). Further, the spleen weights directly
correlated with tumor weights in both groups of mice (Fig.22I). Histological analyses of
spleen sections showed splenomegaly was predominantly due to increases in EMM in the
sub-capsular and red pulp areas, as previously reported [418]. Individual tumor cells
and/or clusters of a few tumor cells were observed in all spleens independent of the dietary
group (Fig. 22G). However, the incidence of distinct histologically observed metastasis
was non-significantly (33%) lower in the spleens from ω-3 diet-fed mice (4/10) compared
to the ω-6 group (6/10) (p=0.6).

Bone metastases by 4T1 tumors have been rarely reported, with the exception of subclone 4T1.2 tumor cells which were selected for their propensity to develop bone
metastases [419].

In the current study, we report dietary PUFA regulation of bone

metastases in this 4T1 orthotopic primary tumor bearing mice model. The presence of
osseous metastases was suggested by the observation of hind-limb paralysis in the ω-6
group of mice. We analyzed bone metastasis in the longitudinal sections of femurs and
tibias from both hind limbs of mice autopsied on day 35 post tumor injection to evaluate
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the effects of dietary PUFAs on bone metastases (n=10 mice/group). Mice fed the ω-3
diet had an 80% lower incidence of bone metastasis in at least one leg (1/10 mice) relative
to the incidence in the ω-6 group (5/10 mice) (p=0.1). Similarly, (3/10) mice on ω-6 diet
had metastases in the femur and/or tibias from both hind limbs, which was not observed
in mice fed the ω-3 diet (0/10) (p=0.08) (Table-8). Further, there were significantly fewer
(median=0; range: 0-1) and smaller (median=0; range: 0-0.099mm2) HO-met/s per
femurs/tibias in ω-3 diet-fed mice, compared to the retrospective analyses of number
(median=0; range: 0-6) and size (median=0; size: 0-0.346 mm2) of metastases in the ω-6
diet-fed mice (Fig. 22J-22K). Histopathological analyses showed the larger metastases of
the ω-6 group were localized to the femur metaphyses, specifically around the growth
plate, while smaller metastases were present throughout the distal and proximal
epiphyses and diaphyses of the femurs and epiphyses of the tibias. The only metastasis
detected in an ω-3 diet-fed mouse was localized in the femur diaphysis medullary space
(Fig. 22J). Despite variations in the location of metastases, all of the detected metastases
in long bones were adjacent to trabecular bone, indicating potential interactions of tumor
cells and sites of active hematopoiesis/osteogenesis in bone microenvironments.
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Metastases Incidence
Mice with overt-met
[n (%)]

Mice with HOmet [n (%)]

Lung
Liver

mice/
group
(n)
20
20

heart

20

2 (10%)*

12 (60%)

Kidney (at least
one)

20

2 (10%)*

15 (75%)

Kidneys (Both)

20

2 (10%)

7 (35%)

10

Ovary (at least
one)

n/a

n/a

10

Ovary (both)

n/a

n/a

10

Bone (one leg)

n/a

n/a

10

Bone (both leg)

n/a

n/a

10

Organ

W3
W6
20(100%) 20(100%)
8 (40%)
15 (75%)

mice/group
(n)
W3
n/a
n/a
n/a
n/a
2
10
(20%)
1
10
(10%)

W6
n/a
n/a
6
(60%)
6
(60%)
2
0 (0%)
(20%)
1
9
(10%)* (90%)
0
6
(0%)*
(60%)
1
5
(10%)
(50%)
3
0 (0%)
(30%)
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Table 8. Dietary LC-ω-3FA regulation of incidences of metastasis

Mice autopsied on day 35 post tumor injection were analyzed for incidence of overt
metastases (overt-met) (n=20 mice/group) and histologically observed metastases (HOmet) (n=10 mice/group). The results are presented as number of mice with at least one
metastasis in the indicated organ (n) and percent representation per total animal analyzed
in the group (%). *p<0.05 ω-3 versus ω-6 diet-fed mice. Fisher exact test for the difference
in proportions was used to analyze statistical difference. n/a indicates either the analysis
was not applicable or not done.
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Figure 22. Dietary PUFA regulation of 4T1 metastasis to the lungs, liver and femur.
Mice from two experiments were autopsied on day 35 post tumor injection and analyzed
for overt metastases (overt-met) (n=20/group) and histologically observed metastases
(HO-met) (n=10mice/group). (A) Hematoxylin and eosin (H & E) stained section of lungs
with HO-met. (B) Median number of overt-mets and (C) median lung weights at autopsy.
(D) H & E liver sections with HO-met. (E) Median number of overt-met on the liver surface
and (F) median liver weights at autopsy. (G) H & E stained sections from spleens showing
foci of myeloid cells. (H) Spleen weights. (I) Linear regression analysis of tumor weight.
(J) H & E stained sections of decalcified femurs that had HO-met. (K) One mouse from
the ω-3 group has one smaller HO-met while 5 mice in the ω-6 group had small to large
sized HO-met. Images (A), (D), (J) and (K) were taken at 100x. Images of G and J were
taken at 25x and 400x magnification respectively. *p<0.05 compared to the mice fed ω-6
diet (Mann-Whitney test).
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Figure 23. Influence of tumor weight on lung and liver weight

Mice autopsied on day 35 post tumor injection (n=20) were evaluated for lung, liver and
tumor weight. Relationship of tumor weights with (A) lung weights and (B) lung overt
metastases counts and (C) liver weights at autopsy. Pearson’s correlation analysis was
performed.
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5.3.3. Effect of dietary PUFA in 4T1 tumor metastasis to heart, kidneys and ovaries
Heart, kidneys, and ovaries are not primary targets of 4T1 mammary tumor metastases
[409, 420, 421] and therefore are infrequently reported. In this study, we observed an 83%
lower incidence of cardiac metastases in mice receiving dietary LC-ω-3FAs (2/20 mice)
compared to the incidence in mice on the ω-6 diet (12/20 mice) (p<0.05) (Table-8). Mice
from the ω-3 group with cardiac metastases had a single nodule of overtmetastases
(median=0; range: 0-1) on the pericardium, which was a significantly lower number
compared to the frequency found on the pericardium from the mice fed ω-6 diet
(median=1; range:0-5). Histological analysis of myocardial metastases deeper in the
cardiac tissue was performed by evaluating the frequency and size of histologically
observed metastases per cross section of cardiac tissue (n=10/group) (Fig. 24A-24B).
The results showed the incidence of cardiac histologically observed metastasis in cardiac
tissue was 67% lower in mice fed the ω-3 diet (2/10) relative to the incidence in the ω-6
group (6/10) (p=0.16). Both of the mice from the ω-3 group with myocardial metastases
had a single histologically observed metastasis (median=0; range: 0-1) while mice on the
ω-6 diet had a median=1; range of 0-5 metastatic foci in heart tissue (p=0.07). The median
size of cardiac histologically observed metastatic foci in the ω-3 group was significantly
lower (median=0; range: 0-1.730) mm2 compared to metastases size in ω-6 group
(median= 0.491; range: 0-7.698) mm2 (p<0.05). The cardiac metastases in mice fed the
ω-3 mice were limited to the pericardium; while the metastatic foci were present in
pericardium, as well as deeper in the cardiac tissue of the mice from the ω-6 group.

Renal metastases were analyzed by counting the number of overt metastases nodules on
the renal membrane, histologically observed metastases per renal cross-section and by
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determining the size of the histologically observed metastases (Fig. 24C-24D). We
analyzed metastases in both kidneys of the mice and expressed our data as the incidence
of metastases in one kidney or both kidneys per mouse. The incidence of having
overtmetastases in at least one kidney of the mice fed ω-3 diet (2/20) was significantly
(87%) lower relative to the incidence in the ω-6 group (15/20). Similarly, there was a 72%
lower incidence of overtmetastases in both kidneys of mice fed ω-3 diet (2/20) relative to
the ω-6 group (7/20) (p=0.4) (Table-7). Further, the median number of overt metastases
per kidney for the ω-3 group (median: 0 range: 0-2) was significantly lower from that of
the ω-6 group (median:1, range:0-4). Histological analysis (Fig. 24C - 24D) confirmed that
the incidence of histologically observed metastasis in at least one kidney was 83% lower
in the mice fed ω-3 diet (1/10 mice) relative to the ω-6 group (6/10 mice). None of mice
from the ω-3 group had histologically observed metastases on both kidneys in the ω-3
group; while, (2/10) of mice on the ω-6 diet had metastasis in the histological sections
from in both kidneys. The single metastatic lesion found in the kidney of a mouse from
the ω-3 diet was found attached to the renal peri-capsular area, but did not invade into the
renal parenchyma. In contrast, amongst the 20 metastatic lesions analyzed in the kidneys
from mice fed the ω-6 diet, 35% were located in the peri-capsular fat and attached to the
renal capsule, 45% were located on the adrenal gland and 20% were located in the renal
parenchyma. The median size of histologically observed renal metastases in a ω-3 dietfed mice (median=0; range:0-0.222 mm2 ) was significantly lower compared to the median
size from kidney of ω-6 diet-fed mice (median=0; range: 0-3.554 mm2). Overall, the results
suggest that the incidence of kidney metastases (both overt and histologically observed)
were significantly lower in the mice fed the ω-3 diet compared to the mice fed the ω-6 diet.

Representative images of an ovarian cross-section with histologically observed
metastases and variations in their size between the dietary groups are presented in (Fig.
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24E-24F) (n=10/group). Among the ovarian cross-sections examined, the ovaries with
intact capsule, cortex, medulla and follicles were included in the quantitative analysis of
histologically observed metastases. The incidence of having metastasis in at least one
ovary was significantly lower (89%) in mice fed ω-3 diet (1/10 mice) relative to the
incidence in the ω-6 diet-fed group (8/9 mice). Similarly, in the ω-3 diet-fed group, none
of mice had metastasis in both ovaries (0/9 mice), while 86% (6/7mice) had metastasis in
both ovaries in mice on the ω-6 diet. There was significantly fewer number of metastatic
lesions met (median=0; range: 0-3), and the lesions were significantly smaller in size
(median=0; range: 0 - 0.010 mm2) in the mice fed the ω-3 diet compared to the frequency
(median=3; range: 0-8), and size (median= 0.088; range: 0 - 0.939 mm2) of ovarian
metastases in mice fed the ω-6 diet. Collectively, these results suggested that mice on the
ω-3 diet had a significantly lower incidence/frequency and smaller ovarian metastases
compared to the respective observations in the mice fed the ω-6 diet.
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Figure 24. Dietary PUFA regulation of 4T1 metastasis to the heart, kidneys and
ovaries.

Mice (n=10/group) autopsied on day 35 post tumor injection were analyzed for
histologically observed metastases (HO-met). (A) Hematoxylin & eosin (H & E) stained
cardiac cross section showing myocardial HO-met. (B) Two of the ten mice fed the ω-3
diet had small cardiac HO-met and six of the ten mice on the ω-6 diet had larger HO-met.
(C) H & E stained renal cross-sections showing HO-met in each dietary group. (D) One of
the ten mice fed the ω-3 diet had one small renal HO-met in one kidney, while six of the
ten mice on the ω-6 diet had larger HO-met. (E) H & E stained ovarian cross-sections
showing HO-met in each dietary group. (F) One of the ten mice fed the ω-3 diet had small
ovarian HO-met, while eight of the nine mice on the ω-6 diet had larger HO-met. Scale
bars in images (A), (C) and (E) represent 200 µm length. Horizontal line in (B), (D) and (F)
represents median. *p<0.05 mice fed ω-3 versus ω-6 diet.
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5.3.4. Metastases in the contralateral mammary gland
The fifth left MG was injected with tumor cells and the fourth right MG was assessed for
the presence of metastasis in CMG that is distant to the primary tumor. Out of n=10
mice/group in which metastases were analyzed histologically in CMGs, metastases were
observed in three mice in the ω-3 group (range: 0-1 /CMG) and four mice in ω-6 group
(range 0-6 /CMG) respectively (p=0.4). In addition to studies into metastases to the CMG,
we also examined metastases to the associated MG lymph node (Fig. 25A - 25B). Among
the analyzed lymph nodes in the CMG sections, metastases were observed in 100% of
lymph nodes from both dietary groups. We did not find any lymph node in the tumor
injected MGs, which might be due to the aggressive growth of the tumor throughout the
MG.

In a histological analysis, tumor cell morphology of the CMG metastases from the ω-6 diet
appeared more proliferative, compared to metastases in CMGs from ω-3 mice, an
observation confirmed by Ki67 staining. In the Ki67 IHC studies, the

frequency of

proliferating tumor cells in the CMGs from ω-3 diet-fed mice were 74% lower compared to
tumor cells from the CMG from the ω-6 group (n=3, p<0.05) (Fig. 25C-25D). In addition to
the CMG metastases, the mammary ducts in the CMG from ω-6 fed mice had a
significantly higher number of proliferating cells (Ki67+), which was rarely observed in the
mammary ducts from the ω-3 group. Our analysis of 10 fields/sample for n=10 mice/group
showed that ω-3 diet-fedmice had 97% fewer proliferating cells in the ductal epithelial
layer (Fig. 25E-25F) relative to mice on the ω-6 diets (p<0.05). We previously showed that
NTB mice on the ω-3 diet had thinner epithelia, ductal stroma, and fewer proliferating
epithelial cells and macrophages in adipose tissue of MFPs compared to mice in the ω-6
fed group [110]. The current analysis of CMGs from TB mice support these previous
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observations; but the extent of effects may be influenced by the presence of the primary
tumor. In the current study, the 4T1 TB mice fed the ω-3 diet had 59% fewer F4/80+
macrophages in the periductal area and 52% fewer in the adipose tissues of the CMG,
compared to the respective analysis in CMG from TB mice fed ω-6 diet (n=10, p<0.05)
(Fig. 25G-25J). The infiltrating macrophages in the CMG from 4T1 TB mice were
increased (data not shown) and appeared to be larger and morphologically activated, with
multiple cytoplasmic granules, compared to those observed in the MGs from NTB mice
independent of the dietary group (Fig. 26A-26B). These results suggest, dietary PUFA
might influence the number of infiltrating macrophages in both NTB MGs and TB CMGs
but the presence of primary tumor further enhance the number and activity of infiltrating
macrophages. Additionally, individual tumor cells were observed around the ducts in
association with an increased number of infiltrating macrophages, notably in the CMGs
from the ω-6 group. Collectively, our data document that prior exposure to dietary PUFAs
modulate the CMGs microenvironments to be tumor promoting or suppressing, depending
on the type of PUFA, and might further regulate the proliferation of tumor cells in the CMG
metastases.
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Figure 25. Dietary PUFA regulation of contralateral mammary gland metastasis.

Mice (n=10/group) autopsied on day-35 post tumor injection were analyzed for
histologically observed metastases (HO-met) in contralateral mammary gland (CMG). (A)
H & E stained CMG sections showing tumor HO-met arrested in the CMG (B). Incidences
of HO-met in the CMG lymph node (LN) and the CMGs. Note, that a CMG LN was
sectioned in only six of the ten CMG. (C) Proliferating tumor cells in CMG HO-met as
shown by Ki67 staining. (D) Quantitative analysis of proliferating tumor cell frequency in
the HO-met of the CMGs. (E) Ki67 staining for proliferating cells in the ductal wall of CMGs
and (F) their frequency. (G) F4/80+ macrophages in the ductal wall of CMGs and (H) their
frequency. (I and J) F4/80+ macrophages in adipose tissue of CMGs. Images of (A) were
taken at 100x and those of (C), (E), (G) and (I) were taken at 200x. *p<0.05 mice fed ω-3
versus ω-6 diet and were analyzed using t-test.
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Figure 26. Differential morphology of F 4/80+ macrophages in MGs from NTB and
TB mice
Mammary glands (MGs) from NTB mice were collected after feeding the diets for 16
weeks. Contralateral MGs were collected from mice autopsied on day 35 post tumor
injection. The morphological differences of F 4/80+ macrophages were shown in (A) MGs
from NTB mice and (B) CMGs for TB mice from the each of dietary group. Arrows showing
F 4/80+ macrophages.
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5.3.5. Dietary PUFA regulation of mammary tumor cell proliferation, apoptosis and
neo-vascularization

Mammary tumors from mice (n=10 mice/group) were collected on day 35 post tumor
injection for the analysis of dietary PUFA regulation of the tumor microenvironment. We
obtained representative CS from these tumors containing oxic, hypoxic and necrotic tumor
zones. The sub-capsular, oxic areas of tumors were used for all IHC evaluations. Our data
showed that a diet high in LC-ω-3FA, fed for 16 weeks, prior to tumor challenge decreased
the number of proliferating (Ki67+) primary tumor cells by 44% (49 ± 7 cells/HPF)
compared to the tumors from the mice fed the ω-6 diet (87 ± 7 cells/HPF) (p<0.05) (Fig.
27A and 27B). In contrast, the tumors in the ω-3 fed mice had a 50% higher frequency of
apoptotic tumor cells (8 ± 1 cells/HPF) relative to the tumors from the mice fed ω-6 diet
(4 ± 1 cells/HPF) (p<0.05) (Fig. 27C-27D).
PUFA regulation of intra-tumoral neo-vascularization was also evaluated as CD31+
vessels in oxic areas of the tumors. These studies showed that mice fed an ω-3 diet had
34% fewer neo-vascular vessels (14 ± 1 vessels/HPF) relative to the counts in the ω-6
diet-fed mice (22 ± 2 vessels/HPF) (p<0.05) (Fig. 27E-27F). Morphologically, the vessels
in the tumors from the ω-3 group were smaller and of uniform size; while the vessels in ω6 fed mice were larger, connecting with an irregular structure. The number of CD31+
vessels, and the number of proliferating tumor cells were positively correlated with the size
of the tumors, while an inverse correlation was observed between the number of apoptotic
cells in the tumors and the tumor size (Fig. 27G-27I). We note that the tumor sizes of the
mice on ω-3 diet were significantly smaller relative to tumors of mice on the ω-6 diets (Fig.
21C-21D). Further, a direct correlation was found between the CD31+ vessels and the
number of F4/80+ cells in tumors (Fig. 27J) indicating a potential role of tumor infiltrating
macrophages in enhancing neo-vascularization.
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Figure 27. Dietary PUFA regulation of 4T1 tumor proliferation, apoptosis and neovascularization.

Mice (n=10/group) were autopsied on day 35 post tumor injection and well oxygenated,
peripheral tumor sections analyzed by immunohistochemistry (IHC). (A) Representative
images of tumor tissue stained with Ki67 staining. (B) Frequency of proliferating tumor
cells. (C) Tumor tissue showing TUNEL+ nuclei. (D) Differences in TUNEL positive
apoptotic cells between the dietary groups. (E) Intra-tumoral neo-angiogenesis as shown
by CD31+ vessels in actively growing areas of tumor. (F) Differences in tumor associated
neo-angiogenesis between the dietary groups. Correlation analysis between tumor
weights and (G) Ki67+ cells. (H) TUNEL+ nuclei. (I) CD31+ vessels per high power field
(HPF). Relationship between the number of CD31+ vessels in tumor with (J) the number
of F4/80+ cells and (K) the number of CD3+ cells in tumor. Pearson’s correlation analysis
was used for statistical test. Images (A), (C) and (E) were taken at 400x. *p<0.05
compared to the mice fed ω-6 diet.
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5.3.6. Dietary PUFA regulation of mammary tumor inflammatory
microenvironments
Tumor infiltrating neutrophils were assessed as the frequency of elastase positive (NE+)
cells, as were the frequency of F4/80+ macrophages and CD3+ T-cells to characterize the
tumor microenvironment between the dietary groups (n=10). There were 52% fewer
neutrophils infiltrating the tumors from mice fed the ω-3 diet (10 ± 2 cells/HPF) compared
to tumors from mice fed the ω-6 diet (22 ± 4 cells/HPF) (p<0.05) (Fig. 28A-28B). Similarly,
infiltrating F4/80 positive macrophages were 49% lower in mice fed the ω-3 diet (5 ± 1
cells/HPF) compared to the mice on the ω-6 diet (10 ± 1cells/HPF) (p<0.05) (Fig. 28C28D). In contrast, mice on the ω-3 diet had a 102% more infiltrating T-cells (23 ± 3
cells/HPF) compared to tumors from mice on the ω-6 diet (11 ± 1 cells/HPF) (p<0.05) (Fig.
28E-28F). Based on studies that have shown that the neutrophil to lymphocyte ratio (NLR)
can be used as an independent prognostic factor and that a high NLR is associated with
shorter survival of patients [422] we assessed these ratios as well. Feeding a LC-ω-3FA
diet for 16 weeks prior to tumor challenge significantly lowered the NLR by 76% in 4T1
mammary tumors compared to the mice fed the isocaloric, isolipidic ω-6 diet. Further, the
NLR directly correlated with tumor size (Fig. 28J). In addition, a direct correlation between
tumor size and infiltration by neutrophil-elastase positive (NE+) myeloid cells and
macrophages, but an inverse correlation with infiltrated T-cells (Fig. 28G-28I) was noted.
Further, the number of T-cells in tumors was inversely correlated with the intra-tumoral
neo-vascularization (Fig. 27K) and directly correlated with the number of apoptotic tumor
cells (Fig. 28K) Thus, the differences in the tumor microenvironments may be associated
with both tumor size and indirectly or directly associated with diet. This suggests a critical
role for dietary PUFA composition in the regulation of the inflammatory tumor
microenvironment, and that an increase in a dietary LC-ω-3FA may regulate tumor growth
by decreasing inflammatory cells and increasing lymphocyte infiltration.
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Cytokines and chemokines are mediators of inflammation, including myeloid cell
proliferation and infiltration, and can have a critical role in tumor growth and progression,
depending on the type and function of the cellular mediator. The mRNA expression of
inflammatory and immune regulatory mediators in tumors and spleens was analyzed from
mice autopsied on day-35 post tumor injection (n=10/group). Sections of tumors from
subcapsular, actively growing tumor areas were collected for the evaluation of mRNA
expression to avoid the influence of hypoxic condition on the mRNA expression of the
target genes. Among the analyzed target genes, there was no difference in mRNA
expression levels of NFkB, G-CSF, GM-CSF, TNFα, CCL2, PTGS2, LEP, IGF1, CXCL5,
CXCL1 and AREG in tumors between the dietary groups. Unexpectedly, we observed a
significant (6 fold) higher expression level of IL10 mRNA in the tumors from mice fed ω-3
diets relative to the expression in tumors from ω-6 diet-fed mice (Fig. 29A). We compared
the expression levels of the indicated genes in tumors of both groups with the respective
gene expression levels in NTB spleens to evaluate if mRNA expressions was directed by
tumor growth and/or dietary PUFA differences. Our data showed that the tumor mRNA
levels of PTGS2, CCL2 and G-CSF from both dietary groups were significantly higher
relative to the respective mRNA levels in NTB spleens. In contrast, IL10 mRNA level was
not different in the tumors of the ω-3 group but significantly lower in the tumors from ω-6
group relative to the level in NTB spleens (Fig. 29B). Further, there was a indirect
correlation between the mRNA levels of IL10 with tumor size (Fig. 29C) but no relationship
was observed in the levels of G-CSF, PTGS2 and CCL2 with tumor size (Fig. 29D-29F).
Collectively our data showed that the mRNA expression of PTGS2, CCL2 and G-CSF
were associated with the presence of 4T1 tumors and that diets may have minimal effects
on their expression; however, the IL10 expression in the tumors might have been
modulated by dietary PUFA composition.
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Figure 28. Dietary PUFA regulation of 4T1 tumor inflammatory cell infiltration.
Mice (n=10/group) autopsied on day 35 post tumor injection were assessed by IHC for
leukocyte infiltration of well oxygenated, peripheral tumor sections. (A) Infiltration of
neutrophil-elastase positive (NE+) myeloid cells in tumor. (B) Quantitative differences in
the number of infiltrated cells per high power field (HPF) between the groups. (C)
Infiltration by F4/80+ macrophages in tumors. (D) Differences in the number of invading
macrophages per HPF between the groups. (E) T-cell infiltration assessed as CD3+ cells.
(F) Plot comparing the frequency of T-cells per HPF infiltrating the tumors. Correlation
analysis of tumor weights. (G) Neutrophil-elastase+ cells. (H) F4/80+ nuclei and (I) CD3+
cells per HPF (Pearson’s correlation analysis). (J) Relationship between neutrophil to
lymphocyte ratio (NLR) (evaluated by NE+cell number/ T-Cell number) and tumor weight
(Pearson correlation analysis). (K) Correlation analysis of CD3+ T-cells with apoptotic cells
in tumor. Images (A), (C) and (E) were taken at 400x. *p<0.05 fed ω-3 versus ω-6 diet
(independent sample t-test for IHC data and one sample t-test for qPCR data).
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Figure 29. Dietary PUFA regulation of inflammatory mediators
Tumor tissue from peripheral tumor sections, and sections of spleen were collected from
mice autopsied on day 35 post tumor injection for evaluation of mRNA expression by qRTPCR (n=10/group). (A) qPCR analysis of the mRNA levels of the indicated genes in the
tumors from ω-3 (W3) diet-fed mice. Data are expressed as the fold change (FC) relative
to the corresponding mRNA levels in the tumors from ω-6 group. (B) mRNA levels as a
FC of the indicated genes in tumors from ω-3 and ω-6 diet-fed mice relative to the
expression levels in the spleen from NTB control mice. (C) Correlation analysis of
comparing FC of IL10 mRNA in tumors (D), G-CSF, (E) PTGS2 and (F) CCL2 relative to
the levels in NTB spleen versus tumor weight (D). For statistical analysis, dCts were
compared by Student’s t-test in (A) and (B). *p<0.05 versus ω-6 diet group and #p<0.05
versus NTB spleen. Pearson’s correlation analysis was performed for (C-F).
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5.4. Discussion
In this study, we present evidence that LC-ω-3FAs-containing diets in adult life
significantly decreased 4T1 mammary tumor induction, growth, metastasis to multiple
organs and enhanced survival of mice compared to mice pair-fed with an isocaloric,
isolipidic ω-6FA diet. The outcomes were consistent with the observed differences in
tumor microenvironments including tumor cell proliferation, apoptosis, neo-vascularization
and infiltrating immune cells between the two dietary groups. We have previously shown
that feeding a LC-ω-3FAs diet for 16 weeks of adult life resulted in decreased MG density,
ductal epithelial cell proliferation and decreased expression of inflammatory mediators in
MGs [110] and liver [266]. In our current study, we extended these observations to dietary
PUFA-mediated alterations in mammary tumor microenvironments that regulate tumor
growth and metastasis.

The observations of significantly lower body weight gains in mice fed an ω-3FA diet
compared to the mice fed an ω-6FA diet during NTB phase is consistent with our previous
studies using the same dietary model [110, 266]. BALB/c mice are refractory to obesity
[7], such that their body weights did not increase significantly , following consumption of a
high fat diet (60% calories from fat) for 16 weeks [7]. Thus our observation of significant
differences in body weights, on diets with 36% calories from fat, after a 16 week diet
feeding period, may be due to lack of body fat deposits on the mice fed LC-ω-3FAs diets,
rather than a significant increase in body weights on the ω-6 diet group [110]. The potential
mechanisms behind the difference in the body fat depositions are more likely

by

differential regulation of metabolism and adipogenesis by dietary PUFAs [361, 365].
During tumor bearing phase, mice fed the ω-6 diet lost more weight compared to their
body weights prior to tumor injection. During tumor growth, body weight is more influenced
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by tumor associated metabolic disorders, including cachexia and adipose tissue atrophy
than the effects by a dietary calories and composition [423, 424]. Further, when the energy
generated from dietary calories is not sufficient to fulfil the requirement for hyperproliferative tumor cells, beta-oxidation of body fats occur to generate energy
endogenously, resulting in the weight loss [425]. In these studies, tumors were initiated
earlier, growing faster resulting in around double sized tumors on day 35 and had more
metastasis in the mice fed a ω-6 diet compared the mice from ω-3 group, so it is likely
that they lost more weight due to tumor growth associated factors as discussed before.

Whether tumor growth and metastasis are regulated by PUFA composition or specific
PUFA metabolism is not directly addressed in our studies. However, we have separated
PUFA composition from caloric composition with the use of an isocaloric diet. This
provides a model to address the role of ω-3 versus ω-6FA composition on tumor growth
and metastasis. Further, the timing (in utero, pre/puberty or adult) of dietary PUFA
consumption may also have a critical role in these parameters as well as mammary
tumorigenesis. The results from the studies based on in utero/prepubertal dietary
exposure helps to understand the role of PUFAs in mammary tumorigenesis during MG
development. Studies with autochthonous mammary tumors have shown that fish oilbased diets markedly suppress mammary tumor incidence, multiplicity and MG
hyperplasia in murine mammary tumor virus (MMTV)-HER-2/neu transgenic mice [426,
427]. Similarly, pre-pubertal consumption of a low-fat (16% calories from fat) ω-3 diet but
not a high-fat (39% calories) ω-3 diet induced mammary epithelial differentiation by
reducing TEBs, increasing apoptosis and reducing cell proliferation, as well as, decreasing
mammary tumor incidence, compared to a low-fat ω-6FA diet [118, 428]. These results
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emphasized the critical role of calories from FAs as well as dietary composition in
mammary tumorigenesis.
The current study is based on dietary consumption during adult life using isocaloric and
isolipidic diets to assess the role of PUFA composition on the growth of orthotopically
implanted mammary tumors. . As we started the diets earlier than tumor injections, our
study emphasizes the potential prophylactic role of dietary LC-ω-3FAs in the control of
tumor growth and metastasis by modulating microenvironments by prior exposure of the
diets. Among the 40 mice/group in two studies, two mice from the ω-3 group did not
develop tumors. Potential reasons for this might be due to technical issues related to the
low number of tumor cells injected (5,000 4T1 cells), compared to most prior reports [7,
429, 430]. Alternatively, the delay in tumor development in the ω-3 group may be due to
ω-3FAs mediated microenviromental changes. We report that mice fed the ω-3 diet had
a significant delay in tumor induction resulting in 50% smaller tumors at autopsy on the
day 35 post tumor injection, compared to the mice fed the ω-6 diet. These findings are
consistent with previous studies using autochthonous mammary tumors in rodents fed ω3FA-enriched diets [426, 427] or studies with the fat-1 transgenic mice capable of
endogenously producing ω-3FA [125] and orthotopic mammary tumor models [431, 432].
However, this is the first study using rodents receiving isocaloric and isolipidic diets and
pair feeding in the analysis of tumor growth and metastases to multiple organs.

4T1 mammary carcinoma tumors spontaneously metastasize to multiple organs [433] in
a process involving both soil and seed properties [227, 230]. BCs usually metastasize to
lymph nodes, bone, lungs and liver [230, 434] and less frequently to the ovaries [405],
heart, and kidneys [406, 407].

The 4T1 mammary tumor is an aggressive tumor

spontaneously metastasizing to the lungs [228] and less frequently to other organs
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including the liver, brain, bone [7, 408-411, 420], heart, and kidney [408, 411] while, no
report published to our knowledge, has described metastasis to ovaries and CMGs by the
parental 4T1 tumor cells. In our present study, we report dietary PUFA regulation of a
frequency and number of spontaneous metastasis to both common and infrequent organs.
The presence of pulmonary metastases was anticipated, as lungs are preferential site of
metastasis in most murine mammary tumor models. Further, the direct correlation of lung
weights and pulmonary overt metastases with the tumor size indicates the potential role
of slower tumor growth in ω-3 diet-fed mice in having less burden of pulmonary
metastases compared to the ω-6 group is a novel observation.
Although, the incidence of hepatic metastasis was lowered by 35% in the ω-3 group, we
did not observe significant differences in either hepatic overt metastases counts or liver
weights between the dietary groups. We previously reported that the liver weights of NTB
mice fed an ω-6 diet were significantly lower compared to the livers from mice fed the ω3 diet. The differences in liver weights were accompanied by differences in hepatic storage
of fat versus glycogen in mice given ω-6 or ω-3 diets respectively [266]. Thus, our
observation of similar liver weights in TB mice between the dietary groups may be due to
an increase in liver weights of TB mice on the ω-6 diet, potentially by the presence of a
greater number of metastases in the hepatic parenchyma (Fig. 22D). Spontaneous bone
metastases are infrequently reported by primary 4T1 tumors, compared to their
occurrence following intra-cardiac or intra-tibial inoculation of 4T1 cells or the bone trophic
variant that favors colonization of the femurs/tibias (4T1.2) [419, 435, 436]. In the current
study, using a low number of 4T1 parent cells, we observed dietary PUFA regulation of
bone metastases and an 80% lower incidence of spontaneous femur/tibia metastases in
mice fed an ω-3 diet relative to mice given an ω-6 diet. Previous studies have shown that
dietary fish oil prevents osteolytic lesions following intra-cardiac injection of MDA-MB-231
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breast cancer cells and bone metastases [437]. These data were supported by the findings
that DHA and EPA significantly attenuated the migration/invasion of MDA-MB-231 BC
cells in-vitro as well as reduced cell migration to bone [437, 438]. Further, other studies
have shown a beneficial role of fish oil in bone health, including inhibitory activities of DHA
for osteoclastogensis [413] and calcium bioavailabity [439], and a negative correlation of
the dietary ω-6:ω-3 ratio with bone formation [412, 440]. Thus, it is unclear, if a dietary
PUFA modulation of osteolytic pre-metastatic niches in bone acts as a chemoattractant
for metastases to bone, or PUFA modulated bone metastases regulate osteolysis
suggesting that further mechanistic studies of bone metastases are needed.
Cardiac and renal metastasis are rarely reported metastatic sites for any tumor type. The
lower incidence may be due to the lymphatic network in these organs, composition of the
tissue microenvironments or physiological functions of the organ (for example, myocardial
contractions) [406, 441]. However, it is also possible that metastases to these sites may
have been overlooked when focusing on the burden of metastases in the more common
metastatic sites. This is supported by the frequent findings of cardiac metastases in postmortem examinations [442-444]. In this study, a diet enriched in ω-3FA was associated
with lower incidences of cardiac and renal metastases, relative to the respective
incidences in mice fed an ω-6 diet. Further, the observation of a significantly lower number
and size of histologically observed metastases in the heart and kidney of mice given the
ω-3 diet suggests a role of the dietary LC-ω-3FAs on the establishment and growth of
metastatic cells in those tissues, potentially due to modulated tissue microenvironments.
However, our study is the first reporting dietary PUFA regulation on cardiac and renal
metastasis of a murine carcinoma, thus further mechanistic studies are warranted.
Although the ovary is not a preferential site for BC metastasis, ovarian metastasis have
been detected in autopsies from young women with BC [405, 445]. Differential diagnosis
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of ovarian metastasis by BC are challenging because ovarian cancer is frequently
diagnosed as a primary tumor rather than a metastatic lesion [446]. We did not find any
previous reports of spontaneous 4T1 ovarian metastasis or for any other mammary
tumors. Interestingly, we observed a significant decrease in number of mice with ovarian
metastasis that were fed the LC-ω-3FA diet relative to mice in the ω-6 group. Further,
metastasis were found extensively in the follicular regions in mice fed an ω-6 diet, while
the growth was limited to medullary region of ovaries in mice fed the ω-3FA diet, indicating
the critical role of PUFAs in growth of tumor cells in the ovarian microenvironment.
Potential mechanisms are the regulation of prostaglandin E2 and estrogen levels by LCω-3FA, as reported with ovarian cancer growth [447-449]. However, further mechanistic
studies in animal models of mammary tumors are needed to evaluate the specific roles of
LC-ω-3FAs in BC ovarian metastasis.
CBC metastases have been diagnosed in 11% of BC survivors [450]. CBC can be a new
cancer or invasion of metastatic tumor cells in the second breast, but due to challenges in
differential diagnosis of the clonal origins, most CBC are treated as a second BC [450,
451]. A recent study reported a direct relationship between breast density and incidence
of CBC in women with a primary BC [452]. Recently, we showed that the MGs of NTB
mice fed a LC-ω-3FA diet had significantly lower ductal densities and macrophage
infiltration, relative to the MGs from NTB mice given an ω-6 diet [453]. However, there are
no reports on the association of LC-ω-3FA in the induction of CBC, nor murine studies on
the role of ω-3FA, on metastasis to CMG. In the current study, we did not find significant
differences in the incidence of CMG metastases between the dietary groups.
Nevertheless, there were significantly fewer proliferating tumor cells in the metastases of
CMG of mice fed an ω-3 diet, which was accompanied by fewer proliferating epithelial
cells in the ductal epithelium and infiltrated macrophages relative to the respective findings
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in mice given an ω-6 diet (Fig. 25C-25H). Additionally, the macrophages infiltrated in tumor
tissue were larger and granulated compared to the macrophages we observed in MGs
from NTB mice (Fig. 26). These data suggest that tumors’ growth might regulate the
activation of macrophages in CMGs from TB mice, however further studies are warranted
to evaluate the macrophage phenotypes. Collectively, our previous data from NTB mice
[453] and our current analyses of CMG metastases in 4T1 TB mice, suggests that the
consumption of LC-ω-3FAs may suppress pro-inflammatory mediators and growth factors,
thus modulating the microenvironment, inhibiting successful 4T1 metastasis in the CMG
of mice fed the ω-3 diet. These observations are supported by previous findings of the
ability of ω-3FA to inhibit mammary tumor growth in-vitro [454] and in-vivo [401, 455].
Splenic BC metastases are a rare event in humans [456] and have been infrequently
reported in mice bearing 4T1 murine carcinomas [408, 457]. Splenomegaly in a 4T1 tumor
bearing mouse is strongly associated with extramedullary hematopoiesis, driven by
myeloid growth factor secretion by 4T1 cells [206, 458, 459]. In these studies, as we
expected, we observed splenomegaly in TB mice from both dietary groups compared to a
normal mouse spleen; however, mice from the ω-3FA group had significantly smaller
spleens, relative to those from ω-6FA diet-fed mice. Spleen weights were directly
correlated with tumor size in both groups and the histology demonstrated sub-capsular
myeloid hyperplasia. Thus, the observation of smaller spleens in the ω-3 groups may be
associated with the decreased tumor size.
The tumor microenvironment has a crucial role in tumor progression. In these studies, we
observed a significantly lower number of proliferating tumor cells, a greater number of
apoptotic tumor cells and less neo-vascularization in the sub-capsular oxic areas of tumors
from mice fed an ω-3 diet, relative to the same analyses in the ω-6 fed groups. DHA has
been shown to induce tumor cell apoptosis and reduce proliferation in vitro and in vivo,

174
potentially by increasing lipid peroxidation [460], tumor cell cytotoxicity [400], inhibition of
pro-inflammatory eicosanoids [461] and cell cycle arrest [462, 463]. The induction of tumor
cell apoptosis has an important role in cancer therapy and represents a target for many
treatment strategies. As LC-ω-3FAs appear to cause selective cytotoxicity towards cancer
cells with little or no toxicity to normal cells, many studies have assessed the role of ω-3
PUFAs as a therapeutic adjuvant, to improve the efficacy and tolerability of traditional
anticancer therapies [400, 464-466].
Neo-vascularization is essential for tumor metastases, thus it is an important target in the
treatment of solid tumors, including BC [467, 468]. Our observation of lower numbers of
CD31+ vessels in tumor tissue from an ω-3 diet-fed mice suggests a decrease in tumor
neo-vascularization by dietary LC-ω-3FAs. In addition to a direct effect of active
metabolites of LC-ω-3FAs on mediators of neo-vascularization, such as vascular
endothelial growth factor (VEGF) [469], modulation of tumor infiltrating inflammatory cells
might also indirectly regulate neo-vascularization. Recent evidence indicates that tumorassociated immune cells, including macrophages, neutrophils, and mast cells can
stimulate tumor angiogenesis [470-473]. We found that infiltration of macrophages and
neutrophils in tumor oxic areas from mice fed ω-3 diets was significantly lower, relative to
their infiltration in the tumors from ω-6 diet-fed mice. Further, the number of neutrophils
and macrophages in tumor tissue directly correlated with tumor size and a direct
correlation was observed between the numbers of macrophage with the extent of neovascularization in tumors. These results suggest that macrophages mediating
downregulation of neovascularization might be one of the potential mechanisms of tumor
growth suppression by dietary LC-ω-3FA. Our results are supported by previous findings
on the effects of LC-ω-3FA metabolites in the suppression of tumor-associated
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macrophage infiltration and the association of macrophages with tumor angiogenesis
[130, 474-476].
The presence of tumor infiltrating T-cells has been associated with a better prognosis and
response to cytotoxic treatments in BC patients [477]. In contrast, a neutrophilic response
can inhibit immunity by suppressing the cytotoxic activity of T-cells and is associated with
a poor prognosis in cancer [478].

The NLR of blood is an indicative of systemic

inflammation and clinical studies have demonstrated the prognostic value of a systemic
NLR

in multiple cancers, including BC [201, 422]. We evaluated NLR in tumor

microenvironment in this study as an index of pro-tumorigenic immune response. Our
finding of a greater number of T-cells and fewer neutrophils in tumors from mice fed a diet
rich in LC-ω-FAs, relative to the numbers in the ω-6 diet group, and a direct correlation of
NLR with tumor size indicates the potential of dietary LC-ω-3FAs in tumor growth
suppression by decreasing tumor supporting inflammation. Further, our results also
support a potential role of LC-ω-3FA as an adjuvant to enhance tumor therapies [479481].
In an analysis of potential mediators of inflammation and/or immune-regulation in the
tumor microenvironment, the expression of IL10 was significantly higher in tumors and
spleens of ω-3 diet-fed mice relative to the ω-6 group And IL10 expression in tumors was
negatively correlated with tumor size. These data suggest a potential role for dietary LCω-3FAs in the regulation of tumor and systemic inflammation via IL10 mediated pathways.
In tumor immunology, IL10 has multifaceted roles and has been associated with both poor
and good cancer prognoses [482-484]. It has been suggested that IL10 contributes to an
immune suppressive tumor microenvironment, however, recent studies have shown a role
for IL10 in stimulating antitumor activity of CD8+ T-cells [485] suggesting IL10 as a
potential therapeutic target for cancer treatment [486, 487]. The ω-3FAs have been
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associated with increased IL10 production in in-vitro and in-vivo studies, [488, 489] but the
role of LC-ω-3FA mediated IL10 in tumor microenvironment has not been fully elucidated.
In the present study, since increased IL10 expression in tumors was associated with tumor
size, our data indicates a potential novel mechanism of dietary ω-3FA mediated tumor
growth suppression; however, future mechanistic studies are warranted.
In our studies, we did not observe any significant difference in the expression of the
cytokines and growth factors we analyzed in tumors between the dietary groups, although
the expression of PTGS2, CCL2 and G-CSF were significantly higher in the tumors from
both groups relative to the respective levels in NTB spleens. Studies have shown 4T1
tumor message level of G-CSF [490, 491], PTGS2 (COX-II) [492] and CCL2 [493] were
associated with tumor growth and metastasis. It is noted that in our prior study [490], the
G-CSF message was associated with tumor cells and not infiltrating leukocytes, consistent
with in vitro studies showing high levels of G-CSF message and protein with 4T1 tumor
cells [491, 494]. Thus, our data indicate that the increase in intra-tumoral expression of GCSF, COX-II and CCL2 might be tumor cells dependent phenomenon and the dietary
PUFA may not significantly regulate those inflammatory mediators.
In this study, we reported the effects of dietary PUFAs in mammary tumor using 4T1
murine cell line and BALB/c mice. To validate that these effects are not limited to a single
tumor cell line and mouse strain, further studies are warranted using different mammary
tumor cell lines and mouse strains. Our findings suggest a potential prophylactic role of
dietary LC-ω-3FAs in breast cancer, and also emphasize for the need of future studies
(mechanistic/translational/clinical) to evaluate the therapeutic role of LC-ω-3FAs in breast
cancer growth, metastasis and in clinical management of co-morbidities in survivors.
There are ongoing clinical trials on the role of ω-3FAs in breast cancer prevention
(https://clinicaltrials.gov/ct2/show/NCT02295059) and a recent clinical study showed the
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beneficial effects of ω-3FAs. They are able to reduce arthralgia associated with aromatase
inhibitors treatment in obese breast cancer patients. Moreover, clinical studies focusing
on the role of LC-ω-3FAs as an adjuvant therapy and translational studies in
understanding of modulation of microenvironments of primary tumor and metastatic sites
would provide an insight on targeting LC-ω-3FAs associated pathways for an
advancement of anti-cancer therapies.
In summary, using isocaloric, isolipidic diets in a pair-fed model, we conclude that dietary
LC-ω-3FAs suppress mammary tumor growth resulting in lower frequency of metastases
to the preferential sites such as lungs and prolonged survival of the mice. Moreover,
considering the difference in the metastatic burden (incidence/frequency/size) in multiple
organs (specifically low preference metastatic sites: heart, kidney, ovaries, bone and
CMGs) between the ω-3 and ω-6 dietary groups, out data indicate dietary PUFA
composition have additive effects in metastasis, in addition to the regulation of metastasis
by primary tumor growth. Further, analyses of the tumor microenvironments showed
significantly lower neo-vascularization, macrophage infiltration, and NLR and higher T-cell
infiltration, tumor cell apoptosis and increased IL10 expression in the ω-3 diet-fed mice.
Together, these factors might contribute the suppressive effects on to the tumor growth
by dietary ω-3 PUFAs.
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Chapter 6:
Discussion/Summary and Future Directions
6.1. General discussion and summary
Dietary calories versus dietary composition are crucial factors in studies analyzing the role
of nutritional components in pathological outcomes. For instance, both hypercaloric and
hyperlipidemic diets induce obesity, which is a co-morbidity for multiple metabolic
disorders and a risk factor for BC development and negative outcomes [495-497]. Animal
studies have shown that high-fat diets stimulate increased food consumption and weight
gain through its low satiety properties [498]. Thus, balancing of total dietary calories,
calories from fat and food intake is important in the studies of fat composition as regards
to downstream effects. Among dietary FA studies, both ω-6 and ω-3FAs are essential FAs
that are competitive substrates for downstream pro- and anti-inflammatory pathways,
respectively. Evolutionary studies have indicated that humans evolved on diets that
contained an ω-6:ω-3 ratio of about 1:1; however, most current Western diets are high
caloric, high fat and have an ω-6:ω-3FA ratio of 20-25:1 and mostly lack significant
amounts of LC-ω-3FAs [25]. Animal studies evaluating the effects of dietary fats have
focused on high versus low fat diets; which also have a differential ratio of ω-6:ω-3FAs
and caloric consumption from fats [7, 118]. Thus, the present studies used isocaloric,
isolipidic diets and pair-feeding to evaluate dietary ω-6 and LC-ω-3FAs effects on tissue
microenvironments, in the regulation of mammary tumor growth and metastasis.
During preliminary optimization studies for the pair-fed model, we found that mice
administered the ω-3 diet consumed less diet compared to the mice receiving the ω-6 diet.
These observations suggested that the presence of fish oil in ω-3 diets makes them less
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palatable to mice or decreased satiety, resulting in thecconsumption of lower amounts of
food than isocaloric, isolipidic ω-6 diets, which have higher levels of olive oil and safflower
oil. Thus, we used the ω-3 diet as the baseline diet for pair-feeding and the same amount
of the diet consumed by the ω-3 group was given to mice from the ω-6 group on the next
day, so that the overall food intake by each group was balanced throughout the studies.
Using the optimized pair-feeding model, we investigated the effects of dietary PUFAs on
tissue microenvironments of the MG, which is the primary site of mammary tumor growth
(Chapter 3), the hepatic microenvironment; one of the major sites of metastasis (Chapter
4) and the cumulative effects of those pre-modulated microenvironments on mammary
tumor growth, metastases and survival (Chapter 5). We extended our analyses of
metastases to common and uncommon sites of metastases indicating dietary PUFA may
modulate the microenvironments of multiple organs, rendering them hospitable sites for
metastatic cell seeding and growth.
Our first series of studies evaluating MG macro- and microenvironments (Chapter 3)
showed that dietary ω-6 and ω-3 PUFAs have differential effects on MG morphologies
including ductal density, including the thickness and morphology of ductal end structures.
Mice fed ω-3 diets had significantly thinner ducts, fewer lateral branches and lack ductal
sprouts, resulting in a significantly lower MG density relative to mice consuming ω-6 diets.
This is an important observation as increased breast density has been associated with
increased risk for BC development [95]. Increases in breast density is most often attributed
to either increased stroma or epithelial mass in the breast. In histological analyses, both
ductal stroma and epithelium were significantly thinner and fewer numbers of proliferating
epithelial cells were observed in the mammary ducts of mice fed an ω-3 diet compared to
the ω-6 group. MG morphogenesis including ductal epithelial cell proliferation during
pubertal life is mainly regulated by estrogen, progesterone and growth hormones, while
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IGF1 also plays a role in branching morphogenesis. During pregnancy and lactating
phases, progesterone and prolactin have major roles in alveolar development and their
differentiation into milk secreting lobules [499]. In our studies, the expression of ESR1
was significantly lower in MGs from the ω-3 group. However, we did not observe
differences in the mRNA expression of the progesterone receptor and prolactin expression
was undetectable. These results can be explained by the use of mice in the studies that
were adults and virgin. It also indicates that the morphological differences we observed
are potentially regulated by other factors/cells in the MG microenvironment. Thus, we
analyzed local adipose tissue, whose fundamental function is to provide physical support
for the MG ductal network, but also has an active role in MG development [261], and
tumorigenesis [500].
The histological analyses of adipocytes in local MG microenvironments, as well as, in
abdominal adipose tissues showed that PUFAs regulate the hypertrophy of adipocytes
independent of total fat calories in the diets. We observed significantly smaller adipocytes
in MFPs and abdominal fat from mice fed ω-3 diets, a finding paralleled by higher mRNA
expression of adipokines including; leptin, IGF1 and IGF1R in the respective tissues.
Excessive adipocyte hypertrophy can induce hypoxic microenvironments in local adipose
tissues [501], which stimulates adipocyte apoptosis followed by the induction of proinflammatory mediators and recruitment of macrophages to clear the apoptotic bodies.
Our results showed that the MG microenvironments had significantly lower inflammation
as shown by fewer numbers of CLS/macrophages and a lower mRNA expression of
inflammatory mediators in mice fed ω-3 diet compared to the ω-6 group. Thus, it is likely
that dietary ω-3 and ω-6 PUFA may regulate FA metabolism in adipose tissues such that
increased dietary levels of ω-3FAs prevent FA storage by adipocytes compared to the
same levels of dietary ω-6FAs. Further, the prevention of local adipocyte hypertrophy
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might be one of regulatory mechanisms by which ω-3FAs limit pro-inflammatory
microenvironments in MGs.
Thus, our studies examining dietary PUFA regulation of MG microenvironments, showed
that the increased consumption of LC-ω-3FA lowers MG density and can prevent chronic
inflammation of local adipose tissue, potentially by controlling adipocyte hypertrophy and
associated adipokine and cytokine expression. Local expression of leptin can regulate
proliferation of both normal and malignant breast epithelial cells [316] and local adipose
tissue, and chronic inflammation has been found to contribute to BC development [403].
Therefore, we postulate that alterations in MG macro/microenvironments by ω-3 and ω-6
PUFAs regulate MG tumorigenesis by providing an unfavorable or favorable
microenvironment for tumor growth.
Since the liver is a common metastatic site in breast cancer, the second phase of our
studies investigated dietary PUFA modulation of the hepatic macro/microenvironment.
Hepatocytes metabolize dietary macromolecules, and depending on the excess energy
state, they can transiently store glycogen and FAs. The chronic storage of FAs by
hepatocytes leads to fatty liver disease, and if uncontrolled, progresses to hepatic
inflammation and fibrosis. Chronic consumption of alcohol or high caloric/high fat diets
have been associated with fatty liver diseases. Our studies showed that dietary LC-ω-3FA
limits hepatic FA storage compared to mice fed an isocaloric and isolipidic ω-6 diet. In
contrast, lobular hepatocytes from mice fed the ω-3 diet had significantly more glycogen
deposits compared to the mice given the ω-6 diet. These results indicate that dietary ω-3
and ω-6 have differential metabolic preferences/fates such that increased levels of ω3FAs potentially promote FA metabolism and/or distribution of FAs/energy to extrahepatic
tissue as needed. In contrast, high levels of ω-6FAs (or lack of LC-ω-3FA) may promote
FAs storage in hepatocytes and metabolism of glycogens to generate energy and
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distribution as needed. In either situation, the difference in hepatic storage of fat versus
glycogen can influence the hepatic microenvironment in many ways. The observation of
increased hepatic steatosis in the ω-6 diet group was also accompanied by increased
EMM, lower numbers of proliferating hepatocytes and higher numbers of apoptotic
hepatocytes, all of which might contribute to significantly lower liver weights of mice from
the ω-6 group relative to the ω-3 group. Collectively, dietary PUFA composition modulates
hepatic macro and microenvironments such that an absence of LC-ω-3FAs and increased
ω-6:ω-3 FAs promote hepatic steatosis, which may further regulate hepatocyte apoptosis,
proliferation and hepatic myelopoiesis. Therefore, we hypothesize that these alterations
in the hepatic microenvironment by PUFA composition might differentially regulate hepatic
metastasis from mammary tumor..
After evaluating the effects of dietary PUFA composition on the primary tumor site (MG)
and one of the major metastatic sites (liver) in NTB mice, we investigated the effects of
chronic dietary pre-exposure of PUFAs on 4T1 mammary tumor growth and metastases.
Our data showed that diets high in LC-ω-3FAs, consumed for 20 weeks, resulted in a
significant delay in tumor induction, smaller tumor size, and prolonged survival. Metastasis
is the main factor that regulates primary tumor survival. Thus, we analyzed mammary
tumor metastases in multiple organs and analyzed the tumor microenvironments of 4T1
TB mice autopsied on day 35-post tumor injection. Mice fed diets high in LC-ω-3FAs had
lower frequencies and/or incidences of spontaneous metastases in both common and
uncommon sites compared to the mice fed ω-6 diets. The lungs are the most common site
of metastases in the 4T1 mammary tumor model. We observed lung metastases in 100%
of mice from both of the groups; however, there was a significantly lower frequency of
overt-metss and pulmonary weights. Additionally, histological analyses suggested that
dietary LC-ω-3FAs lowers pulmonary metastases. Hepatic metastases are also reported
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in imaginable 4T1 models. In this study, quantitative analysis of the hepatic metastasis
burden was difficult to evaluate. In the studies on NTB mice (Chapter 4), we showed that
liver weights of mice fed ω-6 diets were significantly lower due to hepatic steatosis
compared to the observations in the ω-3 diet-fed mice. In 4T1 TB mice, there was no
difference in liver weights between the dietary groups. Altogether, the differential
outcomes of liver weights in NTB and TB mice indicates that mice fed ω-6 diet potentially
had increased hepatic metastases replacing hepatic fat content such that liver weights
increased in TB mice compared to NTB mice fed the same diet. Further, histological
analysis confirmed our hypothesis that hepatic metastases in mice fed the ω-3 diet were
mostly limited to subcapsular areas, while METs grew extensively in deeper hepatic tissue
in the mice from the ω-6 fed group.
Bone is also a common metastasis site in breast cancer patients but less commonly
reported in rodent’s mammary tumor models including in 4T1 (parent) mammary tumors
[238, 419]. Analysis of bone metastases in the hind limbs of mice fed an ω-3 diet, there
was an 80% lower incidence of bone metastases and the metastases were significantly
smaller relative to the mice fed a ω-6 diet. A single bone metastasis was found in only one
mouse in the ω-3 group, which was significantly smaller and located in the medullary
space of the femural diaphysis. Further, all analyzed bone metastases were located in
trabecular bone, which indicates a potential role of osteoclasts in the formation of bone
metastases. However, further studies are required to validate the role of a diet modulated
pre-metastatic niche in the establishment of bone metastases.
In addition to metastases in common sites, our data showed the incidence/frequency of
metastases in uncommon sites including heart, kidneys and ovaries were significantly
lower by feeding diets containing LC-ω-3FAs. The metastases in mice fed ω-3 diets were
significantly smaller and were limited mostly to the subcapsular regions of the heart,
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kidneys and ovaries. In the ovaries, the metastases were located outside of follicular
regions unlike the metastases in the deeper tissue of heart, kidney and inside follicular
regions of ovaries from mice fed an ω-6 diet. The difference in the metastatic growth in
the mentioned organs might be regulated by the metastatic niche in these sites [235].
However, in our current study, we did not analyze the effects of dietary PUFAs on the
modulation of microenvironments in these organs, nor did we evaluate the metastatic
sites. Thus, further studies are warranted to evaluate the mechanism(s) behind the
outcomes of the current study.
Our studies in NTB mice (discussed in Chapter 3) showed that dietary LC-ω-3FAs lowers
MG ductal density, ductal epithelial cell proliferation and local inflammation in MGs relative
to the mice fed an ω-6 based diet. As discussed above, modulation of the MG
microenvironments due to ω-3 consumption suppressed primary tumor growth.

We

extended our studies to evaluate the role of modulated MG microenvironment in
metastases to the CMG. There were metastases in the CMG associated LNs analyzed in
all of mice, which is expected as we evaluated metastases in the late stage of tumor
growth (day 35 post tumor injection). Further, there were insignificantly fewer mice with
CMG metastases in mice from the ω-3 group. However, when the metastatic
microenvironments were analyzed, we observed that there were significantly lower levels
of proliferation by tumor and ductal epithelial cells and lower infiltration by macrophages
to the CMGs from ω-3 diet-fed mice compared to the ω-6 group. The macrophages in the
CMGs of TB mice morphologically resembled activated (large and granulated structure)
macrophages as compared to macrophages in the MGs of NTB mice. Collectively, our
data showed that feeding of PUFA diets for 20 weeks prior to tumor injection modulated
CMG microenvironments, which potentially regulated the growth of metastases number
by suppressing or promoting proliferation of tumor cells in CMGs.
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Major factors that regulate local tumor growth and metastases are related to the
modulation of tumor microenvironments including neovascularization and recruitment of
pro- or anti-tumor inflammatory cells. The analysis of the tumor microenvironment showed
that tumors in the ω-3 group had significantly lower numbers of proliferating tumor cells
(Ki67+)/high power field (HPF), lower neo-vascularization measured as CD31+ vessels
and infiltration by neutrophil elastase+ cells, and macrophages (F4/80+) relative to the
tumors from mice in the ω-6 group. Tumor cell proliferation, intra-tumoral
neovascularization and infiltration of macrophages and neutrophils directly correlated with
tumor size indicating their direct roles in the promotion of tumor growth. In contrast, tumors
from the ω-3 fed mice had significantly higher numbers of apoptotic tumor cells
(TUNEL+)/HPF and infiltrating CD3+ T-cells, both of which indirectly correlated with tumor
size indicating their role in the suppression of tumor growth. Further, the macrophage
infiltration is directly correlated with neovascularization, while infiltration of T-cells is
directly correlated with the number of apoptotic tumor cells. Collectively, our data on the
inflammatory microenvironment of tumors on day 35 showed that the increased infiltration
of T-cells and decreased infiltration by tumor promoting myeloid cells including neutrophils
and macrophages might regulate tumor microenvironments in mice fed ω-3 diets resulting
in the suppression of tumor growth compared to the mice on an ω-6 diet.
Finally, we analyzed the mRNA expressions of cytokines/adipokines and growth factors
to understand their potential role in dietary PUFA mediated regulation of tumor
microenvironments. When the mRNA expression in tumors were compared to the
respective mRNA expression in spleens from NTB control mice, G-CSF, PTGS2 and
CCL2 were highly expressed in 4T1 mammary tumors in both dietary groups and the
expression was not different between the tumors from the dietary groups. These results
indicates that the expression of G-CSF, PTGS2 and CCL2 is largely regulated by 4T1
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tumors such that, the effects of dietary PUFA interventions in their expression was minimal
during tumor growth. Further, we did not observe any difference in the expression of NFkB,
GM-CSF, LEP, IGF1, CXCL5, CXCL1 and AREG either as compared to the expression in
NTB spleen nor in tumors between the dietary groups. It should be noted that we evaluated
mRNA expression in the tumor tissue that were collected on day 35 post tumor injection.
Thus, it is likely that cytokine expression levels may have been upregulated in the early
phases of tumor growth during recruitment of inflammatory cells, and that by day 35, the
expressed mediators may have been used for the respective signaling processes.
Unexpectedly, we observed that the mRNA expression of IL10 in tumors from ω-3 dietfed mice was significantly higher (six fold) relative to the expression in the tumors from the
ω-6 diet-fed mice. Further, the levels of IL10 mRNA were inversely correlated with the
tumor size indicating a potential role of IL10 in the suppression of tumor growth. However,
further mechanistic studies are required to confirm the role of IL10 in LC-ω-3FA mediated
tumor suppression.
It is estimated that metastasis is responsible for about 90% of deaths due to cancer and
represents the central clinical challenge of oncology of all types of cancers including BC
[502, 503]. Our studies shows lower incidence and frequencies of metastatic tumor
growths in multiple organs in mice fed a diet high in LC-ω-3FAs, which are in
correspondence with a significant longer survival of mice in the group compared to the
mice fed ω-6 diet. The death due to metastasis (typically in BC) is not due arresting of few
tumor cells from blood stream into a distant organ, rather it is due to the consequences
related to the uncontrolled proliferation of metastatic tumor cells in the organ, affecting its
physiological functions needed for life. Metastasis is a sequential process and for a
successful metastatic growth, roles of both tumor microenvironments and pre-metastatic
tissue microenvironments are crucial [504-506]. Most of metastasis and survival studies
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focus on tumor microenvironments and less emphasis is given on the role of premetastatic niche. As per seed and soil hypothesis, all organs are not hospitable for all
tumor types so specific tumor types have organ preferences for metastasis. However, as
showed by our studies, dietary factors such as PUFAs can modulate organ
microenvironments modulating the metastatic growth in the organ. Thus, further studies
should be done to understand the role tissue microenvironments and the modifying factors
that can modulate pre-metastatic niche in favoring of tumor growths.
In conclusion, from the NTB studies, we showed that a dietary ω-3 and ω-6 PUFAs
differentially modulated the microenvironments of the primary tumor site and one of the
metastatic sites (liver), which can regulate 4T1 mammary tumor growth and metastasis.
Specifically, dietary LC-ω-3FAs lowers MG ductal density, epithelial cell proliferation and
adipose tissue inflammation in MGs and lowers hepatic steatosis, hepatocyte apoptosis
and EMM in livers of NTB mice. In 4T1 mammary tumors, dietary LC-ω-3FAs delayed
tumor initiation, growth and enhanced survival of the mice by lowering the incidence and
frequencies of metastases to common and uncommon sites. The potential mechanism
includes modulation of inflammatory microenvironments in tumors, specifically increased
infiltration of T-cells and IL10 mediated anti-inflammatory activities.

6.2. Future directions
The present study is the first study analyzing the effects of PUFAs administered as
isocaloric, isolipidic diets using a pair-fed model. From our NTB and TB studies, we
reported many novel observations of tissue microenvironment modulations by dietary
PUFA composition regulating mammary tumor progression and answered critical
questions regarding the importance of PUFA composition in diets. However, our studies
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have raised many important questions that can be addressed in future studies, some of
which are discussed below.
1. We observed the differences in MG ductal branching and sprouting between mice
fed ω-6 and ω-3 diets. Progesterone and prolactin are the major hormones
regulating branching during normal MG developments. We used adult, nulliparous
mice and did not see differences in those hormones. So, it is likely that an
alternative mechanism could play role in the regulation of branching
morphogenesis by dietary PUFAs.
2. There were significantly smaller adipocytes in MG and abdominal fats in a ω-3
diet-fed mice compared to the ω-6 group. The observation raises the question that
dietary PUFA composition potentially regulates FA storage versus metabolism,
which can be addressed in future metabolic studies.
3. There was significantly more hepatic steatosis but lower glycogen deposits in the
hepatocytes of mice fed an ω-6 diet relative to the ω-3 group. It is unclear if
increases in fat droplets in hepatocytes are limiting glycogen storage, or vice
versa. It is possible a different mechanism related to the choice of fat versus
glycogen pathways, is regulated by PUFA composition.
4. In metastasis studies, we evaluated multiple organs (lungs, liver, heart, kidneys,
ovaries, and bone) and found differences in the incidence and frequency of
metastasis in those organs. However, in our NTB studies, we analyzed hepatic
microenvironments only as one of the representative metastatic sites. It is likely
that dietary PUFA composition might have modulated microenvironments of the
other organs to regulate metastatic growth to these sites. Further studies
analyzing each of these organs are needed to address these questions.
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5. Bone metastasis in breast cancer is regulated by cross talk between osteoclasts
and tumor cells. The understanding of how dietary PUFA composition modulates
osteoclastic activities in the presence and absence of tumor will help to
understand if PUFAs aid in the formation of pre-metastatic niches in bone.
6. We analyzed inflammatory microenvironments of tumors on day 35 post tumor
injection for the evaluation of inflammatory cells and cytokines/growth factors.
Since tumor immunology depends on the stage of tumor growth and progression,
time dependent studies will help in understanding PUFA regulation of tumor
immunology during tumor development and metastasis.
7. Examine the therapeutic potential of ω-3 PUFA interventions.
8. Determine the longitudinal response to ω-3 “change over” in tumor bearing mice
9. Determine a dietary PUFA regulation of mammary tumor on brain metastasis.
10. Analyses of metastatic burden between the mice from the dietary groups that are
having similar tumor size.
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